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ABSTRACT
Clinically Relevant and Economic Outcomes of Maintenance Pharmacotherapy in
Chronic Obstructive Pulmonary Disease (COPD)
Anna O. D’Souza
COPD is ranked as the fourth leading cause of death with an estimated cost of $37.2
billion in the U.S. primarily due to exacerbations. Therefore, the Global Initiative for
Obstructive Lung Disease (GOLD) committee has identified a need for assessing the effect
of drug therapies on outcomes of exacerbations, costs, and mortality. This study used
Medicaid data from West Virginia and Kentucky, and involved three phases. Phase I
assessed the costs incurred due to COPD, and the additional cost burden imposed by a
concomitant diagnosis of asthma. Phase II compared the risk and frequency of exacerbations
and COPD-related costs of currently available drug therapies. Phase III assessed the effect of
inhaled corticosteroids (ICS) on mortality using two different study designs, and also tested if
this effect was mediated by the effect of ICS on severe exacerbations. Results of Phase I
showed that recipients with COPD incurred 1.5 times significantly higher healthcare costs
than recipients without COPD, primarily due to differences in hospitalization and ER costs.
Asthma was found to increase the COPD-related cost of a recipient with COPD by 50%.
Results for Phase II showed no differences in reducing exacerbations and total COPD-related
costs in a relatively less severe COPD population between recipients treated with the
combination product of ipratropium/albuterol versus inhaled long-acting beta-agonists.
Phase II also showed that therapy with ICS either alone or in combination with an inhaled
long-acting beta-agonist did not reduce the risk of a severe exacerbation or the frequency of
moderate exacerbations when compared to therapy with short-acting bronchodilators or with
an inhaled long-acting beta-agonist. However, recipients initiated on ICS either alone or in
combination with an inhaled long-acting beta-agonist had higher total COPD-related costs
driven mainly by higher COPD-related prescription drug costs. In Phase III, recipients
initiated on ICS had a 40% reduction in mortality using the case-control design. The cohort
design found a relative risk reduction of 48%, and an absolute risk reduction of 1.7%
corresponding to a value of 59 for number needed to treat. The effect of ICS on mortality
was not mediated by the effect of ICS on severe exacerbations.
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CHAPTER 1: INTRODUCTION AND STUDY OBJECTIVES
INTRODUCTION
The impact of smoking has been most prominent in Chronic Obstructive Pulmonary
Disease (COPD) relative to other diseases (Pauwels, Buist, Calverley, Jenkins, & Hurd,
2001). Although it has been estimated that 15 percent of smokers eventually develop COPD,
the attributable risk fraction due to smoking is very high with smoking being responsible for
80 percent to 90 percent of COPD cases (Sin, McAlister, Man, & Anthonisen, 2003c). The
picture gets even grimmer with recent evidence from one study in Sweden showing that up to
50 percent will progress to develop COPD (Lundback et al., 2003). Thus, it is not surprising
that smoking cessation is the only treatment modality in COPD that affects the progression
and mortality of the disease as was evidenced from a large cohort in the Lung Health Study
(LHS) (Anthonisen et al., 1994). The study showed that smoking cessation led to a 50
percent reduction in the rate of lung function decline (Anthonisen, Connett, & Murray,
2002). These statistics should be comforting knowing that a preventable and treatable
solution is available for COPD. However, availability does not imply attainability. Data
from the LHS also showed that after 11 years, only 22 percent of those in a smoking
cessation program stopped smoking, whereas only 6 percent not in a program stopped
smoking (Murray et al., 2000). Given these data, should we still be concerned about COPD
as a public health problem? The answer is yes, and lies in an understanding of what
constitutes COPD and its consequences on morbidity, mortality, and healthcare costs.
Chapter one will provide a brief description of the COPD disease state and pharmacologic
options used for maintenance therapy that provide an understanding for the need for the
proposed study, and the study goals and objectives.

COPD: Prevalence, Costs, and Management
COPD is defined as a clinical syndrome that refers to the presence of two distinct
pathoclinical entities: chronic bronchitis and emphysema (Mapel, 2004). The definition of
COPD excludes other obstructive pulmonary diseases that are associated with poorly
reversible airflow limitation such as bronchiectasis, cystic fibrosis, fibrosis due to
tuberculosis, and asthma, except if these conditions overlap with COPD. COPD is defined as
1

a syndrome characterized by progressive airflow limitation that is not fully reversible, and is
caused by an abnormal inflammatory reaction to the chronic inhalation of particles, primarily
tobacco smoke (Pauwels et al., 2001). Airflow limitation is the slowing of expiratory airflow
as measured by spirometry (Mannino, 2003). Spirometric measures of airflow limitation
include forced expiratory volume in one second (FEV1) and forced vital capacity (FVC),
which is the maximum volume of air in liters that can be forcibly and rapidly exhaled in one
second or full exhalation, respectively. In patients with COPD, the FEV1 and FVC are
reduced relative to normal predicted values. Airflow limitation can be reversible or
irreversible depending on the response after bronchodilator administration. Based on the
Global Initiative for Obstructive Lung Disease (GOLD) and American Thoracic Society
(ATS) definitions, an FEV1 increase of 12 percent (200 ml) above baseline after
administration of inhaled bronchodilators or corticosteroids is considered to be a
demonstration of reversibility. Originally considered to be a disease with irreversible
airways obstruction (i.e. no response to bronchodilators), recent studies estimate 23 percent
to 42 percent of patients with COPD exhibit bronchodilator reversibility depending on the
criteria used (Calverley, Burge, Spencer, Anderson, & Jones, 2003). Therefore, airflow
limitation in COPD is characterized as not fully reversible rather than the old myth of
irreversible airways obstruction. The progressive nature of the disease refers to the
accelerated decline in lung function as measured using FEV1, from the normal rate in adults
over 30 years of age of approximately 30ml per year to nearly 60ml per year (Anthonisen et
al., 2002).
The available prevalence data of COPD are considered to under-estimate the total burden
of disease, primarily because the disease is usually diagnosed after moderate advancement
has occurred and clinical symptoms become apparent (Pauwels et al., 2001). In 2002, the
National Health Interview Survey (NHIS) in the U.S, estimated that 11.2 million (~5%)
people over 17 years of age reported a physician diagnosis of COPD. Of these, 9.1 million
reported chronic bronchitis and 3.1 million reported emphysema (American Lung
Association, 2004)1. Evidence of under-diagnosis of the condition is seen from prevalence
information objectively obtained using spirometry from the 1994 National Health and

1

COPD totals do not take into account the overlap of persons with both diseases. Therefore, COPD totals will
be lower than the sum of chronic bronchitis and emphysema estimates.

2

Nutrition Examination Surveys (NHANES). In this study, 24 million people over 25 years of
age had COPD, more than twice that of the 2002 NHIS estimate that used physician
diagnosis as a criterion.
The decline in lung function in COPD impacts mortality due to the development of
several fatal conditions such as respiratory failure, cor pulmonale, and pulmonary embolism.
Mortality in COPD is further compounded by the fact that a majority of deaths are attributed
to other causes, primarily cardiovascular. In one study, approximately 45 percent of
decedents with COPD mentioned on their death certificates have COPD listed as an
underlying cause of death (Mannino, Brown, & Giovino, 1997). In the U.S., COPD and
allied conditions (includes asthma and bronchiectasis) were the fourth leading cause of death
in 2002 (NHLBI, 2004). On a global level COPD was ranked as the sixth leading cause of
death in 1990, and is projected to rise to third by 2020 (Murray & Lopez, 1997).
Costs of COPD
A highly prevalent and fatal disease, COPD also exerts substantial economic
consequences to the U.S. healthcare system. In 2004, the National Heart, Lung and Blood
Institute (NHLBI) estimated that COPD cost the U.S. healthcare system a total of $37.2
billion (NHLBI, 2004). The direct costs totaled $20.9 billion and the indirect cost due to
morbidity and mortality totaled $7.4 billion and $8.9 billion, respectively. This section will
review COPD cost-of-illness studies in the U.S. to identify components of care that are major
cost drivers, and factors affecting costs. This information is useful for developing
interventions to target high-risk, high-cost sub-groups.
Two studies using a composite of national databases in the U.S. assessed costs related to
COPD, and reached different conclusions (Wilson, Devine, & So, 2000; Ward, Javitz, Smith,
& Bakst, 2000). Wilson et al. found hospitalizations (57%) and medications (40%) to be the
first and second highest cost categories (the cost of oxygen therapy was not estimated)
(Wilson et al., 2000). On the other hand, Ward et al. found oxygen therapy (35%) and
hospitalizations (24%) to be the first and second highest cost categories (Ward et al., 2000).
COPD-related medications comprised only 7% of total costs in study by Ward et al. as
determined from data of the National Medical Expenditure Survey 1987 (NMES) and the
National Ambulatory Medical Care Survey 1990 (NAMCS), as opposed to the estimate of
Wilson et al. that was based on expert opinion of prescription drug patterns. Strassels et al.
3

analyzed the 1987 NMES only, and also found that all prescription drugs used by patients
with COPD (COPD-related and non-COPD related) accounted for 8 percent of total costs,
while hospitalizations were 70 percent of total costs (Strassels, Smith, Sullivan, & Mahajan,
2001).
Wilson et al. and Ward et al. assessed the cost of only COPD-related care; however
Strassels et al. additionally assessed the cost of non-COPD related care. Thus, average cost
per patient with COPD for Wilson et al. was $896 (1996 USD) while Strassels et al. found an
average of $6,469 (1987 USD) per patient with COPD of which only 25 percent was related
to COPD. Another study found that pulmonary-related outpatient utilization, drugs, and
oxygen therapy accounted for only 25 percent of the difference in total outpatient and
pharmacy utilization between COPD and non-COPD patients (Mapel et al., 2000a).
Similarly, analysis of managed care data showed that 23 percent of total monthly health care
costs were related to COPD (Kesten S, 2001). These findings indicate that although COPD
itself can increase costs for patients, the presence of smoking-related comorbidities (e.g.
coronary heart disease, congestive heart failure, hypertension, malignant disease, gastritis)
have an enormous influence on total costs incurred by a patient with COPD (Mapel et al.,
2000a). Thus, it is important to include costs of non-COPD related care to permit accurate
estimation of costs incurred by patients with COPD.
Analyses that compare total costs (COPD and non-COPD related) between COPD and
non-COPD patients provide estimates of the cost difference between these subsets, and allow
one to determine the magnitude of the amount that is incurred due to the presence of COPD.
Mapel et al. found that total health care costs in patients with COPD were twice those of nonCOPD patients with an incremental cost of $6,039 per case (Mapel et al., 2000a). These
differences were evident in all components of health care (inpatient, outpatient, and
pharmacy services), with the largest difference for inpatient services. Similar to findings by
Strassels et al., Grasso et al. also found that per capita expenditures for Medicare
beneficiaries with COPD were 2.4 times those of average Medicare beneficiaries (Grasso,
Weller, Shaffer, Diette, & Anderson, 1998). Most studies have found a ratio of 2:1 when
comparing COPD and non-COPD patients except one where total monthly costs per patient
were six times higher than non-COPD patients (Kesten S, 2001).

4

The analysis by Strassels et al. (Strassels et al., 2001) noted that approximately 20
percent of patients with COPD account for about 74 percent of total expenditures, while
Grasso et al. (Grasso et al., 1998) found that 10 percent of patients accounted for nearly half
of total expenditures. This is probably a reflection of the level of disease severity and higher
number of co-morbidities of this subset of the COPD population. The impact of disease
severity level on costs has been assessed in two studies. Using disease severity based on
FEV1 according to ATS criteria, one study found that annual median costs per patient for
severe COPD (stage III) were $10,812, more than twice that of patients with moderate COPD
(stage II), $5,037 (Hilleman, Dewan, Malesker, & Friedman, 2000). Similarly, costs of
patients with moderate COPD were nearly three times greater than costs of patients with mild
COPD. As expected, hospitalizations accounted for the largest proportion of total costs
regardless of disease severity, whereas oxygen therapy accounted for almost 15 percent to 20
percent of total costs only for moderate and severe patients, respectively. The other study
assessed disease severity from patient’s perceptions or scores on the Medical Research
Council Dyspnea Scale (MRC) (Halpern, Stanford, & Borker, 2003). Patients with severe
COPD, as measured by either the MRC scale or patient’s perceptions, incurred almost three
to six times higher costs than mild or moderate patients with COPD. Similar to disease
severity, decrease in self-reported health status is related to increase in costs of COPD
(Strassels et al., 2001).
Age does not seem to influence the total costs incurred by patients with COPD, with costs
being slightly higher in those over 64 years compared to those younger than 65 years
(Strassels et al., 2001; Mapel et al., 2000a). Conflicting evidence exists for variation in total
COPD costs by physician specialty. One study found no significant differences in charges
for care rendered by pulmonologists, general internists, or family physicians (Strauss,
Conrad, LoGerfo, Hudson, & Bergner, 1986). On the other hand, Hilleman et al. found care
provided by pulmonologists to be higher than that provided by primary care physicians
($4,026 vs. $7,805) (Hilleman et al., 2000). Interestingly enough though, patients with
moderate and severe COPD treated by pulmonologists ($4,439 and $10,226, respectively)
had significantly lower total costs than those treated by primary care physicians ($5,270 and
$11,105, respectively).
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Co-morbidities, particularly cardiovascular-related causes, substantially increase the costs
for patients with COPD as seen in the evidence above. According to recent estimates,
patients with COPD with a concomitant diagnosis of asthma constitute almost half of all
patients with COPD (Mapel et al., 2000b; Mannino, 2003). Asthma and COPD are both
obstructive lung diseases with airflow limitation. The difference however, is that in asthma;
the response to bronchodilator administration is primarily reversible while in COPD it is
partially reversible or irreversible. Thus, patients with concomitant asthma and COPD
probably represent a sub-group of patients with COPD with more reversibility relative to
patients with COPD without asthma. This however, has not been documented as yet. The
impact of this reversibility on prognosis and response to treatment is of increasing interest in
COPD currently, and recent evidence suggests that degree of bronchodilator reversibility
may not impact these factors (Tashkin & Kesten, 2003).
Only two studies have provided some information regarding the impact of a concomitant
diagnosis of asthma in patients with COPD. Data from the 1996 NHIS survey showed that
participants reporting both COPD and asthma had more days of restricted activity (62.5 vs.
31.0 days), bed confinement (31.5 vs. 13.1 days), and work loss (8.2 vs. 2.4 days) than did
participants with COPD alone (Mannino, 2002). The increased use of resources is also
reflected in a Canadian study that determined spirometry and drug use in COPD and asthma
patients (Anthonisen, Woodlrage, & Manfreda, 2005). Patients with COPD and asthma had
considerably higher rates of drug use and slightly higher spirometry rates than patients with
COPD-only. The rate of use of inhaled corticosteroids was similar to the rate of use in
patients with only asthma, and that of inhaled anti-cholinergics was similar to that in COPDonly patients. These data suggest that a concomitant diagnosis of asthma in patients with
COPD may identify a high-cost group. However, none of the cost-of-illness studies have
stratified based on presence of asthma. Such studies are needed so that appropriate targets
for disease management can be determined.
Management of COPD
The enormous clinical and economic impact of COPD has prompted the development of
the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) in 1997. The
specific aim of GOLD is to improve the prevention and management of COPD by providing
the best available evidence on effectiveness of therapeutic options and validated current
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concepts of COPD pathogenesis (Pauwels et al., 2001). This committee has adequately
outlined the goals of COPD management that include reduction of disease progression and
mortality, relief of symptoms, improvement in exercise tolerance and health status, and
prevention of exacerbations and complications. These goals should be accomplished by a
management plan which includes four components:
1. Diagnosis and monitoring of the disease
2. Reduction of risk factors
3. Management of stable COPD
4. Management of exacerbations
There are several therapies available, both pharmacologic and non-pharmacologic, that
form aspects of the above four-component plan (Table 1). Management consists of a
stepwise increase in treatment depending on the severity of the disease. Once symptom
control has been achieved, reduction of therapy is usually not possible because of the
progressive nature of the disease. Some therapies are applicable to all patients with COPD
such as smoking cessation, immunizations, and bronchodilators. However, not all therapies
need to be used simultaneously in all patients with COPD. When multiple therapies are used
in combination, they should be incorporated in a pre-determined plan so as to assist
integration in a coordinated manner. Since the proposed study will evaluate the effectiveness
and costs of pharmacotherapy, further sections will focus on the role of pharmacotherapy in
COPD.
TABLE 1: Therapies for management of COPD
Smoking cessation
Immunizations: Influenza and Pneumococcal
Pharmacotherapy: Bronchodilators, Inhaled and oral corticosteroids, antibiotics
Oxygen
Pulmonary Rehabilitation
Mechanical ventilation
Surgery: Lung volume reduction, lung transplantation
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Pharmacologic Options for Maintenance Therapy in COPD
Two components of the COPD management plan refer to management of a stable state
and an exacerbated state. The stable state refers to the presence of all or few symptoms such
as cough, sputum production, wheezing and dyspnea without the need for additional
treatment or management. A patient with COPD also experiences exacerbations which are
defined as episodes with increase or worsening of symptoms relative to the day-to-day
fluctuations of the stable state that may require additional medical treatment (Burge &
Wedzicha, 2003). The relevant question then would be “is pharmacotherapy required only
when symptoms exacerbate, or is there a need for maintenance therapy for the stable state?”
Evidence from controlled clinical trials of drugs suggests that maintenance pharmacotherapy
is indeed beneficial. Benefits of this approach include reduction in the frequency or severity
of exacerbations, and improvement in symptom scores, exercise tolerance and overall healthrelated quality-of-life (HRQol) (Tashkin & Cooper, 2004; Sin et al., 2003c).
Two broad categories of drugs are used for maintenance therapy of COPD:
bronchodilators and inhaled corticosteroids (ICS). Bronchodilators include drugs from three
distinct classes: beta-agonists, anti-cholinergics, and methylxanthines. Beta-agonists and
anti-cholinergics are considered treatments of choice, and include short-acting and longacting formulations. Methylxanthines are infrequently used due to numerous side effects,
and are currently used only as additional therapy for advanced disease and those with less
than optimal control with inhaled bronchodilators.
FIGURE 1: GOLD treatment algorithm
Stage 0
At risk

Stage I
Mild

Stage II
Stage III
Stage IV
Moderate
Severe
Very Severe
Initiation of Maintenance Pharmacotherapy

Avoid risk factors; influenza vaccination
Add short-acting bronchodilators as needed
Add regular treatment with 1 or more long-acting
bronchodilators
Add inhaled corticosteroids if
repeated exacerbations
Add Oxygen
therapy if
chronic
respiratory
failure
Adapted from Reference (GOLD, 2004)
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The therapeutic algorithm outlined by the GOLD initiative (figure 1) depicts a stepwise
increase in pharmacologic therapy as disease severity increases, based on FEV1 level
(GOLD, 2004). Patients with stage 1 (mild COPD) are defined as those with few or
intermittent symptoms. Thus, pharmacotherapy for mild COPD is on an as-needed basis,
generally using short-acting bronchodilators such as albuterol. At this point it should be
noted that pharmacotherapy for mild COPD is on an as-needed basis, while maintenance
pharmacotherapy is relevant only for moderate-to-severe COPD.
Short-acting bronchodilators are to be used as rescue medication as-needed at all stages.
Among short-acting bronchodilators, current recommendations are that use of short-acting
beta-agonists alone should not be considered for maintenance therapy, and are to be used
only as rescue medication. On the other hand, the short-acting anti-cholinergic, ipratropium,
has been the drug of choice for maintenance therapy. Although it can be used on an asneeded basis, its slower onset of action compared to short-acting beta-agonists, does not
make it suitable for this purpose. Considered to be equivalent to ipratropium, a combination
of ipratropium (short-acting anti-cholinergic) and albuterol (short-acting beta-agonist)
occupies an important place in maintenance therapy for COPD (Petty, 1995; Rennard, 1995).
Regular treatment with a long-acting bronchodilator is now recommended for patients
with stage II (moderate COPD) disease because of reasons of efficacy and convenience.
Additionally, a combination of long-acting bronchodilators from two different classes (betaagonists and anti-cholinergics) is increasingly being considered, following the extremely
effective combination of two short-acting bronchodilators from these two classes (Tennant,
Erin, Barnes, & Hansel, 2003). However, no clinical studies are available currently
regarding the efficacy of combination of long-acting bronchodilators. For combination
therapy, a single drug may be administered or a combination product may be used. The two
short-acting bronchodilators, albuterol (beta-agonist) and ipratropium (anti-cholinergic) are
available in a combination product. Oral theophylline may also be considered for stage II
patients, although this option is usually less preferred. As is evident in figure 1, the use of
bronchodilators is recommended for all disease severity stages. However, as disease severity
increases to stage III (severe) and stage IV (very severe), addition of inhaled corticosteroids
(ICS) is usually recommended. These drugs are also recommended for those with stage II
with frequent exacerbations.
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The present study will evaluate outcomes of maintenance pharmacotherapy in COPD,
and will be discussed below. First, a discussion of relevant outcome measures in COPD is
important before presenting evidence of the efficacy and effectiveness of pharmacotherapy.
Outcome Measures in COPD Pharmacotherapy
FEV1 is an important clinical measure in COPD that indicates the degree of airflow
limitation, a primary characteristic of COPD (Pauwels et al., 2001). However, the use of
FEV1 as a sole outcome measure to evaluate treatment effectiveness in COPD has its
limitations due to several reasons. First, COPD is a complex multisystem disorder that
affects not only the lungs but also other organs. In addition, the pathophysiological
processes that occur in the lungs are not captured entirely by FEV1, such as lung
hyperinflation leading to increases in lung volumes and abnormal gas exchange at the
alveolar level (Briggs, Jr., 2004). The problem is compounded because of the difficulty in
measuring lung volumes in a reproducible manner to guide therapy decisions. In fact, the
sensation of breathlessness (dyspnea), and exercise tolerance are better indicators of changes
in lung volumes (O'Donnell, 2000). Symptom scores, exacerbations, and HRQol can be
described as more summative measures that capture physical and psychosocial aspects of this
disease (Jones, 2001). The inadequacy of FEV1 as an outcome measure is also seen in the
poor correlation of this measure with symptom score, HRQol, and dyspnea (O'Donnell, 2000;
Jones, 1995). Among the outcome measures, exacerbations are the most highly and
positively correlated with FEV1. However, there are still about 20 percent of patients with
moderate-to-severe disease (lower FEV1) that do not experience any exacerbations (Burge et
al., 2000).
Second, bronchodilators are considered standard drug therapy in COPD, and their
primary mode of action is airway smooth muscle relaxation (Lipson, 2004). FEV1 is an
incomplete surrogate clinical marker of this outcome, and represents only a portion of the
complex clinical consequences of COPD (Jones & Kaplan, 2003a; O'Donnell, 2000).
Additionally, drugs can induce changes in other areas such as improvement in dyspnea and
symptoms through other mechanisms. Therefore, evaluation of treatment options in COPD
cannot solely be restricted to the improvement in FEV1.
Third, since COPD is described as a disease that is partially reversible (a low FEV1 that
responds partially or not at all to bronchodilators or steroids), it seems almost paradoxical to
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use FEV1 as a sole outcome measure on which to base the effectiveness of therapy (Celli,
2000).
This multifaceted nature of COPD has led to the use of other outcome measures to
evaluate the effectiveness of therapy in COPD. Examples of other outcome measures to
evaluate the effectiveness of COPD therapies include, but are not restricted to; improvements
in dyspnea, exercise tolerance, symptoms (exacerbations) and HRQoL (Gross, 2003). The
tangible nature of these outcomes to the patient as well as their clinical relevance due to their
prognostic characteristics provide adequate justification for use of these outcome measures
(Fan, Curtis, Tu, McDonell, & Fihn, 2002; Nishimura, Izumi, Tsukino, & Oga, 2002).
Moreover, there is conflicting evidence that drugs in COPD impact disease progression as
measured by FEV1 and mortality. Therefore, other outcome measures assume greater
importance in evaluating COPD pharmacotherapy.

Summary of Efficacy and Effectiveness Evidence
Inhaled Broncodilators: Long-acting beta-agonists and Short-acting anticholinergics
Desirable features of long-acting beta-agonists, salmeterol and formoterol, such as the
extended duration of bronchodilation and twice daily administration have increased the
popularity of these agents for maintenance therapy in COPD. A recent update to the GOLD
guidelines recommends that long-acting beta-agonists are more effective and convenient than
the short-acting anti-cholinergic, ipratropium (GOLD, 2004). However, data from four
comparative trials provide inconsistent results regarding the impact of long-acting betaagonists with ipratropium, particularly for exacerbations. A recent review of these trials
using a best evidence synthesis approach instead of a meta-analysis, concluded that longacting beta-agonists were comparable to ipratropium in terms of lung function as measured
by FEV1 and dyspnea reduction (Husereau, Shukla, Boucher, Mensinkai, & Dales, 2004).
Salmeterol showed inconsistent results, with one trial showing a significantly longer time to
an exacerbation relative to ipratropium (Mahler et al., 1999), while another trial showed no
differences in the proportion of patients with exacerbations requiring oral corticosteroids
(Rennard et al., 2001). Only one of two formoterol trials assessed exacerbation rate, and
found the long-acting beta-agonist to reduce the percentage of bad days (mild exacerbations)
relative to ipratropium, but have no impact on moderate or severe exacerbations (Dahl et al.,
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2001). The inconsistency of the effect of long-acting beta-agonists on exacerbation rate is
also seen in comparison to placebo. Sin et al. conducted a meta-analysis from eight
randomized trials of at least 3 months of the impact of long-acting beta-agonists and found a
21 percent significant reduction compared to placebo on rate of exacerbations (Sin et al.,
2003c). In contrast, a Cochrane review found an insignificant 31 percent risk reduction
compared to placebo (Nannini, Lasserson, & Poole, 2003). Another review has attributed the
lack of an effect to the duration of trials (Tashkin et al., 2004). Most of the trials were
conducted for a maximum of 12 weeks.
Observational studies have assessed the impact of long-acting beta-agonists on
exacerbations over a period of one year. Only severe exacerbations have been evaluated in
these studies. Two studies used a similar cohort design with administrative claims databases,
and assessed the risk of an exacerbation requiring hospitalization after one year following
initiation of therapy (Burney et al., 2003; Rascati, Stanford, & Borker, 2005). A trend
towards a reduced risk was seen for long-acting beta-agonists compared to ipratropium that
was not statistically significant in both studies. Study design aspects such as inadequate
control of disease severity, and lack of assessment of other outcomes such as moderate
exacerbations and costs suggest the need for additional studies to establish the value of longacting beta-agonists in COPD relative to ipratropium.
Inhaled corticosteroids (ICS)
As disease severity increases, the GOLD guidelines recommend addition of ICS for the
treatment of COPD (Pauwels et al., 2001). There is much controversy regarding the use of
ICS for COPD (Calverley, 2000; Barnes, 2000a). Although, considered as first-line therapy
in asthma, differences in inflammatory processes between asthma and COPD do not
adequately support the use of these drugs for COPD (Barnes, 2000b). There was major
interest in determining if ICS could reduce the progression of COPD given their
effectiveness in asthma. Six randomized controlled trials with duration of at least 2 years
showed no impact on the rate of decline in lung function (Vestbo et al., 1999; Pauwels et al.,
1999; Burge et al., 2000; Lung Health Study Group, 2000; Renkema, Schouten, Koeter, &
Postma, 1996; Weir, Bale, Bright, & Sherwood, 1999). However, two meta-analyses that
pooled data from these trials reached opposite conclusions. The first meta-analysis found a
statistically and clinically insignificant difference of +5.31 ml/year in the rate of FEV1
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decline (Highland, Strange, & Heffner, 2003), whereas the second meta-analysis found a
statistically significant difference of 7.7 ml/year (Sutherland, Allmers, Ayas, Venn, &
Martin, 2003). The clinical significance of the estimate from the latter study is questionable
because of the small magnitude.
The lack of an effect on disease progression leads one to conclude that ICS may not
impact mortality. This has been shown in all clinical trials and meta-analyses, but not
observational studies. Six observational studies have found an effect on decreasing mortality
by 25 percent to 75 percent (Sin & Man, 2003a; Sin et al., 2003a; Soriano, Kiri, Pride, &
Vestbo, 2003; Soriano et al., 2002; Burney et al., 2003). Two observational studies however,
mirror clinical trial results (Suissa, 2003; Fan et al., 2003). Some researchers have attempted
to explain the 25 percent to 75 percent reduction in mortality found in observational studies
as evidence that ICS may actually modify the progression of the disease based on the
significant reduction in lung function decline found in the meta-analysis described above
(Burge & Lewis, 2003). It is important to explain reductions of such magnitude from
observational studies given the totality of evidence that ICS do not modify the progression of
the disease. One possible hypothesis is that ICS are able reduce mortality by reducing the
rate or severity of exacerbations. Exacerbations are known to have a significant impact on
mortality (Groenewegen, Schols, & Wouters, 2003), and thus the effect of ICS on mortality
may be mediated through its impact on exacerbations.
Of six randomized trials that reported ICS use and exacerbations, two showed statistically
significant differences (Burge et al., 2000; Paggiaro et al., 1998) while four did not show any
significant difference (Vestbo et al., 1999; Bourbeau, Rouleau, & Boucher, 1998; Weir et al.,
1999; Lung Health Study Group, 2000). A meta-analysis that pooled data from these studies
showed that ICS reduced the risk of exacerbations by 30 percent (RR=0.70; 95% CI: 0.58 to
0.84) (Alsaeedi, Sin, & McAlister, 2002). The beneficial impact of ICS on exacerbations
needs to be described beyond summary estimates. Analyses from the two clinical trials that
found a beneficial effect of ICS on exacerbations have found no impact on the total
proportion of patients using ICS who experienced at least one exacerbation (Burge et al.,
2000; Paggiaro et al., 1998). However, there was a significant difference in the proportion of
patients experiencing moderate to severe exacerbations. Thus, ICS may significantly impact
the severity of the exacerbation but not the overall frequency.
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The inconsistency of the effect of ICS on exacerbations has been seen in observational
studies for severe but not moderate exacerbations. Five observational studies found that ICS
significantly reduced the risk for exacerbation requiring hospitalization (Sin & Tu, 2001; Sin
et al., 2003a; Soriano et al., 2003; Burney et al., 2003; Rascati et al., 2005), and two
observational studies found no significant effect (Fan et al., 2003; Bourbeau, Ernst, Cockcoft,
& Suissa, 2003). Two clinical trials have shown that the risk for moderate exacerbations is
also reduced (Burge et al., 2000; Paggiaro et al., 1998). However, in only two observational
studies that have assessed this outcome, no significant effects were found (Fan et al., 2003;
de Melo, Ernst, & Suissa, 2004a). On the contrary, a trend for increased risk of moderate
exacerbations was noted (de Melo et al., 2004a).
Combination of inhaled corticosteroids and long-acting beta-agonists
Combination therapies are gaining importance in COPD due to the chronic and
progressive nature of COPD, as well as complementary mechanisms of actions of drugs from
different classes. The combination of ICS and long-acting beta-agonists are increasingly
being considered as an important combination as these two classes of drugs have
complementary effects on each other’s mode of action, providing additive or synergistic
effects (Sin, Johnson, Gan, & Man, 2004). Unlike the conflicting evidence regarding the use
of ICS on exacerbations, the use of the combination of ICS and long-acting beta-agonist have
shown a reduction in exacerbation rates in most clinical trials, meta-analyses, and
observational studies.
At least three randomized trials have assessed the impact of the fluticasone/salmeterol
combination (Mahler et al., 2002; Calverley et al., 2003a; Cazzola et al., 2003; Dal Negro,
Pomari, Tognella, & Micheletto, 2003; Hanania et al., 2003), and two trials have assessed the
impact of the budesonide/formoterol combination (Calverley et al., 2003b; Szafranski et al.,
2003). All trials showed a significant reduction in risk for moderate to severe exacerbations
of 25 percent to 30 percent. This reduction in risk is similar to that observed in the trials of
monotherapy with ICS mentioned previously. Several observational studies have also
determined risk reductions for the combination therapy only for severe exacerbations
(Burney et al., 2003; Soriano et al., 2003; Rascati et al., 2005). Almost all observational
studies have found risk reductions of 35 percent to 40 percent, with one study showing a 74
percent reduction (Burney et al., 2003).
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The relevant question then asks if the combination therapy is as effective as its
monotherapy components or does the combination have any additive or synergistic effects.
All the clinical trials have assessed combination therapy relative to patients using each
component as monotherapy or a placebo group. Three of these clinical trials have reported
the reduction in exacerbations of the combination therapy relative to the ICS alone and the
long-acting beta-agonist alone (Calverley et al., 2003a; Calverley et al., 2003b; Szafranski et
al., 2003). Two of three trials found that the combination was equally effective as the ICS
alone (Szafranski et al., 2003; Calverley et al., 2003b). In contrast, only one trial found no
difference between the combination therapy and the long-acting beta-agonist alone
(Calverley et al., 2003a). The other two trials found significant risk reductions in
exacerbations of 23 percent to 30 percent for combination therapy compared to the longacting beta-agonist alone (Calverley et al., 2003b; Szafranski et al., 2003). Results of three
meta-analytic reviews combining data from all or some of these trials also revealed the same
pattern (Sin et al., 2003c; Sin et al., 2004; Nannini et al., 2003). These data suggest that it is
probably the inhaled corticosteroid component that maybe integral to providing a protective
effect against exacerbations.
The consistency of the beneficial effect on exacerbations of ICS component was also
observed when the ICS and the long-acting beta-agonist were each compared to the placebo
group. When considering the overall rate of both moderate and severe exacerbations, only
one (TRISTAN) of three trials found a significant reduction for both the long-acting betaagonist and ICS component compared to placebo (Calverley et al., 2003a). When
considering only exacerbations requiring oral corticosteroid courses however, only the
TRISTAN trial showed a significant reduction of 29 percent for long-acting beta-agonists
compared to placebo (Calverley et al., 2003a). On the other hand, all three trials showed that
the ICS component significantly reduced risk in exacerbations requiring oral corticosteroid
courses by approximately 30 percent compared to placebo (Calverley et al., 2003a; Calverley
et al., 2003b; Szafranski et al., 2003).

Pharmacoeconomic evaluations in COPD
Drugs prevent, alleviate, or cure illness or complications, and hence can impact the
economic burden of a disease. Pharmacoeconomic studies basically evaluate the economic
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impact of drug therapies, and are frequently required to demonstrate the cost-effectiveness of
therapies (Drummond MF, O'Brien BJ, Stoddart GL, & Torrance GW, 1997a). These studies
need to assess not only the acquisition cost of the drug, but also the cost of the disease such
as physician visits, emergency room (ER) visits, and hospitalizations (Drummond MF,
O'Brien BJ, Stoddart GL, & Torrance GW, 1997c). Depending on the perspective of the
analysis, different kinds of costs can be included. For instance, only direct costs maybe
important for a health insurer’s perspective, but for an employer indirect costs of reduced
productivity are equally relevant. Pharmacoeconomic studies can be conducted using data
from randomized clinical trials, by creating decision analysis models, or by analyzing claims
databases (Drummond MF, O'Brien BJ, Stoddart GL, & Torrance GW, 1997b)
At least four studies have established the cost-effectiveness of ipratropium. The
comparators of interest in these studies were mostly theophylline or albuterol. Three studies
used retrospective claims data (Sclar, Legg, Skaer, Robison, & Nemic, 1994; Hilleman et al.,
2000; Jubran et al., 1993), while the fourth used data from a randomized clinical trial
(Friedman et al., 1999). Two of three database studies compared only costs between patients
initiated on ipratropium, and not effectiveness measures. Sclar et al. found that patients
initiated on monotherapy with albuterol, theophylline, or a corticosteroid in the first six
months incurred significantly higher expenditures per month by $30.00 to $50.00 compared
to ipratropium (Sclar et al., 1994). Hilleman et al. stratified patients based on disease
severity level, and found that within each disease severity level, ipratropium had the lowest
cost per patient per year (Hilleman et al., 2000). A difference ranging from $200 to almost
$900 was found between the ipratropium and other therapy groups. The third database study
computed costs as well as an effectiveness measure called complication-free therapy month
(CFTM) over one year between ipratropium and theophylline (Jubran et al., 1993). A CFTM
was defined as a month without an unscheduled visit to a physician and without a clinical
exacerbation or a complication of therapy. Similar to previous studies, ipratropium was
found to cost less (annual cost = $932 vs. $1,373) and have greater CFTMs (11.30 vs. 10.68)
than theophylline, thereby being cost-effective as well as cost-saving. Both the Hilleman et
al. study and the latter study showed that the lower acquisition cost of theophylline compared
to ipratropium did not lower overall costs because of increased clinic visits and
hospitalizations due to increased toxicity. Friedman et al. assessed the cost-effectiveness of a
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combination of ipratropium and albuterol compared to each of the individual drugs using
data on costs and efficacy from two clinical trials (Friedman et al., 1999; Petty, 1995). The
treatment arms containing ipratropium were dominant in the study with 33% fewer
exacerbations and consequent decreases in resource use (hospital days, antibiotic use and
corticosteroid use) and costs compared to albuterol. The mean total per patient cost was
$269, $156, and $197 for albuterol, ipratropium and ipratropium-albuterol combinations,
respectively. The combination of ipratropium and albuterol versus ipratropium alone was not
significantly different indicating similar cost-effectiveness.
Following these preliminary studies, ipratropium or the combination of ipratropium and
albuterol has been established as first-line therapy in COPD. Therefore, future
pharmacoeconomic studies should focus on comparing new therapies such as long-acting
beta-agonists to ipratropium or to the combination of ipratropium and albuterol. Three
pharmacoeconomic studies of long-acting beta-agonists have been identified, two conducted
alongside clinical trials (Jones, Wilson, & Sondhi, 2003b; Hogan, Geddes, & Gonzalez,
2003) and one using a claims database (Howard KB, McLaughlin, Pathak DS, Okamoto L, &
Bowers B, 2001). One study assessed the cost-effectiveness of salmeterol relative to placebo
and not ipratropium (Jones et al., 2003b). Results showed salmeterol to have higher total
costs of ₤90.10 (95% CI: ₤20.09-₤154.11) as well as increased effectiveness on all outcome
measures over 16 weeks. A pharmacoeconomic study of formoterol however, assessed costs
and effectiveness relative to ipratropium over 12 weeks (Hogan et al., 2003). A major
limitation of the study precluding the use of the results in decision-making is that no a priori
economic data were collected except for the use of rescue medications, and only cost of study
drugs and rescue medications were considered in this analysis. Incremental analyses showed
that formoterol 12µg cost $1,611 per additional change in FEV1 and $25 per additional
change in St. George’s Respiratory Questionnaire (SGRQ) units compared to ipratropium.
However, in this trial, the difference between ipratropium and formoterol on both measures
of FEV1 and SGRQ units were statistically but not clinically significant (Dahl et al., 2001).
In addition, data from another formoterol trial shows equal efficacy with ipratropium on
similar outcomes (Wadbo et al., 2002).
Friedman et al. conducted a hypothetical analysis based on data from two different trials
of ipratropium and salmeterol (Friedman & Hilleman, 2001). The trials found similar
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reductions in exacerbations for salmeterol and ipratropium (37% vs. 33%, respectively). The
authors estimated health care costs per patient per year based on a prior pharmacoeconomic
analysis, and found that salmeterol would have higher costs ($1,059) compared to
ipratropium ($788). The costs for salmeterol were estimated and not empirically assessed.
One study compared six-month COPD-related costs between patients initiated on salmeterol
or ipratropium using the Pharmetrics database, which includes medical and prescription
claims from several managed care plans (Howard KB et al., 2001). The choice of drug
therapy did not impact COPD-related costs or total health care costs. The study also found
that ipratropium users had a significantly higher risk for a COPD-related ER visit (OR = 1.9,
95% CI: 1.1-3.2) or hospitalization (OR = 1.5, 95% CI: 1.2-2.0). Therefore, the authors
concluded that the higher acquisition cost of salmeterol was justified, since it prevented the
need for higher resource items like ER visits and hospitalizations, thereby showing no
differences in either COPD-related or total costs when compared to ipratropium. However,
the authors do mention the possibility that the ipratropium group was probably sicker due to
higher pre-index costs. Neither the study design nor the analyses attempted to account for
this possible source of selection bias. In addition, exacerbations not requiring
hospitalizations were not assessed, which has been shown in clinical trials to not differ
appreciably between these two therapy groups.
Two studies have assessed the costs and effects of ICS in COPD. One study conducted a
pharmacoeconomic analysis (Ayres, Price, & Efthimiou, 2003) alongside a six-month
clinical trial (Paggiaro et al., 1998) compared to usual care. Study results showed fluticasone
to be cost-saving when evaluated from a societal perspective (direct and indirect costs were
included), while it was cost-effective from a payer’s perspective (only direct costs were
included). The second study used a Markov model to answer the question of which
population of patients with COPD, based on disease severity levels, would most benefit from
treatment with ICS (Sin, Golmohammadi, & Jacobs, 2004). A Markov model was
constructed using a time horizon of three years and health states corresponding to disease
severity stages of COPD according to the American Thoracic Society (ATS)
criteria(American Thoracic Society, 1995). Four strategies were compared for patients with
COPD: treat no patients with ICS, treat all patients with ICS, treat only stage 2 or 3
(moderate-to-severe) patients with ICS, or treat only stage 3 (severe) patients with ICS. A
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0.01 difference in quality-adjusted life year (QALY) was found between treating no patients
with COPD with ICS or treating only the moderate and severe populations. The incremental
cost-effectiveness ratio was $11,000 per QALY gained for treating only severe patients, and
$17,000 per QALY gained for treating both moderate and severe patients compared to
treating no patients with COPD. Limitations of this analysis relate to assumptions of the
model such as rate of lung function decline due to ICS, and not accounting for adverse
effects.

Rationale for Use of West Virginia and Kentucky Medicaid Claims Data
Administrative claims databases have become important sources of data for
pharmacoepidemiologic research, which generally refer to effectiveness studies of drugs.
Randomized controlled trials are invaluable for determining the efficacy of drug therapies
that determine whether the drug works at all compared to no therapy or standard therapy.
These trials are usually conducted in a highly selected patient population, under a uniform
protocol, and increased monitoring. In contrast, effectiveness aims to assess the impact of
the drug in all subsets of the population for whom the drug in indicated, in different settings
where practice patterns vary from recommended guidelines, and on outcomes seldom
assessed in clinical trials such as overall medical costs.
The Medicaid program provides coverage for hospitalizations, ER visits, outpatient visits,
and prescription drugs. Thus, researchers can capture a person’s health care encounters over
a longitudinal time frame dependent on data availability, and determine inter-relationships
between different components of health care use. The Medicaid claims data will be used for
the proposed study, and is considered appropriate for several reasons. The outcomes of
interest in the study such as hospitalizations, exacerbations not requiring hospitalization, and
costs can be obtained from the database at a relatively low cost relative to that incurred in a
clinical trial. Also, the Medicaid program provides comprehensive prescription drug benefits
to a low-income population that rarely have other sources of prescription drug insurance, thus
ensuring minimal out-of-system prescription drug use. In COPD, additional use of
prescription drugs reflects greater severity, and hence the advantage of complete capture of
prescription drug use in the Medicaid database is important to the study design.
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The Medicaid program is a health insurance program for the indigent, disabled, and
members of families with dependent children, jointly funded by the federal and state
government. Thus, the population is relatively homogeneous, and represents a sub-group of
lower socioeconomic status. This is particularly relevant for the COPD population, since low
socioeconomic status is considered a risk factor for developing COPD, probably reflecting
exposures to indoor and outdoor air pollutants, crowding, poor nutrition, or other factors
related to socioeconomic status (Pauwels et al., 2001).
The Medicaid population of West Virginia and Kentucky will specifically be used for the
proposed study. These states are of particular importance given that COPD is the third or
fourth leading cause of death in both states (West Virginia, 2005; Kentucky, 2005). Also, the
western, mountainous states in the U.S. have the highest COPD death rates, while West
Virginia and Kentucky are the only two states in the South Atlantic Region that have rates as
high as these western states (NHLBI Fact Sheet, 2005). The presence of dual eligibility of
Medicaid patients in the Medicare system in those over 64 years of age does not allow
capture of all medical and prescription claims for this subset. Accordingly, the present study
will only be able to analyze data of those between 35 to 64 years of age. This can be
considered particularly relevant due to two reasons. The study population that includes the
states of West Virginia and Kentucky has one of the highest rates of smoking among youths,
which leads to a higher prevalence of COPD in a relatively younger population. Also,
demonstrating a beneficial impact of drug therapy on mortality will be particularly useful for
a younger population.

20

NEED FOR THE STUDY
Goals of management in COPD include lessening airflow limitation, preventing and
treating secondary medical complications, such as hypoxemia and infections, and decreasing
respiratory symptoms and improving HRQol. A fourth reasonable goal in a cost-conscious
environment is to use health-care resources efficiently given the enormous economic impact
of the condition (Pauwels et al., 2001). To facilitate this goal, economic information
regarding treatments should be made available for incorporation into treatment guidelines.
For example, information from earlier pharmacoeconomic analyses (Hilleman et al., 2000;
Jubran et al., 1993; Sclar et al., 1994) helped establish ipratropium as the drug of choice in
COPD that complemented earlier treatment guidelines (Friedman, 1995).
Recent developments such as the introduction of new bronchodilators and new evidence
of the importance of ICS have expanded pharmacotherapy options for managing COPD.
Guidelines are being updated and new evidence is being incorporated every year. For
example, the 2001 guidelines recommend regular treatment with long-acting bronchodilators
for moderate-to-severe COPD only on the basis that it was more convenient. The 2003
update now recommends regular treatment with long-acting bronchodilators for moderate-tosevere COPD given evidence that it was more effective and convenient than short-acting
bronchodilators. Pharmacoeconomic evidence supplements the development of guidelines,
and is required in a cost-conscious environment.
A lack of economic evaluation studies have been identified in the literature, primarily
because of a prior lack of pharmacotherapeutic options (Ramsey, 2000). Since 2002, there
have been a few pharmacoeconomic evaluations in COPD to address this gap in the
literature. Prior studies of the cost-effectiveness of COPD therapies, such as long-acting
beta-agonists, have not compared all relevant comparators simultaneously thus providing an
inadequate picture of their cost-effectiveness. Also, studies that did accommodate several
comparators have not assessed costs and lack assessment on other important outcomes.
Pharmacotherapies in COPD act through mechanisms other than improvement in FEV1 to
produce improvements in terms of symptom scores, exercise tolerance, quality of life, and
dyspnea. Therefore, several experts acknowledge that it is important to assess the
effectiveness of these therapies on outcomes other than physiologic measures (Gross, 2003).
Health care resources such as unscheduled doctor visits or ER visits, acute exacerbations, and
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mortality have been identified as important outcomes. Available literature using claims
databases have generally tended to focus on outcomes such as hospitalization and mortality.
Total resource use or exacerbations not requiring hospitalizations are stronger outcomes,
since they are relevant to the payer and patient, and also its use in assessing effectiveness of
therapies may have more power than those of the other outcomes (Burney et al., 2003).
A major disadvantage of conducting pharmacoeconomic studies using claims databases is
the lack of randomization between therapy groups. This leads to a selection bias with the
result that a more severe group may receive a particular type of therapy different from a less
severe group. The studies in COPD using claims databases have not used appropriate
techniques to account for a selection bias between patients receiving particular therapies.
Therefore, there is a need to conduct separate evaluations of pharmacotherapies in COPD
based on disease severity levels, using appropriate econometric techniques to account for
selection bias.
Prior to conducting an economic evaluation, a cost-of-illness study is important to
identify cost drivers in the Medicaid system. No study has yet been conducted in this
population, and is required given their low socioeconomic status. Furthermore, the high
prevalence and mortality rates in West Virginia and Kentucky justify using Medicaid data
from these states. Cost estimation of the COPD population by their asthma status will help to
identify high-risk groups if any, for targeted interventions.
This study will be conducted in three phases. Phase I will assess the costs incurred by
West Virginia and Kentucky Medicaid due to COPD, and also determine if a concomitant
diagnosis of asthma increases costs for recipients with COPD. Phase II will determine
clinically relevant and economic outcomes of maintenance pharmacotherapy in COPD, and
Phase III will determine the relationship between ICS use in COPD and mortality.
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STUDY GOALS AND OBJECTIVES

Phase I
The goal of Phase I is to identify costs incurred by recipients with COPD in the West
Virginia and Kentucky Medicaid populations.
Research Objective 1: To estimate mean incremental costs incurred due to COPD by
recipients enrolled in West Virginia and Kentucky Medicaid.
Research Objective 2: To compare mean COPD-related costs among recipients with COPD
with and without concomitant asthma enrolled in West Virginia and Kentucky Medicaid.

FIGURE 2: Conceptual Framework for Phase I
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Phase II
The goal of Phase II is to compare clinically relevant and economic outcomes among
alternative pharmacotherapy approaches for maintenance management of COPD.
Part 1
Research Objective 3: To compare the risk and frequency of exacerbations between
recipients with COPD who initiated maintenance therapy with ipratropium or monotherapy
with a long-acting beta-agonist.
Research Objective 4: To compare COPD-related costs between recipients with COPD who
initiated maintenance therapy with ipratropium or monotherapy with a long-acting betaagonist.
Part 2
Research Objective 5: To compare the risk of a severe exacerbation among recipients with
COPD who initiate therapy with a combination of an inhaled corticosteroid and a long-acting
beta-agonist, inhaled corticosteroid alone, inhaled long-acting beta-agonist alone, or only
short-acting bronchodilators.
Research Objective 6: To compare the frequency of moderate exacerbations among
recipients with COPD who initiate therapy with a combination of an inhaled corticosteroid
and a long-acting beta-agonist, inhaled corticosteroid alone, inhaled long-acting beta-agonist
alone, or only short-acting bronchodilators.
Research Objective 7: To compare COPD-related costs among recipients with COPD who
initiate therapy with a combination of an inhaled corticosteroid and a long-acting betaagonist, inhaled corticosteroid alone, inhaled long-acting beta-agonist alone, or only shortacting bronchodilators.

24

FIGURE 3: Conceptual Framework for Phase II
OUTCOMES
Exacerbations

Drug Therapy

COPD-related costs

Phase III
The goal of phase III is to determine the association between use of inhaled corticosteroid
12d all-cause mortality using two different study designs, and to ascertain if any association
found is mediated by exacerbations.
Research Objective 8: To compare the odds of exposure to inhaled corticosteroids between
those who died and those who did not die during the study period (case-control study design).
Research Objective 9: To conduct a mediation analysis to examine the relationship between
use of inhaled corticosteroid, exacerbations and death (cohort study design).
FIGURE 4: Conceptual Framework for Phase III
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STUDY SIGNIFICANCE
The proposed study will help to identify cost drivers and high-risk groups in the Medicaid
sub-population. These data can be used to develop targeted interventions, especially
smoking cessation programs for these sub-groups. In addition, the proportion of the COPD
population with concomitant asthma will be identified, which can provide an indication of
the appropriateness of therapy with ICS. Also, assessment of the effectiveness and costs of
therapies are particularly important in COPD currently due to the availability of new drugs.
The combination of ipratropium and albuterol or ipratropium alone is a relatively inexpensive
option for maintenance therapy in COPD. The high acquisition cost of long-acting betaagonists needs to be justified in terms of the outcomes when compared to the inexpensive
option of ipratropium. Evidence from observational studies regarding the impact of ICS on
mortality is not supported by clinical trials. This study will assess the impact of these drugs
on mortality, as well as attempt to provide an explanation for this effect by determining if
this effect is mediated through the effect of these drugs on exacerbations. This will provide
preliminary evidence for any beneficial effect that may be observed in future clinical trials of
ICS.
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CHAPTER 2: LITERATURE REVIEW
Chapter 2 provides an overview of the literature pertinent to the understanding of the
goals and objectives of the study. Specifically, this chapter provides an overview of the
disease state, outlines pharmacotherapeutic strategies for maintenance treatment, and
provides empirical evidence of the efficacy and effectiveness of pharmacotherapies.

INTRODUCTION TO THE DISEASE STATE- COPD

Pathogenesis, Pathophysiology, and Symptoms
One of the important aspects of the new COPD definition is acknowledgement of the fact
that inflammation is the driving mechanism behind the abnormalities noted in the airways,
parenchyma, and pulmonary vasculature of patients with COPD (Pauwels et al., 2001).
Inflammation results from inhalation of toxic substances, primarily chemicals in cigarette,
cigar, and pipe smoke. These substances activate inflammatory cells such as macrophages,
T-lymphocytes (CD8+), and neutrophils. The activated inflammatory cells in turn cause
elevated levels of proteases and certain cytokines such as leukotriene B4, interleukin (IL)-8
and tumor necrosis factor (TNF) –α, which are ultimately responsible for structural changes
in the airways (Briggs, Jr., 2004). These inflammatory mediators perpetuate the
inflammatory processes even after cessation of exposure to noxious particles. In addition to
inflammation, an imbalance of proteinases and antiproteinases in the lungs, and oxidative
stress are also considered to be important in the pathogenesis of COPD.
The inflammatory processes described above lead to pathologic changes in COPD that
occur in four compartments of the lungs to varying degrees in patients with COPD: central
airways (trachea, bronchi, and bronchioles greater than 2 to 4 mm in internal diameter),
peripheral airways (small bronchi and bronchioles less than 2mm in internal diameter), lung
parenchyma, and pulmonary vasculature (Pauwels et al., 2001). Changes in the central
airways include enlargement of mucus-secreting glands (mucus gland hypertrophy), and an
increase in the number of goblet cells associated with mucus hypersecretion (goblet cell
hyperplasia). The peripheral airways experience repeated cycles of injury and repair of the
airway wall that increases the collagen content and forms scar tissue. These changes modify
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the structure of the airway wall that narrows the lumen and produces fixed airway
obstruction. Destruction of the lung parenchyma involves dilatation and destruction of the
respiratory bronchioles generally characterizing emphysema. The result of this process is
that a loss of lung elastic recoil and intraluminal pressure occurs in the terminal airways, and
causes small airways to lose their patency leading to airflow limitation (Mannino, 2003).
This emphysematous destruction can occur diffusely in some parts of the lung or throughout
the entire lung depending on the stage of the disease. Thickening of the vessel wall occurs
because of increases in smooth muscle cells, proteoglycans and collagen, and infiltration by
inflammatory cells leading to pulmonary vascular changes.
Pathologic changes described above result in physiologic changes such as increases in
smooth muscle tone, mucus hypersecretion, cilia dysfunction, and airflow limitation (Briggs,
Jr., 2004). Patients with COPD can no longer exhale efficiently and, in response, lung
volume increases (pulmonary hyperinflation), especially during exercise, trapping air,
decreasing inspiratory capacity, and inducing dyspnea (breathlessness). For a patient with
advanced COPD, the complex of peripheral airways obstruction, parenchymal destruction,
and pulmonary vascular abnormalities reduces the lung’s capacity for gas exchange,
producing hypoxemia (reduced oxygen) and hypercapnia (increased carbon dioxide). This
defect in gas exchange is the primary reason for chronic respiratory failure. Pulmonary
hypertension is the major cardiovascular complication of COPD, and is associated with the
development of cor pulmonale. The physiologic changes noted in COPD give rise to
characteristic symptoms such as cough, sputum production, and dyspnea on exertion
(Pauwels & Rabe, 2004). Other relatively non-specific symptoms include wheezing and
chest tightness that may vary between days and over the course of a single day.

Risk Factors
Inflammation in COPD results from three categories of environmental risk factors:
tobacco smoke, occupational exposure, and indoor and outdoor air pollution (Pauwels et al.,
2001). Tobacco smoke is probably the only risk factor that has substantial evidence for a
causal rather than a statistical association with COPD risk. Cigarette smokers by far have
greater decreases in the annual rate of lung function decline, more respiratory symptoms, and
higher death rates than non-smokers (Anthonisen et al., 2002). Pipe and cigar smoking does
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not impact morbidity and mortality rates as high as cigarette smoking but it is still higher
than that due to not smoking (Pauwels et al., 2001). Intense exposure to occupational agents
such as dust, gases, irritants or fumes for sufficiently extended periods of time are associated
with an increased risk of developing COPD, independently of cigarette smoking (Kauffmann,
Drouet, Lellouch, & Brille, 1979). The effect is additive in the presence of cigarette
smoking. Pollution from outdoor sources is considered to be very small and has less
evidence compared to that from indoor sources. Indoor air pollution from biomass fuel,
burned for cooking and heating in poorly ventilated dwelling results in high levels of
particulate matter that activate the inflammatory processes in COPD (Behera & Jindal, 1991)
(Samet, Marbury, & Spengler, 1987).
The high variation in susceptibility of COPD between individuals has led to the belief
that there are genetic or host factors that are responsible for the development of COPD.
Individuals with a severe deficiency of α1-antitrypsin, a major inhibitor of serine proteases,
have increased risk of developing COPD (Konzem SL & Stratton MA, 2002). Smoking in
these individuals increases the risk appreciably, and also results in earlier age of onset
compared to similar individuals who do not smoke. Other host factors such as airway hyperresponsiveness and asthma are also identified as important risk factors (Pauwels et al., 2001).
Exposure to cigarette smoke and occupational agents are also known to cause an increase in
airway hyper-responsiveness, further demonstrating the interaction between host and
environmental factors. Abnormal lung growth during gestation or due to childhood
exposures is also considered a host factor (Stein et al., 1997) (Todisco et al., 1993) (Morgan,
1998).
Other environmental influences such as a history of severe childhood respiratory
infections leads to reduced lung function and increased respiratory symptoms in adulthood
(Pauwels et al., 2001). Also, low socioeconomic status is associated with an increased risk of
developing COPD (Prescott, Godtfredsen, Vestbo, & Osler, 2003). This variable may
probably reflect increased exposure to indoor and outdoor air pollution, crowding, or poor
nutrition (Prescott & Vestbo, 1999).
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Diagnosis and Severity Staging
A potential diagnosis of COPD should be considered in any patient who has cough,
sputum production, dyspnea, or a history of exposure to risk factors for the disease (cigarette
smoking, and/or exposure to environmental or occupational pollutants) (Pauwels et al.,
2001). Physiological confirmation of a diagnosis of COPD should be done using spirometry.
Spirometry measures the maximum volume of air forcibly exhaled from the point of maximal
inhalation (FVC) and the volume of air exhaled during the first second of this maneuver
(FEV1). The ratio of these two measurements is then calculated. A diagnosis of COPD is
confirmed in those with a post-bronchodilator FEV1 < 80% of the predicted value in
combination with an FEV1/FVC < 70%. The values of FEV1 and FVC are usually
represented as a percentage of predicted values of FEV1 because universally applicable
reference values for FEV1 and FVC are not available.
Once diagnosed, there are no widely accepted staging or severity scoring systems for
patients with COPD, and results of the spirometry testing are generally used for staging and
monitoring the disease course. The disease staging based on level of FEV1 and FVC is
intended to serve as a general approach to management due to the fact that management of
COPD is largely symptom-driven with only an imperfect relationship between the degree of
airflow limitation and symptoms (Jones et al., 2003a). Since spirometric tests measure only a
small aspect of the effects of COPD, additional testing such as measurement of lung
hyperinflation, and documentation of comorbidities such as chronic respiratory failure are
used to further determine the disease severity level of a COPD patient (Pauwels et al., 2004).
The recent GOLD severity staging system is based on post-bronchodilatory FEV1 values
(Table 2) (Fabbri & Hurd, 2003). It should be noted that only 18.5 percent of patients
classified as stage 0 actually progress to more severe airflow limitation at 15 years (Vestbo &
Lange, 2002).
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TABLE 2: Classification of severity of COPD
Stage

Spirometric Abnormality
% predicted FEV1
FEV1/FVC

Characteristic symptoms

0: At Risk

Normal

Normal

Cough, sputum production

1: Mild
COPD

> 80%

< 70%

With or without cough,
sputum production

2: Moderate
COPD

50% < FEV1 < 80%

< 70%

With or without cough,
sputum production,
dyspnea

3: Severe
COPD

30% < FEV1 < 50%

< 70%

With or without cough,
sputum production,
dyspnea

< 30%

< 70%

Cough, sputum
production, dyspnea

4: Very
Severe
COPD

Complications

Chronic
Respiratory
Failure

Adapted from Updated GOLD Guidelines 2003 (Fabbri et al., 2003).

Epidemiology
The available data on the prevalence, morbidity and mortality of COPD are considered to
under-estimate the total burden of disease primarily because the disease is usually diagnosed
after moderate advancement has occurred and clinical symptoms become apparent (Pauwels
et al., 2001). This section will specifically focus on estimates of prevalence, mortality and
economic burden in the U.S.
Prevalence
Prevalence estimates for COPD in the U.S. are generally obtained annually from the
National Health Interview Survey (NHIS) and in 1988 and 1994 from the National Health
and Nutrition Examination Surveys (NHANES) (Mannino, Homa, Akinbami, Ford, & Redd,
2002). The two differ in that estimates from the NHIS are based on a self-reported physician
diagnosis of COPD, while the NHANES is based on spirometric assessment. While the
estimates were certainly higher in the NHANES, the trends in prevalence rates by age and
race were similar in the two surveys. The prevalence rate for COPD overall (including both
chronic bronchitis and emphysema) increased with increasing age in both NHIS (2000) and
NHANES (1994) estimates. However, it should be noted that regardless of method of
prevalence assessment, 57 percent (NHANES) to 70 percent (NHIS) of individuals are
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between 25 to 64 years of age. Racial differences in prevalence rates are apparent with
whites having a higher prevalence rate than blacks. The NHIS showed higher prevalence
rates for females compared to males while the opposite was reflected in the NHANES.
Prevalence rates as ascertained from the NHIS for the components of COPD (chronic
bronchitis and emphysema) are presented for 2002 by demographic characteristics in table 3.
Different conclusions from the overall COPD prevalence can be noted for different
demographic categories. Most importantly, the prevalence of emphysema is appreciably
higher in those over 65 years of age and in males compared to those under 65 years and
females, respectively.
TABLE 3: Prevalencea of chronic bronchitis and emphysema by demographic characteristics in
2002
Demographic Category

Chronic Bronchitis

Emphysema

44.3

15.2

18-44

34.8

2.7

45-64

55.1

19.7

> 65

54.1

47.6

Male

29.3

18.5

Female

58.1

12.2

White

45.7

17.1

Black

46.1

8.3

Overall
Age (years)

Gender

Race

a

Rate per 1000 persons
Source: National Center for Health Statistics, National Health Interview Survey 2002 (American Lung
Association, 2004).

Mortality
Similar to prevalence data, mortality data also under-estimate COPD as a cause of death
as the disease is more likely to be cited as a contributory rather than an underlying cause of
death, or may not be cited at all. Evidence is available that shows that most decedents with
COPD have their deaths attributed to other causes, primarily cardiovascular. In 1998, only
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45 percent of decedents with COPD mentioned on their death certificates had COPD listed as
an underlying cause of death (Mannino et al., 1997). According to current estimates from the
National Heart, Lung and Blood Institute (NHLBI), COPD and allied conditions (includes
asthma and bronchiectasis) were the fourth leading cause of death in 2002 in the United
States (NHLBI, 2004). On a global level COPD was ranked as the sixth leading cause of
death in 1990 and is projected to rise to third by 2020 (Murray et al., 1997).
Based on estimates from the mortality component of the National Vital Statistics System,
the death rate of COPD in the U.S. using ICD codes specifically for COPD was 66.9 per
100,000 corresponding to 119,054 deaths in 2000 (Mannino et al., 2002). The impact of age
on death rate is exemplified in Figure 1 below. The death rates in whites are almost double
those of blacks (70.1 vs. 42.9 per 100,000, respectively). Males have a higher death rate
compared to females (82.6 vs. 56.7 per 100,000). One should note however, that the ageadjusted death rate for females has more than doubled from 1980 to 2000 from 20.1 to 56.7
per 100,000, whereas the age-adjusted death rate for males showed a modest increase from
73.0 to 82.6 per 100,000 during the same period. This trend can probably be attributed to the
increase in smoking among women since the 1940s (NHLBI Fact Sheet, 2005).

FIGURE 5: COPD death rates in the United States
Source: Mortality Component of the National Vital Statistics System (Mannino et al., 2002)
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Morbidity
The morbidity of COPD is reflected in the amount of direct and indirect costs used for the
management of COPD. Direct costs generally include physician visits, emergency room
(ER) visits, and hospitalizations. Indirect costs include lost productivity in the form of lost
workdays, and reduced productivity while at work. In 2000, COPD accounted for 726,000
hospitalizations as assessed from the National Hospital Discharge Survey (NHDS) with a rate
of 40.6 per 10,000 population (Mannino et al., 2002). Similarly, the National Ambulatory
Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care Survey
(NHAMCS) estimated a total of 7.9 million physician visits (45.0 per 1000) and 1.5 million
ER visits (87.2 per 10,000) in 2000, respectively (Mannino et al., 2002). The rates of
physician visits, ER visits, and hospitalizations in the elderly above 65 years are almost twice
the rates of those under 65 years. However, the COPD population under the age of 65 years
account for half of all outpatient visits, nearly two-thirds of ER visits and a third of all
hospitalizations for COPD (Mannino et al., 2002). Males and females do not differ in the
rates of hospitalizations, ER visits or physician visits. Although whites generally account for
the majority of hospitalizations, ER visits and physician visits, blacks tend to have
substantially lower physician visits and higher ER visits with relatively no difference in
hospitalization rates.
The limitation in airflow results in increase in lung volumes, subsequent dyspnea
(breathlessness), and decreased exercise tolerance. Thus COPD patients experience marked
dyspnea and general malaise that impair their ability to work, thereby rendering COPD as an
extremely disabling illness. Globally, COPD is projected to rank fifth in terms of days lost to
disability (Murray et al., 1997). In the U.S., COPD is responsible for 2.2 million disabilityadjusted life years (DALYs), and 0.5 million potential years of life lost. Generally
considered a disease of the elderly, COPD is moderately prevalent in the working age group
under 65 years (54% to 70%), and is responsible for considerable work loss. Analysis of the
1987 National Medical Expenditure Survey (NMES) showed that COPD patients averaged
3.6 lost workdays of which 28% were COPD-related (Strassels et al., 2001). The impact of
COPD on premature retirement was assessed in a study that determined the relationship
between presence of COPD and probability of labor force participation. In that study it was
assumed that absence of labor force participation was due to COPD by controlling for
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demographic (marital status, family size) and economic factors (education, area of residence)
that can impact this variable. The study showed that COPD patients were 3.9% less likely to
be in the labor force. Increasing severity of COPD was associated with decreased probability
of being in the labor force with mild, moderate and severe COPD patients having 3.4%, 3.9%
and 14.4% lower risk than non-COPD patients. The total absence from participation in the
labor force can under-estimate the impact of COPD on work loss since patients may work but
at reduced productivity levels. The impact on partial work loss or limited ability to work was
assessed in the Confronting COPD U.S. survey. In this study, a third of patients reported that
they were prevented from working due to COPD (Halpern et al., 2003). Eighteen percent of
these patients were limited in their ability to work normally, and 6% missed time from work
due to COPD. These patients reported an average of 18.7 lost workdays in the prior year.
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PHARMACOTHERAPY FOR MAINTENANCE TREATMENT OF COPD
COPD is defined as a partially reversible disease since FEV1 does not increase
appreciably after a trial of inhaled bronchodilators or oral corticosteroids (bronchodilator
reversibility testing). Even though the response to bronchodilator reversibility testing varies
among patients with COPD depending on the severity and nature of the lung damage, current
pharmacotherapy is recommended for all symptomatic patients. Several reasons exist for
justifying the use of drugs for COPD for patients who do not have appreciable increases after
bronchodilator reversibility testing (Konzem SL et al., 2002):


Tests of bronchodilator reversibility are variable and testing on one occasion does not
preclude eliciting a response on another occasion;



As described in earlier sections, COPD is a multi-system disorder. Pharmacologic agents
act through other mechanisms besides bronchodilation, and subjective relief of symptoms
alone provides value to the patient; and



Patients not responding to beta-agonists (type of drug often used for bronchodilator
reversibility testing) may respond to other classes of bronchodilators such as anticholinergics or methylxanthines.
Following the rationale for using drugs for COPD, the goal of pharmacotherapy is to

prevent and control symptoms, reduce the frequency and severity of exacerbations, improve
health status and exercise tolerance. Two broad categories of drugs are used for maintenance
treatment of COPD: inhaled bronchodilators and ICS. Table 4 provides the names of the
drugs by drug class and duration of action.

Medications for Maintenance Therapy of COPD
TABLE 4: Medications for maintenance therapy of COPD (Pauwels et al., 2001) (George, 2004)
BRONCHODILATORS
1. BETA-AGONISTS
Short-acting: Albuterol (Salbutamol), Fenoterol, Terbutaline,
Metaproterenol, Pirbuterol, Levalbuterol, Bitolterol,
Long-acting: Formoterol, Salmeterol
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2. ANTI-CHOLINERGICS
Short-acting: Ipratropium, Oxitropium
Long-acting: Tiotropium
3. METHYLXANTHINES
Theophylline, Aminophylline
INHALED CORTICOSTEROIDS
Budesonide, Beclomethasone, Fluticasone, Triamcinolone

1. Bronchodilators: There are three classes of bronchodilators that are commonly used for
COPD: beta-agonists, anti-cholinergics, and methylxanthines. There are substantial
differences in the mode and site of action within the cell among these drug classes
(Lipson, 2004). However, they are called bronchodilators because the primary effect of
all these classes of drugs is relaxation of airway smooth muscle (Pauwels et al., 2001). In
addition, improved lung emptying, reductions in residual volume and/or delay of the
onset of dynamic hyperinflation during exercise are other changes induced by this class
of drugs (Celli & MacNee, 2004). Except for methylxanthines, the inhaled route of
administration is preferred as opposed to oral administration due to lower side-effects.
Beta-agonists: Beta-agonists relax airway smooth muscle by stimulating β2-adrenergic
receptors, which increases cyclic adenosine monophosphate (cAMP) that produces
functional antagonism to bronchoconstriction (Lipson, 2004). Depending on duration of
the bronchodilation effect, this sub-group has further been categorized into short-acting
and long-acting bronchodilators (See table 3 for examples). Short-acting beta-agonists
have a rapid onset of action and a bronchodilatory effect for 4 to 6 hours (George, 2004).
Therefore, these agents are indicated only on an as-needed basis (Pauwels et al., 2001).
Long-acting beta-agonists are appropriate for maintenance therapy because of their
sustained bronchodilatory action for at least 12 hours (Dougherty, Didur, & Aboussouan,
2003). In addition, other non-bronchodilator effects of long-acting beta-agonists include
reduction in neutrophils (Bloemen et al., 1997), possible decrease in bacterial
colonization by increasing intracellular cAMP in the respiratory epithelium (Dowling,
Johnson, Cole, & Wilson, 1998) (Dowling et al., 1997), and increase in mucociliary
transport (Johnson & Rennard, 2001). Beta-agonists are generally safe medications, and
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have rare side-effects that include tremor, tachycardia, supraventricular arrythmias,
hypokalemia, and transient clinically insignificant decreases in arterial oxygen tension
(Tashkin et al., 2004). These side-effects are almost negligible with inhaled therapy, and
resolve rapidly after treatment withdrawal.
Anti-cholinergics: Anti-cholinergics usually exert their bronchodilatory effect by
competitively blocking the effect of acetylcholine on cholinergic receptors in bronchial
smooth muscle (Lipson, 2004). Also, since these receptors mediate mucus production,
antagonism by anti-cholinergics also reduces sputum production (Tashkin et al., 2004).
Similar to beta-agonists, there are short and long-acting forms of anti-cholinergics, each
having only one product in the U.S., ipratropium and tiotropium, respectively (George,
2004). The short-acting anti-cholinergic, ipratropium, has a slower onset of action and a
prolonged bronchodilator effect compared to short-acting beta-agonists. These features
have placed ipratropium as first-line maintenance therapy in COPD, and less suitable for
use on an as-needed basis for immediate relief (Friedman, 1995). The short half-life of
ipratropium has the disadvantage of frequent dosing. Tiotropium, on the other hand, has
a substantially longer duration of action (24 to 36 hours), and offers several benefits over
conventional therapies (Tashkin et al., 2004). The poor absorption of these agents limits
the adverse effects characteristic of anti-cholinergics, such as dryness of mouth, and
render these agents with an acceptable safety profile (Pauwels et al., 2001).
Methylxanthines: Methylxanthines produce bronchodilation primarily based on their
ability to inhibit phosphodiesterase which increases cAMP levels (Lipson, 2004). Other
mechanisms have been suggested and include inhibition of calcium ion influx into
smooth muscle, prostaglandin antagonism, stimulation of endogenous catecholamines,
adenosine receptor antagonism, and inhibition of release of mediators from mast cells and
leukocytes (Konzem SL et al., 2002). This class of drugs is not considered as preferred
treatment for COPD, and has been relegated to second tier status due to numerous
toxicity problems and frequent monitoring of supratherapeutic levels. The problem is
further compounded since most of the benefits of methylxanthines occur at higher doses,
and toxicity is dose-related.
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2. Inhaled corticosteroids (ICS): ICS in COPD target several aspects of the inflammatory
process in COPD, although this effect is much less prominent compared to asthma. The
mode of action of ICS in COPD is still not fully understood but they exert their beneficial
effects by binding to the intracellular glucocorticoid receptor to form a complex that
enters the cell nucleus to increase or decrease gene transcription (Sin et al., 2004). The
beneficial effect of ICS in COPD is only obtained at moderate to high doses that increase
the possibility of side-effects (George, 2004). Side-effects include skin bruising,
oropharyngeal candidiasis, cataracts, decreases in serum cortisol concentrations, and
decreases in bone density thus increasing the risk for fractures and osteoporosis (Sin et
al., 2003c).
Inhaled Corticosteroids in COPD: Beneficial or Not?
The controversy of whether ICS are beneficial in COPD can best be understood by
describing the inflammatory markers and mediators predominant in COPD, and those that are
significantly affected by ICS. Airways obstruction due to inflammation is a defining
characteristic of both asthma and COPD. However, there are distinct differences in
histologic and cellular characteristics of the inflammatory processes between the two
diseases (Barnes, 2000b). In asthma, airway inflammation results in a predominant increase
in eosinophils, and activation of mast cells and CD4+ T-cells (Decramer & Selroos, 2005).
On the other hand, airway inflammation in COPD shows an increase predominantly in
neutrophils, and activation of macrophages and CD8+ T-cells (Decramer et al., 2005). In
addition, cytokines are released by activation of these cells in both asthma and COPD.
However, in asthma, interleukin-4 (IL-4), IL-5, and IL-13 predominate as opposed to IL-8
and tumor necrosis factor-α (TNF- α) in COPD.
ICS are extremely effective in blocking the process of eosinophilic and mast cell
infiltration making them first-line therapy in asthma (Barnes, 1998). In contrast, there is
evidence that ICS may actually prolong survival of neutrophils, characteristic of COPD
inflammation by suppressing apoptosis of these cells (Keatings, Jatakanon, Worsdell, &
Barnes, 1997) (Culpitt et al., 1999). In addition, inflammatory cells like macrophages and
CD8+ and mediators such as IL-8 and TNF-α in COPD are shown to be steroid resistant. The
debate of the benefit of ICS results from conflicting evidence on several aspects. Contrary to
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the studies mentioned above, some studies contend that ICS reduce neutrophil inflammation
(Confalonieri et al., 1998) (Yildiz et al., 2000) and that increased levels of eosinophilic cells
are found in COPD (Balzano et al., 1999) (Pesci et al., 1998). Also, relatively large
concentrations of mast cells are present in the sub-epithelial layer of COPD airways
(Hattotuwa, Gizycki, Ansari, Jeffery, & Barnes, 2002), which are known to be affected by
ICS. Additional benefits on other inflammatory markers are also suggested (Calverley,
2000). This evidence and the fact that no single biochemical or cellular marker can
adequately describe the airway inflammation in COPD have led some investigators to
hypothesize that some aspects of the inflammatory process, but not all, can be modified by
ICS. However, other investigators disagree with this approach with the consequence of a
major controversy regarding these drugs (Barnes, 2000a; Calverley, 2000).
To estimate the benefits of ICS therapy in COPD, it is important to consider the
proportion of patients with COPD with asthma. A sub-group of patients with COPD that
exhibit a significant increase in FEV1 after oral corticosteroid administration are generally
described as patients with COPD with asthmatic features. This subset has been estimated to
constitute 10 percent of all patients with COPD (Calverley, 2000). However, the absence of
significant reversibility does not imply that these patients with COPD do not have asthma. A
recent population-based study analyzed medical records of all patients with COPD enrolled
in a health maintenance organization (HMO) in 1998 to estimate the proportional distribution
of the sub-types of COPD (Mapel et al., 2000b). They found that almost half (48.5%) of
patients in this COPD population had asthma as either their primary or secondary diagnosis.
It is important to note that almost all patients with COPD that had asthma listed as their
primary diagnosis had either severe asthma with fixed airflow obstruction or were current or
former cigarette smokers. Based on these findings, the authors concluded that most patients
with COPD will experience some benefit from ICS (Mapel, 2004; Mapel et al., 2000b).
Given the controversial role of ICS, it is important to determine the rate of use of this class of
drugs compared to other classes in the general COPD population.

Patterns of Pharmacotherapy Use in COPD
Introduction of long-acting forms of inhaled bronchodilators and recent evidence of the
beneficial impact of ICS in COPD have led to modifications in treatment algorithms for
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COPD. Studies of drug use patterns for COPD are presented in chronological order to enable
assessment of the shift in treatment practices, due to the introduction of new treatments and
evidence. Analysis of the National Medical Expenditure Survey (NMES) in 1987 by
Strassels et al. showed that the most commonly prescribed drugs for COPD in the U.S.
included xanthines (69.7%), and beta-agonists (46.5%). Ipratropium was used by only 2.6
percent of all individuals with COPD at that time (Strassels et al., 2001). The proportion of
subjects using ICS was not mentioned. Hilleman et al. analyzed 1993 and 1994 data on
hospital admissions, clinic visits, and pharmacy use at a university medical center in the U.S.
to determine the distribution of drug use by disease severity level as defined by the American
Thoracic Society (ATS) criteria (Hilleman et al., 2000). At the time of identification of the
patients in the study, 100 percent of patients in moderate and severe COPD were using
combination therapy (treatment with more than one drug) compared to 28 percent of patients
with mild COPD. In terms of drug type, use of inhaled beta-agonists was the highest (77% to
97%), followed by ipratropium (72% to 85%), theophylline, and steroids. Only 5 percent of
patients with mild COPD used steroids (inhaled or oral), increasing to 23 percent for patients
with moderate, and finally 100 percent for severe COPD. Interestingly, use of theophylline
was high, 55 percent, 80 percent and 79 percent in mild, moderate, and severe COPD,
respectively.
A group of researchers interviewed primary care physicians in Canada, and found that
although physicians could adequately distinguish between asthma and COPD conceptually,
their choice of initial drug therapy for these patients was remarkably similar (Kesten &
Chapman, 1993). Beta-agonists were chosen by 53 percent of physicians as initial therapy
for COPD versus 64 percent for asthma. Ten percent of physicians chose anti-cholinergics
for COPD as initial therapy compared with none for asthma, while 12 percent of physicians
chose ICS as initial therapy compared with 5 percent for COPD, thus signifying a relatively
small proportion adhering to recommended therapies for both disorders. These same
researchers conducted a retrospective chart review in 1994 of hospitalized COPD and asthma
patients to determine the medications used at admission to characterize patterns of drug used
in the community (Jackevicius, Joyce, Kesten, & Chapman, 1997). The results showed a
significantly higher proportion of asthma (48%) versus patients with COPD (35%) being
prescribed ICS at admission, whereas patients with COPD were 2.6 times more likely to use
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anti-cholinergics than asthma patients. These findings probably refute the authors’ prior
hypothesis that patients with asthma and COPD are treated similarly by Canadian physicians.
However, the authors expected the difference for inhaled corticosteroid prescriptions to be
larger based on the therapy recommendations at that time. Also, the population was
categorized as having stable or unstable COPD or asthma, based on the primary reason for
the inpatient admission. As such, the stable COPD sub-group was significantly less likely to
receive ICS than the other three sub-groups, which shows that the unstable COPD group may
appropriately have been prescribed ICS.
A study by Van Andel et al. in 1999 pooled data from ten clinical trials investigating
COPD conducted in the U.S. between 1987 and 1995 with a sample size of at least 150 and
comparable entry criteria. Data included the trial subjects’ use of medications in the six
weeks preceding trial enrollment (Van Andel, Reisner, Menjoge, & Witek, 1999) that is
considered to reflect the pattern of therapy as would be seen in clinical practice. The
proportion of patients in each trial using ICS, inhaled beta-agonists, inhaled anti-cholinergics,
oral theophylline, or oral corticosteroid was assessed. Except for inhaled beta-agonists,
significant changes in proportion of patients using a particular drug were seen for all other
types of drugs between 1987 and 1995. Most prominently, the percentage of patients with
COPD using ICS increased from 13.2 percent in 1987 to 41.4 percent in 1995, while those
using oral theophylline decreased from 63.4 percent to 29.0 percent during the same period.
During this time interval, the use of oral corticosteroids and oral beta-agonists decreased
moderately from 30.1 percent to 16.4 percent and from 11.7 percent to 4.5 percent,
respectively. The use of inhaled anti-cholinergics increased from 48.2 percent in 1989 to
53.8 percent in 1995, possibly reflecting the effectiveness of ipratropium. In trend analyses
adjusted for patient baseline severity and duration of disease, the direction of the trend for
inhaled corticosteroid and theophylline use remained significant, while that of other drug
classes were no longer significant. The authors concluded that medication use did not reflect
current treatment standards, since at the time of the study (1999) there was little evidence
regarding the efficacy of ICS for COPD, and theophylline was still considered an important
addition to the therapy of COPD. They attributed the high rate of inhaled corticosteroid use
in COPD to physicians’ perceptions that some benefit was obtained from using ICS. This
study did not report the use of medications by level of disease severity, which may have
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provided a better description of treatment patterns. For example, an increased use of ICS
may have been seen in those with greater disease severity.
Further insights into some characteristics of patients with COPD receiving specific drug
classes can be obtained from two database studies in Canada. Using a cohort of patients with
COPD over 65 years, the yearly prevalence of inhaled corticosteroid use (defined as the
presence of at least one prescription in a specific year) was assessed during a six year period
between 1990 and 1996 using administrative medical and prescription claims data from the
province of Quebec (Blais, Bourbeau, Sheehy, & LeLorier, 2004). The prevalence increased
from 42.2 percent in 1990 to 53.1 percent in 1995 (p = 0.001 test for trend). Determinants of
initiating therapy with ICS was assessed using a case-control study design, where cases were
defined as new users of ICS (defined as patients who were in the cohort for at least two years
before they filled their first prescription of inhaled corticosteroid). Determinants included
those with severe COPD (defined based on use of inhaled bronchodilators in the 3 months
preceding the index date), those with at least one exacerbation requiring medical evaluation
in the month before the index date, those who visited more than three different physicians in
the three months preceding the index date, and those who consulted a respirologist in the
month preceding the index date. Exacerbations were classified into five severity levels based
on the level of medical intervention needed. It was found that the likelihood of initiating
treatment with ICS increased as the intensity of medical intervention needed for the
exacerbation increased. The authors also determined persistency on treatment with ICS and
found that 54 percent were still using ICS after one year, and only 25 percent continued with
treatment for at least five years. Thus, they concluded that although the prevalence of ICS
use increased, the decrease in patient persistency may reflect a perceived absence of relief of
symptoms by patients with COPD using these drugs. However, the objective of this study
was not to assess the impact of ICS on symptoms, and the authors suggested that the costeffectiveness of ICS be evaluated.
Another study in the province of Manitoba compared drug use between patients with a
diagnosis of COPD only, a diagnosis of asthma only and a concomitant diagnosis of COPD
and asthma. Among patients with 6-9 physician visits, 30 percent of COPD only patients did
not receive any drugs compared to 10 percent of both asthma only patients, and COPD and
asthma patients (Anthonisen et al., 2005). In this study, patients with COPD only were
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significantly less likely to receive drugs compared to those with asthma or COPD and
asthma. Patients with COPD and asthma had comparable rates of prescription drug use as
those with only asthma. Consistent with recommendations, COPD only patients were
prescribed beta-agonists and steroids less commonly than asthma only patients (p<0.001),
while ipratropium was prescribed more often in COPD only patients (p<0.0001). Patients
with COPD and asthma had beta-agonist and ICS prescriptions similar to patterns of asthma
only patients, and patterns of ipratropium prescriptions similar to COPD only patients.
Based on prescription refill data, compliance rates for COPD only patients and COPD and
asthma patients were similar (54% vs. 56.4%), whereas asthma only patients had a
compliance rate of 31 percent.
Recent physician surveys have been conducted after publication of the GOLD guidelines
in Belgium, Switzerland, and Greece to determine adherence to guidelines for COPD
management. Only findings regarding pharmacologic management are mentioned in this
section. The Belgian study surveyed both general practitioners (GPs) and pulmonologists,
and found distinct differences in choice of therapy for a new COPD patient (Decramer,
Bartsch, Pauwels, & Yernault, 2003). Approximately 60 percent of GPs would prescribe
either a long-acting beta-agonist or an inhaled corticosteroid for a new COPD patient
compared to 40 percent of pulmonologists. On the other hand, a combination of a shortacting beta-agonist and a short-acting anti-cholinergic would be the first choice for 63
percent of pulmonologists compared to 35 percent of GPs. The fixed combination of a longacting beta-agonist and an inhaled corticosteroid was a first choice for 33 percent vs. 9
percent for GPs and pulmonologists, respectively. When prescriptions of ICS were analyzed
by recommended indications, 49 percent of GPs vs. 25 percent of pulmonologists prescribed
them to all patients with COPD while only 10 percent of GPs vs. 52 percent of
pulmonologists used it in the correct indication (FEV1 < 50% and repeated exacerbations).
The Swiss and Greek studies surveyed only primary care physicians. Forty-nine percent
of Swiss primary care physicians prescribed ICS regardless of indication although a higher
proportion (25%) prescribed these drugs systematically to patients with severe COPD
(Rutschmann, Janssens, Vermeulen, & Sarasin, 2004). Twenty-six percent and 53 percent of
Swiss physicians prescribed short or long-acting beta-agonists as first-line treatment for
COPD. Finally, a survey of Greek primary care physicians determined the proportions of
44

each drug class prescribed for patients with COPD rather than the number of physicians who
prescribed these categories of drugs (Trakada & Spiropoulos, 2000). Results showed that
among all COPD medications, the most common were inhaled beta-agonists followed by
ICS, whereas anti-cholinergics comprised only 8 percent of all COPD medications. The
study concluded that Greek physicians have relatively higher prescribing rates for ICS and
theophylline and lower rates for anti-cholinergics, in contrast to guideline recommendations.
The Confronting COPD survey assessed the burden of COPD on an international level in
patients with COPD or patients who met symptomatic criteria for COPD (Halpern et al.,
2003). Self-report information from patients in the U.S. revealed that 67 percent were taking
prescribed medications for COPD treatment. The most frequently used drugs were shortacting beta-agonists (44%), whereas a dismal 26 percent reported using anti-cholinergics.
Furthermore, the proportion of patients using theophyllines was higher (11%) than those
using long-acting beta-agonists (9%). ICS were used by a third of patients, which was a
lower proportion than that seen in Canada (Blais et al., 2004). The relatively lower
proportions in this study may reflect a factor of the study population rather than evidence of
under-treatment. The Confronting COPD U.S. study included a large majority of mild
COPD or undiagnosed patients that are generally excluded from database studies. Since
therapy is generally on an as-needed basis for this population, a lower than average rate of
drug use may be expected in this study.
This section provided details of patterns of drug use in patients with COPD, and evidence
showed a lower rate of use of anti-cholinergics and long-acting beta-agonists compared to
recommended guidelines. Also, almost half of patients with COPD were prescribed ICS.
This pattern was seen even in the two studies that actually measured prescription drug use in
patients with COPD without a history of asthma (Van Andel et al., 1999; Blais et al., 2004).
It is important to note that all of the above studies were conducted before November 2003, at
which point no ICS had yet been formally approved by the Food and Drug Administration
(FDA) for COPD. In November 2003, the combination product called Advair (inhaled
corticosteroid, fluticasone, and a long-acting beta-agonist, salmeterol) was the first product in
this class of drugs to be approved for COPD in the U.S. The well-established role of ICS in
asthma has probably contributed to perceptions that they may be useful for treatment of
COPD, and hence the increase in the off-label use of these drugs for COPD. The evidence of
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whether patients with COPD will benefit from treatment with ICS can only be ascertained
from randomized controlled trials and observational studies, and is discussed in section III.
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EFFICACY AND EFFECTIVENESS OF
MAINTENANCE PHARMACOTHERAPY IN COPD
The beneficial effect of maintenance pharmacotherapy in COPD needs to be evaluated on
various outcome measures by reviewing evidence from different study designs in the
literature. The evidence is presented from clinical trials, meta-analyses, and observational
studies for each outcome measure. Relevant outcome measures include annual decline in
FEV1, exacerbation frequency, and mortality. Other outcome measures such as lung function
indices other than FEV1, exercise tolerance, dyspnea ratings, symptom score, and healthrelated quality-of-life (HRQol) will not be discussed, since the present study will not be able
to assess these measures due to data availability. Some detail is provided below for
outcomes of mortality and exacerbations regarding their measurement in the literature.

Outcomes to assess pharmacotherapy effectiveness
Mortality: COPD is currently the fourth leading cause of death in the U.S. (NHLBI, 2004).
Thus, there is an interest in developing treatments that prevent mortality in COPD. Also,
mortality in COPD is frequently under-estimated as a majority of deaths in patients with
COPD are attributed to other causes such as cardiovascular, rather than due to COPD
(Mannino et al., 1997). Therefore, mortality as an outcome in COPD has been measured in
the literature as all-cause mortality, and not particularly restricted to COPD-related mortality.
Use of all-cause mortality also eliminates the issue of validity of cause of death from death
certificates, if administrative databases are used for the study (Burney et al., 2003).
Exacerbations: COPD is a progressive disease that is characterized by episodes of increased
severity of symptoms from the normal day-to-day fluctuations. These episodes are generally
called acute exacerbations of COPD, and are the result of a variety of causes including
bacterial and viral infections, pollution events, cold weather, and interruption of regular
treatment (Burge et al., 2003). Acute exacerbations of COPD lack a common definition,
because of their heterogeneous etiology and pathophysiology. Additionally, they exhibit a
variety of specific and non-specific symptoms (Rodriguez-Roisin, 2000). Specific symptoms
include increased dyspnea and/or wheeze, productive cough with altered sputum (amount and
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purulence), sore throat, and fever. Other non-specific symptoms include malaise, fatigue,
insomnia or sleepiness, and depression. Given the heterogeneous nature of exacerbations, a
recent recommendation from a consensus panel has defined exacerbations “as a sustained
worsening of the patient’s condition from the stable state and beyond normal day-to-day
variations that is acute in onset, and may warrant additional treatment in a patient with
underlying COPD” (Burge et al., 2003).
Ascertainment of exacerbations can be done using daily diary cards or retrospective
database sources (Burge et al., 2003). The daily diary card scores the severity of symptoms
relative to a baseline state, and defines the start of an exacerbation as a period of at least two
consecutive days when at least two symptoms have deteriorated. Exacerbations from
retrospective databases are usually identified based on the frequency of medical visits and/or
prescriptions for oral corticosteroids and antibiotics. Most clinical trials have thus
operationally defined exacerbations as a worsening of respiratory symptoms that require
treatment with oral corticosteroids or antibiotics, or both. A recent clinical trial adopted a
different approach to define exacerbations (Oostenbrink, Rutten-van Molken, Al, Van Noord,
& Vincken, 2004; Oostenbrink & Rutten-van Molken, 2004). Similar to other studies, a
COPD exacerbation was defined as a complex of respiratory symptoms (i.e. new onset of
worsening of more than one symptom such as cough, sputum, dyspnea, or wheeze) lasting
for at least 3 days. The difference though, was that the severity of the exacerbation classified
as mild, moderate or severe was based on ratings by the physician-investigator rather than the
patient. These ratings were based on the patient’s ability to function, and not on the intensity
of medical services or drugs used for treating the exacerbations.
Acute exacerbations of COPD occur with a frequency of approximately one per year. As
can be expected, this frequency depends on the underlying COPD severity, and some patients
with moderate-to-severe COPD experience on an average at least three exacerbations per
year. In the ISOLDE trial, 20 percent of patients with moderate-to-severe COPD did not
experience any exacerbation during the 3 year period (Burge et al., 2000). Acute
exacerbations of COPD are important, and are the primary target of intervention because of
their impact on physical, psychological and economic aspects of the disease (Wedzicha &
Donaldson, 2003). Repeated exacerbations of all severity levels contribute to a more rapid
decline in lung function and poorer HRQol (Seemungal et al., 1998; Donaldson, Seemungal,
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Bhowmik, & Wedzicha, 2002). When considering the cost of exacerbations though, severe
exacerbations are more important as they account for 90 percent to 95 percent of the total
costs of acute exacerbations of COPD (Niederman, McCombs, Unger, Kumar, & Popovian,
1999; Oostenbrink et al., 2004).
Table 5 elaborates on different definitions of an exacerbation used in observational
studies. These studies use administrative data to characterize a moderate or severe
exacerbation based on level of healthcare utilization, precluding identification of
exacerbations that do not require health care use.

TABLE 5: Definitions of exacerbations from observational studies of COPD
Study
1. de Melo et al. (de
Melo et al., 2004a).

Definition

Moderate exacerbation Prescriptions for a systemic antibiotic and an oral corticosteroid on the
same day.
Severe exacerbation Hospitalization with a primary discharge diagnosis of COPD
2. Fan et al. (Fan et al.,
2003)
Moderate exacerbation Outpatient visit with a primary ICD-9 code for COPD combined with a
new prescription for a 14 (or fewer) day course of either prednisone or
a commonly used antibiotic (amoxicillin, sulfa drugs, cephalosporins,
quinolones, tetracyclines, and macrolides) that was dispensed and
filled within 24-48 hours of the clinic visit.
Severe exacerbation Hospitalization with a primary discharge diagnosis of COPD
3. de Melo et al. (de
Melo, Ernst, &
Suissa, 2004b).
Type 1 Dispensing of a prescription for a systemic antibiotic
(aminoglycosides, cephalosporins, macrolides, penicillins,
fluoroquinolones, tetracycline derivatives or cotrimoxazole)
Type 2 Dispensing of a prescription for a systemic antibiotic and an oral
corticosteroid on the same day
Type 3 Hospitalization with a primary discharge diagnosis of COPD
4. Blais et al.
(Beauchesne,
Lalande, Fillion, &
Blais, 2005).
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Level 1 No exacerbations
Level 2 Exacerbation requiring only antibiotic treatment (ciprofloxacin 500 mg
or 750 mg, amoxicillin 250 mg or 500 mg, ampicillin 250 mg or 500
mg, trimethoprimsulfamethoxazole 20 mg to 100 mg, 80 to 400 mg, or
160 mg to 800 mg, cefaclor 250 mg or 500 mg, cefadroxil 500 mg,
cefixime 200 mg or 400 mg, cefprozil 250 mg or 500 mg, cefuroxime
250 mg or 500 mg, cephalexin 250 mg or 500 mg, azithromycin 250
mg, clarithromycin 250 mg or 500 mg, and erythromycin 250 mg or
more.
Level 3 Exacerbation requiring a course of oral corticosteroids with or without
antibiotics
Level 4 Exacerbation requiring a visit to an emergency department
Level 5 Exacerbation requiring hospitalization

Inhaled Bronchodilators: Long-acting Beta-agonists and Short-acting Anti-cholinergics
Ipratropium, a short-acting bronchodilator (anti-cholinergic) has been considered as firstline therapy in COPD before the introduction of long-acting bronchodilators. The recent
update to the GOLD guidelines suggests that long-acting beta-agonists and long-acting anticholinergics are more effective and convenient for maintenance therapy than the short-acting
anti-cholinergic, ipratropium, based on data from clinical trials (Fabbri et al., 2003). The
evidence for long-acting beta-agonists relative to ipratropium in particular is inconsistent,
and will be reviewed in this sub-section. The long-acting anti-cholinergic, tiotropium, cannot
be evaluated relative to ipratropium because the drug was launched in the U.S. in 2004 and
data for the proposed study is available only till 2003. The results of the Lung Health Study
established that inhaled bronchodilators do not modify the rate of decline of FEV1 or
mortality, and hence only exacerbations will be considered for this class of drugs.
Clinical Trials and Meta-Analyses:
Compared to numerous trials conducted in comparison to placebo, only four comparative
trials have been identified for the long-acting beta-agonists, salmeterol and formoterol, (two
each). All four trials were parallel group, 12-week trials, and included lung function,
dyspnea score, or exercise capacity as the primary efficacy variable (Mahler et al., 1999;
Rennard et al., 2001; Dahl et al., 2001; Wadbo et al., 2002). Only three trials (2 salmeterol
and 1 formoterol) have reported exacerbations as secondary outcomes that differed in the
definition and manner of reporting (Mahler et al., 1999; Rennard et al., 2001; Dahl et al.,
2001). The salmeterol studies generally used a definition based on need for medical
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treatment, while the formoterol study used a definition based on symptoms and need for
medical treatment. In the trial of Mahler et al., salmeterol had a significantly longer time to
an exacerbation relative to both ipratropium and placebo (Mahler et al., 1999). Also, the
proportions of patients experiencing exacerbations were lowest for salmeterol (20.7%)
compared to ipratropium (30.8%) and placebo (32.9%), which was not statistically tested.
Rennard et al. only considered exacerbations that required treatment with oral corticosteroids
for 14 days or less, and found that the proportion of patients with exacerbations did not differ
among the treatment groups (Rennard et al., 2001). Dahl et al. specified three levels of an
exacerbation (mild, moderate, and severe). Only the first level (mild exacerbations) reported
as percentage of bad days was significantly smaller in the formoterol treatment arm
compared to both placebo and ipratropium (Dahl et al., 2001).
Two studies have pooled data from clinical trials in a meta-analysis. However, these data
have been summarized for long-acting beta-agonists compared to placebo. Both metaanalyses have shown inconsistent results. Sin et al. pooled data from eight randomized,
controlled trials to determine the magnitude of risk reduction for exacerbations relative to
placebo. Of the eight trials, only one showed a significant reduction of 37 percent (Sin et al.,
2003c). The pooled risk ratio however, showed a significant reduction of 21 percent (RR:
0.79; 95% CI: 0.69 to 0.90). The second meta-analysis, a Cochrane review, concluded that
long-acting beta-agonists did not impact the rate of exacerbations compared to placebo
(Appleton, Poole, Smith, Veale, & Bara, 2002). Unlike the meta-analysis by Sin et al., the
Cochrane review restricted the pooled study population to those with <15% FEV1
reversibility after bronchodilator administration. Also, the review only included trials for
salmeterol, since data from formoterol trials were not yet published at the time of the review.
The study found an insignificant risk ratio of 0.69 (95% CI: 0.47 to 1.03) for 50µg of
salmeterol and 0.98 (95% CI: 0.64 to 1.52) for 100µg of salmeterol in the incidence of COPD
exacerbations.
One can hypothesize that patients with COPD with high symptom scores, high use of
rescue medications, high dyspnea scores, and poorer quality-of-life and lung function would
incur higher costs. Although a positive correlation has been established for quality of life
(Fan et al., 2002) and lung function as measured by FEV1 (Hilleman et al., 2000), the same
has not been shown for the other outcomes. However, it is plausible that patients with COPD
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who incur higher costs have high symptom scores, dyspnea scores, and use of rescue
medication. Thus, COPD-related costs can be considered a summative measure that
represents these outcomes. The proposed study seeks to compare long-acting beta-agonists
to ipratropium on COPD-related costs. Thus, data on lung function, exercise capacity,
dyspnea, symptom scores, and HRQol will be reviewed from the four trials comparing longacting beta-agonist to ipratropium mentioned above. The equal efficacy of long-acting betaagonists to ipratropium is also reflected in these four outcome measures. Of the four trials,
only one trial found significant differences between long-acting beta-agonists and
ipratropium in lung function. This trial reported normalized FEV1AUC (area under the
curve) at 12 weeks, and found a statistically significant difference of 57ml and 86ml between
ipratropium and 12µg of formoterol and 24µg of formoterol, respectively (Dahl et al., 2001).
However, the study also reported an a priori difference of 120 ml as clinically relevant,
which was not observed between formoterol and ipratropium. Another study of salmeterol
reported change in FEV1AUC from baseline at hourly intervals, and found salmeterol to be
statistically different from ipratropium at 4 and 6 hours after bronchodilator administration at
the end of 12 weeks (Mahler et al., 1999).
A timed walking test is a measure of functional exercise capacity that indicates the level
of dyspnea. Both salmeterol trials have found no differences between salmeterol and
ipratropium in either the distance walked or the post-walk dyspnea scores using the 6 minute
walking test (Mahler et al., 1999; Rennard et al., 2001). Formoterol also showed similar
results on exercise capacity as measured using the shuttle walking test, with 41 percent in the
formoterol group and 38 percent of patients in the ipratropium group reaching a clinically
significant improvement of >30 m after 12 weeks (difference between groups not statistically
significant) (Wadbo et al., 2002). Dyspnea scores using the Baseline Dyspnea Index (BDI)
and the Transitional Dyspnea Index (TDI) did not differ significantly between salmeterol and
ipratropium groups in both trials. Only one formoterol trial assessed daytime and nighttime
dyspnea scores using a symptom scale, and also found insignificant differences compared
with ipratropium (Wadbo et al., 2002).
Ipratropium and long-acting beta-agonists reported similar symptom scores at the end of
12 weeks in 3 trials (Mahler et al., 1999; Rennard et al., 2001; Wadbo et al., 2002). In one
trial, the daily symptom score was 0.3 units lower in the formoterol group (only for 12µg and
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not 24µg) compared to the ipratropium group that was statistically significant (Dahl et al.,
2001). Increase in symptoms necessitates increased use of rescue medications, measured as
daily number of puffs or inhalations. Therefore, the trials that showed no differences in
symptom scores also showed no differences in daily number of puffs or inhalations of rescue
medication required (Mahler et al., 1999; Rennard et al., 2001; Wadbo et al., 2002), while the
formoterol trial showed significant differences (Dahl et al., 2001). Dahl et al. showed the
mean daily number of puffs of inhaled albuterol during the treatment period to be 1.2, 1.7,
2.5, and 2.0 in the 12µg, 24µg formoterol, ipratropium and placebo group, respectively (Dahl
et al., 2001). Both doses of formoterol produced a significant reduction in the need for
rescue medication versus ipratropium (p< 0.014).
In terms of HRQol, no differences were seen in the total Chronic Respiratory
Questionnaire (CRQ) score between salmeterol and ipratropium (Mahler et al., 1999;
Rennard et al., 2001). Formoterol again showed inconsistent results on the St. George’s
Respiratory Questionnaire (SGRQ). The trial conducted by Dahl et al. found that formoterol
differed statistically from ipratropium by -3.79 units on total SGRQ score, less than the
minimum clinically important difference of four units (Dahl et al., 2001). The other
formoterol trial reported no statistically significant differences between groups (Wadbo et al.,
2002).
Observational Studies:
Two observational studies have compared the use of salmeterol relative to ipratropium on
exacerbations requiring hospitalization, using a similar cohort study design, but different
databases. Five therapy cohorts were compared based on initiation with an index
prescription during a defined period: ipratropium or combination of ipratropium and
albuterol, salmeterol alone, inhaled corticosteroid alone, combination of inhaled
corticosteroid and ipratropium, and combination of inhaled corticosteroid and salmeterol.
The presence of combination therapy was based on patterns of medication utilization defined
in the first 60 days after the index date. The first study used the Pharmetrics database, which
is a collection of managed care medical and prescription claims. The study found that the
use of salmeterol alone did not significantly impact the risk of a COPD-related
hospitalization compared to ipratropium (HR: 0.82; 95% CI: 0.59 to 1.13) (Burney et al.,
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2003). The second study using a state Medicaid database reported similar findings (HR:
0.76; 95% CI: 0.54 to 1.06) (Rascati et al., 2005).

Inhaled Corticosteroids
The decline in FEV1 will be discussed for ICS as the impact on this outcome affects
recommendations for use of these drugs in COPD, and is important to understanding the
impact of these drugs on mortality (Pauwels et al., 2001).
1. Annual Decline in FEV1
The rate of decline in FEV1 indicates progression of the disease, and is usually
represented as a negative number in ml/year. A treatment effect is defined as a unit
difference in the annual rate of decline between groups. Therefore, when comparing a
treatment to a placebo group a positive difference is evidence of a treatment effect. Almost
all studies measured rate of decline in FEV1 for each treatment group in terms of an FEV1
slope. This slope was obtained by averaging individual regression coefficients of a model
regressing FEV1 on time for each individual in the study. Thus, a treatment effect for each
study is determined by calculating a difference in FEV1 slope between treatment groups.
Clinical Trials and Meta-Analyses:
Two long-term, uncontrolled studies showed that systemic corticosteroids slowed the
progression of decline in lung function in patients with moderate-to-severe COPD. These
preliminary findings prompted the scientific community to determine the role of ICS for
COPD, since the inhaled route has a lower probability for long-term side-effects compared to
the systemic route. A number of long-term clinical trials have since then been conducted to
determine the impact of ICS on lung function decline. Earlier trials generally included
asthma patients, did not conduct an intent-to-treat analysis, or lacked sufficient power
(Dompeling et al., 1993; Rutten-van Molken, Van Doorslaer, Jansen, Kerstjens, & Rutten,
1995; Weir et al., 1999; Renkema et al., 1996). To elucidate the impact of ICS in COPD, it
was important to avoid confounding by the beneficial effect of ICS in asthma. Thus, clinical
trials conducted later, specifically used criteria to exclude patients with asthma based on a
diagnosis, evidence of atopy, or significant bronchodilator or steroid reversibility.
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A meta-analysis of three earlier trials with duration of at least 2 years, re-analyzed the
original clinical data of these trials for patients with COPD without evidence of asthma, who
had a mean FEV1 of 46% predicted (n=183 = 1/3rd of the total) (van Grunsven et al., 1999).
Results of the meta-analysis showed that treatment with ICS resulted in a difference of
+0.034 l/year in the annual rate of decline in pre-bronchodilator FEV1 (p=0.026). When the
treatment effect was analyzed by dose of inhaled corticosteroid, the estimate was +0.002
l/year (NS) for the low dose (800μg/day) and +0.039 l/year (p = 0.043) for the high dose
(1500μg/day - 1600μg/day). It should be noted that the sample size for the low-dose group
was only eight.
Following these preliminary findings, several major clinical trials have investigated the
impact of ICS on annual rate of decline in FEV1 in COPD-only patients (Vestbo et al., 1999;
Pauwels et al., 1999; Lung Health Study Group, 2000; Burge et al., 2000; Paggiaro et al.,
1998; Bourbeau et al., 1998). All of these trials showed a trend toward a lower rate of annual
decline in FEV1 among the treatment groups. None of these differences, which ranged from
a minimum of 2.8 ml/year to a maximum of 36.3 ml/year, achieved significance. Even
though a majority of the trials that included only patients with COPD without asthma showed
that use of inhaled corticosteroid did not significantly impact the rate of FEV1 decline, two
meta-analyses pooling data from these trials reached opposite conclusions (Highland et al.,
2003; Sutherland et al., 2003). A meta-analysis by Highland et al. pooled data from studies
by Renkema et al., Weir et al., the Copenhagen study, the European Respiratory Society
Study on COPD (EUROSCOP), the Lung Health Study (LHS), and the Inhaled Steroids in
Obstructive Lung Disease (ISOLDE) study (Highland et al., 2003). Data on a total of 3,571
patients were included (1,784 and 1,787 in the treatment and placebo groups, respectively).
A fixed-effects model was used to combine treatment effects from each study, and the
variance of each study was taken into account by weighting the pooled estimate of the
treatment effect. The pooled estimate for differences in FEV1 decline between groups was
found to be +5.31 + 3.0 ml/year (95% CI: -1.2 to 11.2 ml/year) showing a statistically and
clinically insignificant impact of ICS on progression of COPD. In addition, the study results
showed that the baseline FEV1 did not impact the significance or magnitude of treatment
effect. Thus, those that had a baseline FEV1 < 51% predicted showed a treatment effect of
+11 ml/year (95% CI: -1.0 to 23.1 ml/year), whereas those with baseline FEV1 > 51%
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predicted showed a treatment effect of +2.9 ml/year (95% CI: -4.3 to 10.1 ml/year). This is
important as the GOLD guidelines recommend use of ICS based on FEV1 levels. A doseresponse effect was not analyzed in this meta-analysis.
Five studies included in the meta-analysis by Highland et al. were also included in the
second meta-analysis by Sutherland et al. (Sutherland et al., 2003). A sixth study included in
the latter was the data from the meta-analysis conducted by van Grunsven et al. (van
Grunsven et al., 1999) which included the Renkema et al. study (Renkema et al., 1996).
Thus, this meta-analysis actually included data from subjects enrolled in eight individual
trials. A total of 3,715 patients were included in this study. Using a random-effects model
and in contrast to almost all trials that were included, a significant difference of +7.7 ml/year
(95% CI: 1.3 to 14.2 ml/year) was found, the clinical significance of which is questionable.
Although an explicit dose-response analysis was not conducted, a meta-analysis of trials with
high-dose steroid regimens showed a greater reduction of +9.9 ml/year (95% CI: 2.3 to 17.5
ml/year). Similar to the findings by Highland et al. (Highland et al., 2003), a non-significant
reduction in the rate of FEV1 decline of 18.3 ml/year (95% CI: -1.5 to 38.0 ml/year) was seen
for subjects with a baseline FEV1 < 50% predicted.
2. Mortality
Clinical Trials and Meta-Analyses:
Four major clinical trials have assessed the impact of ICS on mortality (Vestbo et al.,
1999; Pauwels et al., 1999; Burge et al., 2000; Lung Health Study Group, 2000). All four
trials showed a trend for reduced risk of mortality; however none found a significant effect.
The primary outcome of all these trials was the annual rate of FEV1 decline. None conducted
a power analysis to determine if they had sufficient power to detect a difference in the
mortality outcome. A meta-analysis by Alsaeedi et al. combined data from these trials, and
similarly found an overall trend for decreased risk of 0.84 (95% CI: 0.6 to 1.18) (Alsaeedi et
al., 2002). Another scientific review pooled mortality data and found an insignificant
reduced risk for mortality of 0.78 (95%CI: 0.58 to 1.05) (Sin et al., 2003c).
Observational Studies:
In contrast to the above evidence, a few observational studies have found ICS to reduce
mortality by 25 percent to almost 75 percent. One of the first observational studies by Sin
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and Tu analyzed data on hospital discharges, ER and outpatient visits, and prescription
medications for residents of Ontario to determine the relationship between use of ICS and
mortality in elderly patients with COPD who were recently hospitalized for their disease (Sin
et al., 2001). A longitudinal cohort study design was used in which the exposed and nonexposed groups were defined as those being prescribed or not being prescribed ICS within 90
days of discharge from an index hospitalization, respectively. Follow-up began on the date
of discharge of the index hospitalization and continued till death occurred. The study results
showed that after adjusting for relevant covariates, patients who received ICS had a 29
percent lower risk of death compared to the control group. One of the main limitations of the
study was that the follow-up started from the date of discharge of the index admission. Thus,
although events were counted from this date for the non-exposed group, events for the
exposed group were counted from the date of receipt of the prescription of inhaled
corticosteroid. This aspect of the study design creates a particular kind of bias called
immortal time bias which basically refers to the creation of an immortal time period for the
exposed group. This period is created as a result of the definition of exposure status, and is
termed immortal because no events can be counted for the exposed group during this time
period. This bias has the effect of increasing the number of events counted in the nonexposed group, thereby under-estimating the risk ratio. This bias was exemplified using the
same study design but with another database by Suissa et al. (Suissa, 2003). In response to
Suissa’s analysis, the authors addressed the impact of immortal time bias by excluding all
who died within the first 90 days of discharge. The results did not change with relative risk
estimates for all-cause mortality 0.79 (95% CI: 0.71-0.88).
Sin et al. also analyzed the impact of varying doses (low, medium and high) of ICS on
mortality over a 3 year follow-up period from the date of an index hospitalization (Sin et al.,
2003a). In this study design, the exposure was defined as having any prescription for an ICS
anytime from the date of discharge of the index hospitalization to the end of follow-up (date
of death or 3 years). A daily dose was computed using the total amount dispensed for the
first prescription and the period of time elapsed between the first two prescriptions. Since all
ICS were considered, the daily dose was calculated in terms of beclomethasone equivalents.
The cohort was then categorized into five mutually exclusive categories: not dispensed, low
(< 500μg/day), medium (501-1000μg/day), high (> 1000μg/day), and indeterminate dose.
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Similar to the previous analysis, therapy with ICS showed a 25 percent reduction in all-cause
mortality rate. When analyzed by dose level, those on low-dose, medium-dose or high-dose
experienced a 23 percent, 52 percent and 45 percent reduction in all-cause mortality
compared to those who did not receive any ICS. The authors tried to address immortal time
bias by performing a subgroup analysis excluding all patients who had less than 90 days, 6, 9
and 12 months of follow-up, and hence a lower probability of receiving ICS. However, in
this case, the follow-up time was 3 years. Thus, there is a slight possibility that those who
were categorized as not receiving ICS were classified as such because they died. This has
the impact of increasing the events in the non-exposed group and a consequent treatment
effect for the exposed group.
Another group of researchers using the UK General Practice Research Database (GPRD)
assessed the impact of fluticasone, an ICS, on mortality (Soriano et al., 2002). A cohort
study design was used by defining drug exposure on an intent-to-treat basis. Thus, users of
fluticasone were physician-diagnosed patients with COPD who received at least three
prescriptions for these drugs over an initial 6-month period. The reference group comprised
patients who had not received ICS since diagnosed with COPD, but had at least three
prescriptions for other COPD-related drugs over an initial 6-month period. To address the
issue of immortal time bias, patient follow-up time only started a day after the 6-month
period during which exposure was assessed and continued till the patient died or 3 years were
complete. The adjusted survival analyses showed that the use of fluticasone alone resulted in
a 38 percent reduction in mortality risk over a 3 year period compared to the reference group.
An additional analysis comparing the use of any ICS demonstrated a class effect with an
adjusted survival rate of 77.9 percent. A secondary objective of the study was to assess if a
dose-dependent effect on survival could be demonstrated. To assess this objective, a nested
case-control study design was used. The total number of prescriptions during the entire
period of follow-up was used to calculate the cumulative amount of exposure to each
treatment type, and then assess a mean annual exposure to treatment. The results of the doseresponse analysis mirrored the results of the cohort study design. The use of each additional
annual prescription of fluticasone significantly reduced the risk of death by 13 percent.
These same authors further conducted another analysis using the study design by Sin et al. to
assess the use of ICS on death or re-hospitalization (Soriano et al., 2003). Thus, exposure
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was defined as use of at least one prescription for an ICS within 90 days after a first (index)
hospitalization for a COPD-related condition. Follow-up was assessed from the date of
discharge of the index hospitalization to a maximum of 1 year after this date or till death or
re-hospitalization occurred. In this study, immortal time bias was addressed by restricting
the analyses to patients who survived for a period of 30 days after the index hospitalization.
Adjusted survival analyses showed that the use of ICS alone reduced the risk of rehospitalization or death by 16 percent. A separate risk ratio for death was not computed.
Two more studies assessing the impact of ICS on mortality were conducted. The results
of these two studies were not formally published but were published as part of a paper from a
symposium discussing the issues of observational studies in COPD (Burney et al., 2003).
Therefore, details of the study designs are not available, and only certain results are
mentioned. One study was conducted by researchers in the Netherlands using data from the
Integrated Primary Care Information (IPCI) database. A similar cohort design used in the
study by Soriano et al. (Soriano et al., 2002) was used where exposure was defined as having
at least two prescriptions of fluticasone after a COPD diagnosis. To ensure that patients had
at least moderate-to-severe COPD, patients 50 years of age and older were required to have
at least two bronchodilators. Study results showed that exposure to fluticasone significantly
reduced the risk for mortality by 66 percent (Hazards ratio (HR) =0.34; 95% CI: 0.18 to
0.66), a risk reduction more than twice as high than that seen in the study by Soriano et al.
(Soriano et al., 2003; Soriano et al., 2002). The other study in the U.S. used administrative
databases from two health maintenance organizations (HMO). A cohort design was used
where a person was considered exposed if they had at least 90 days (not necessarily
consecutive) of prescription fills. Study results showed a significant survival advantage for
exposure to ICS (HR=0.59; p=0.0001). However, the impact of ICS alone on mortality was
no longer significant when the cohort was restricted to those without a prior diagnosis of
asthma (HR=0.74; p=0.1).
Unlike the observational studies described above, and similar to the findings of
randomized controlled trials, two studies did not find a protective effect of ICS on mortality.
These studies used specific study designs or analytical techniques that would account for
immortal time bias. The first study by Suissa et al. was described earlier (Suissa, 2003).
Another study by Fan et al. used medical and prescription claims data from a Veterans
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Affairs health system (Fan et al., 2003). The patients were identified if they had an
outpatient clinic visit or a hospitalization with a primary or secondary diagnosis of COPD
between February 1997 and December 1999. This visit date was then considered the index
date, and defined their time of entry into the cohort. To ensure that these were patients with
COPD, only those over 45 years of age and with at least one pulmonary medication in the 90
day period before the index visit were included. Study subjects were required to have a
minimum of a year of follow-up to assess the outcome of death. A cohort study design was
used using three methods to define exposure to ICS depending on timing of drug use. In all
three methods, a person was considered exposed if prescriptions were filled for more than 80
percent of days during a defined time interval of 90 days. Thus, exposure was defined in
terms of baseline use, average use and recent use. Immortal time bias was accounted by
using the concept of a 90-day interval before event occurrence to determine exposure status.
Survival analysis using time-dependent methods showed that exposure to ICS was not
associated with a decrease in mortality, regardless of the dose of ICS used (low/high).
Although the rate ratios were less than 1 showing a trend towards decreased mortality, a null
effect was found with confidence intervals including 1. The timing of drug use (baseline,
average, or recent) did not impact the magnitude or direction of the risk ratios.
3. Exacerbations
Clinical Trials and Meta-Analyses:
The meta-analysis by van Grunsven et al. found ICS to modify the rate of FEV1 decline
but did not find any beneficial effect on the rate of exacerbations. The treatment group had
0.9 exacerbations per year and the placebo group had 1.0 exacerbation per year (van
Grunsven et al., 1999). They attributed the lack of effect to differences in definitions of
exacerbations among the included trials. Alsaeedi et al. conducted a meta-analysis by
combining data from six recent randomized, placebo-controlled trials of at least six months
duration using the DerSimonian-Laird random-effects model. Of the six trials, two showed
no reduction in risk (Vestbo et al., 1999; Bourbeau et al., 1998) while four showed
statistically significant effects (Burge et al., 2000; Paggiaro et al., 1998; Weir et al., 1999;
Lung Health Study Group, 2000) as calculated from data in the published studies by the
authors. Of the four studies that showed an effect in the meta-analysis, published articles of
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two of the trials did not show any differences in exacerbations. One of the trials showed a
trend towards decreased exacerbations that was not statistically significant (Weir et al.,
1999). The primary reason was that the sample size was very low (n = 98). For the second
trial, the meta-analysis defined exacerbations as hospitalization for respiratory conditions,
and calculated a significant risk reduction of 0.46 (95% CI: 0.26 to 0.80). However, the
published article of this trial did not clearly define nor specify exacerbation as an outcome
measure (Lung Health Study Group, 2000). This article reported that there were no
significant differences between the treatment groups in unscheduled visits, ER visits, or
hospitalizations.
Like the meta-analysis by van Grunsven et al., the definitions of exacerbations also
differed among all the included trials (Alsaeedi et al., 2002) in the meta-analysis by Alsaeedi
et al. However, the latter showed that the use of ICS led to a 30 percent reduction in
exacerbations with a relative risk = 0.70 (95% CI: 0.58 to 0.84). The test for heterogeneity
was significant (p=0.03), indicating that the effects varied among studies. The Copenhagen
City Lung Study was primarily responsible for the heterogeneity, and reported a risk ratio of
0.96 (95%CI: 0.77 to 1.20) (Vestbo et al., 1999). This may have been due to the study
definition of an exacerbation (more cough or phlegm than usual instead of worsening of
symptoms with the need for additional medication). Exclusion of this study further lowered
the relative risk to 0.67 (95% CI: 0.63 to 0.71) without evidence of heterogeneity. A doseresponse effect could not be demonstrated because of the similarity in doses used in the trials,
and neither was a separate analysis done based on disease severity. Another recent scientific
review (Sin et al., 2003c) by some of the same authors who conducted the above metaanalysis, combined data from all six trials included in the above meta-analysis as well as an
additional study (van, V, Monninkhof, van der, Zielhuis, & van Herwaarden, 2002) published
in 2002. Summary effect estimates of the review showed a 24 percent reduction in
exacerbations with a risk ratio of 0.76 (95% CI: 0.72 to 0.80).
The lack of effect in the Copenhagen study (Vestbo et al., 1999) has also been attributed
to the mild disease severity level of the clinical trial population. This led to the hypothesis
that the beneficial effect of ICS may be modified by disease severity. Evidence from two
sources reveals that ICS significantly reduced the risk for exacerbations in those with
moderate-to-severe COPD compared to patients with mild COPD. A secondary analysis of
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the ISOLDE clinical trial data showed that the total exacerbation rate differed significantly
between the fluticasone and placebo group (1.47/year vs. 1.75/year) in patients with
moderate-to-severe COPD (< 50% FEV1 predicted) (Jones, Willits, Burge, & Calverley,
2003). On the other hand, patients with mild COPD with > 50% FEV1 predicted showed no
difference in total exacerbation rate (fluticasone: 0.67/year and placebo: 0.92/year).
Although not an explicit comparison, the scientific review mentioned above (Sin et al.,
2003c) noted that the Copenhagen City Lung study (Vestbo et al., 1999), which had the
highest mean FEV1 value (2.38L), failed to demonstrate a beneficial effect of ICS on
exacerbation rate compared to the other studies which had a mean FEV1 < 70% predicted.
Data from the clinical trials that have demonstrated a beneficial impact of ICS on
exacerbations also showed that this impact was more prominent for moderate to severe than
mild exacerbations. A six-month trial conducted by Paggiaro et al. (Paggiaro et al., 1998)
that assessed the effect of fluticasone propionate on the rate of exacerbations, showed no
significant differences in the total number of patients who had at least one exacerbation or
the total number of exacerbations. However, a significantly higher proportion of patients in
the placebo (86%) compared to the fluticasone group (60%) experienced a moderate-tosevere exacerbation. Similar to the trial by Paggiaro et al., the proportion of patients in the
ISOLDE trial experiencing at least one exacerbation was not different between the treatment
groups (Burge et al., 2000). However, among patients experiencing moderate exacerbations
(exacerbations requiring oral corticosteroids), the number of patients was reduced by 50
percent in those treated with fluticasone compared to placebo, regardless of the underlying
COPD severity. Thus, results from these studies suggest that ICS may significantly impact
the severity of the exacerbation but not the overall frequency.
Discontinuation of ICS therapy has been shown to be detrimental for patients with COPD
as seen in a recent clinical trial called COPE. The COPE study enrolled patients from an
outpatient pulmonary clinic to assess the impact of discontinuing maintenance therapy with
inhaled fluticasone (van, V et al., 2002). In this study, 244 patients were treated with inhaled
fluticasone (1000μg/day) for four months. After this phase, 123 were randomized to
continue and 121 to discontinue with their fluticasone therapy for 6 months. Unlike the
previous studies, where difference in the exacerbation rate was assessed, the outcome in this
study was risk of a first and second exacerbation after discontinuation. A hazard ratio of 1.5
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(95% CI: 1.05 to 2.1) for a first exacerbation and of 2.4 (95% CI: 1.5 to 3.9) for a second
exacerbation in favor of the fluticasone group was found. Also, 21.5 percent of patients in
the placebo group experienced recurrent exacerbations compared to 4.9 percent in the
fluticasone group. Effect modification based on disease severity was also seen in this study
with the hazard ratio of a first exacerbation for those who discontinue fluticasone being 2.1
(95% CI: 1.1 to 3.6) among patients with FEV1 < 50% predicted compared to 1.2 (95% CI:
0.8 to 2.0) among those > 50% predicted.
Observational Studies:
Observational studies have provided conflicting evidence regarding the impact of ICS on
the risk of exacerbations. Some of the observational studies that assessed the impact of ICS
on death discussed in the previous section have also assessed the impact on exacerbations.
Four studies focused on exacerbations that require hospitalizations, and found a significant
effect. Similar to their findings on mortality, Sin et al. (Sin et al., 2001) and Soriano et al.
(Soriano et al., 2003) found that ICS reduced the risk of an exacerbation requiring a
hospitalization by 24 percent and 16 percent, respectively. Another study attempted to
compare hospitalization risk of various initial treatment regimens using the Pharmetrics
database (Burney et al., 2003). The study results showed that compared to the ipratropium
therapy cohort, patients treated with ICS alone reduced the risk for a COPD-related
hospitalization in the 12-month follow-up period by 29 percent. Analysis of a state Medicaid
database using a similar cohort design as the Pharmetrics study found a 16 percent reduction
in risk of hospitalization that was not statistically significant (HR:0.84; 95% CI: 0.69 to 1.03)
(Rascati et al., 2005).
Two observational studies did not find a significant impact of ICS on exacerbations. Fan
et al. found an insignificant effect of ICS on exacerbations requiring hospitalization (Fan et
al., 2003). Bourbeau et al. analyzed administrative data of the Saskatechewan universal
healthcare system using a nested case-control study design (Bourbeau et al., 2003), and
reached the same conclusion as Fan et al. A nested case-control uses the case-control
analytical technique within a cohort of patients. The cohort in this study included patients
with COPD on regular therapy with COPD-related drugs and those with a first
hospitalization with a primary diagnosis of COPD, ensuring a moderate-to-severe subgroup
of patients with COPD. The outcome of interest was a re-hospitalization for COPD, and thus
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the case patients were defined as those who were re-hospitalized with a primary diagnosis of
COPD. Use of ICS was defined in relation to the timing of the outcome (re-hospitalization)
and in terms of dose. Thus, any use was defined as the dispensing of one or more
prescriptions in the year prior to the index date. Current use was defined as a prescription
being dispensed within 60 and 30 days of the index date for the high-dose and low-dose
formulations, respectively. Past use was defined as the exposure for subjects with any use
but not current use. In addition, similar to the dose-response analysis by Sin et al., a mean
daily dose was calculated in the prior year, and categorized as < 400μg/day, 401-800μg/day,
and > 800μg/day. Conditional logistic regression analysis revealed that exposure to ICS
defined as any, current or past use did not result in any benefit in preventing exacerbations
requiring hospitalizations. This result is in direct contrast to the afore-mentioned studies, and
does not support findings from a few randomized controlled trials of ICS (Burge et al., 2000;
Paggiaro et al., 1998).
Acute exacerbations in COPD are defined as an increase in symptoms of COPD that
often require a change in regular medication. These exacerbations, regardless of whether
they require hospitalization, are important since they impact morbidity and quality of life
(Seemungal et al., 1998; Donaldson et al., 2002). Only two studies assessed the impact of
ICS on exacerbations that do not require hospitalization, and found no effect. A study
conducted by de Melo et al. using the Saskatechewan database, assessed the impact of ICS
on the rate of a first acute exacerbation (de Melo et al., 2004a). Thus, a cohort of patients
with COPD was defined by selecting individuals > 55 years who had received at least three
prescriptions for COPD-related medications during a year, between January 1, 1990 and
December 31, 1997, and who had not experienced an acute exacerbation before this criteria
was met. On cohort entry, individuals were followed from the date of the third prescription
to the date of a first exacerbation, death, emigration from the province, or December 31,
1999 to allow for a minimum follow-up of 2 years. The first occurrence of an acute
exacerbation was chosen as the outcome of interest since recurring exacerbations cause a
persistent deterioration in overall well-being, and hence it was felt important to determine if
ICS could delay the time to a first acute exacerbation. An acute exacerbation was defined in
terms of the extent of healthcare use based on the availability of data. A moderate
exacerbation was defined by prescriptions for a systemic antibiotic and an oral corticosteroid
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on the same day, whereas a severe exacerbation was defined as a hospitalization with a
primary discharge diagnosis of COPD. A nested case-control design was used where cases
were defined as those who experienced an acute exacerbation. Use of ICS was defined
similar to the study by Bourbeau et al. in terms of any use, current use, and past use. The
only difference was that a prodromic phase of a COPD exacerbation was considered as a
period of 15 days before the occurrence of an exacerbation during which dispensing of an
ICS could occur. This period was excluded for defining any and past use, while current use
was analyzed by including and excluding this period. Results of the conditional logistic
regression analysis showed that exposure to ICS defined in terms of any use, current use and
past use exhibited an increase in the risk for a first exacerbation. Thus, rate ratios ranged
from 1.27 to 1.52 to describe the increased risk of a first exacerbation due to ICS.
Similar to these findings, Fan et al. also assessed the effect of ICS on exacerbations not
requiring a hospitalization and found a null effect. In contrast to the definition used by de
Melo et al. (de Melo et al., 2004a), Fan et al. (Fan et al., 2003) defined moderate
exacerbations as outpatient visits with a primary ICD-9 code for COPD combined with a new
prescription for a 14 (or fewer) day course of either prednisone or a commonly used
antibiotic (amoxicillin, sulfa drugs, cephalosporins, quinolones, tetracyclines, and
macrolides) that was dispensed and filled within 24-48 hours of the clinic visit.

Combination of Inhaled Corticosteroid and a Long-Acting Beta-Agonist
Long-acting beta-agonists and ICS have different mechanisms of action, and target
different aspects of the pathophysiologic processes in COPD. Therefore, it is hypothesized
that their combination can be expected to have a synergistic or additive effect. Molecular
evidence of this interaction between the drug classes shows that corticosteroids increase beta2 receptor synthesis through which long-acting beta-agonists exert their action, and longacting beta-agonists prime the glucocorticoid receptor for steroid-dependent activation and
nuclear translocation (Sin et al., 2004). Two combination products have been evaluated in
clinical trials. One combination product consisting of the long-acting beta-agonist salmeterol
and the ICS, fluticasone has recently been approved by the Food and Drug Administration
(FDA) for COPD. The other combination product, not yet approved by the FDA for COPD,
includes the long-acting beta-agonist formoterol and the ICS, budesonide. At least four
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randomized, clinical trials have been conducted to determine if the interaction effect of this
combination translates into important outcomes such as reductions in exacerbations and
mortality. Some of the observational studies discussed in the prior section analyzing the
effectiveness of ICS, have also assessed the impact of the combination of ICS and longacting beta-agonists. Therefore, the study designs will not be reiterated in this section, and
only results of the combination therapy will be detailed.
1. Exacerbations
Clinical Trials and Meta-Analyses:
Three randomized clinical trials that have assessed the impact of combination therapy on
the rate of exacerbations have found a significant reduction compared to placebo therapy,
with reductions ranging from 25 percent to 30 percent (Calverley et al., 2003a; Calverley et
al., 2003b; Szafranski et al., 2003). Moderate exacerbations were defined as worsening of
symptoms requiring treatment with antibiotics and/or oral corticosteroids, while severe
exacerbations were generally those requiring hospitalization for respiratory conditions. Only
one study found that combination therapy also significantly reduced the risk for mild
exacerbations (Szafranski et al., 2003). They defined mild exacerbations as days with at least
four inhalations of reliever medications above the mean use, and were calculated from daily
diary cards. These trials also individually assessed the impact of combination therapy on
exacerbations requiring only oral corticosteroid courses, and found risk reductions of higher
magnitude ranging from 31 percent to 45 percent compared to the risk reduction for overall
exacerbations (Szafranski et al., 2003; Calverley et al., 2003a; Calverley et al., 2003b).
Three meta-analyses pooled data from these trials. Sin et al. pooled data from two trials
that assessed the impact of the combination of budesonide/formoterol and another of
fluticasone/salmeterol on exacerbations, and found that combination therapy reduced the risk
by 30 percent (RR=0.7, 95% CI: 0.62 to 0.78) (Sin et al., 2003c). A second meta-analysis
conducted later by Sin et al. pooled data from four trials, including those from the previous
analysis (Sin et al., 2004). However, one of the trials (Mahler et al., 2002) that was included
in estimating the pooled risk ratios of reduced exacerbations withdrew patients if they
experienced more than one exacerbation resulting in hospitalization or treated with an
inhaled or oral corticosteroid. This criterion could reduce estimation of any treatment effect.
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It is unclear how the inclusion of this study affected the pooled risk ratio of exacerbations.
However, the proportions withdrawn due to exacerbation were similar across treatment
groups in that trial (Mahler et al., 2002). This meta-analysis showed that the combination of
ICS and long-acting beta-agonists resulted in a 48 percent reduction in exacerbations (95%
CI: 60% to 32%). Unlike the other meta-analyses discussed so far, a Cochrane review
pooled data from three clinical trials (Calverley et al., 2003a; Calverley et al., 2003b;
Szafranski et al., 2003) that had similar definitions of exacerbations, and found a
significantly reduced risk of 24 percent for combination therapy compared to placebo
(RR=0.76; 95% CI: 0.68 to 0.84) (Nannini et al., 2003). Thus, magnitude of risk reduction of
25 percent to 30 percent for moderate to severe exacerbation from two meta-analyses mirror
that obtained in the original trials for combination therapy of ICS and long-acting betaagonists.
It is also important to know the effectiveness of the combination compared to the
monotherapy components to determine any additive or synergistic effects. Most of the data
from the clinical trials showed no difference in reducing exacerbations between the
combination therapy and the ICS component. Only one trial reported a significant risk
reduction of 22.7 percent for exacerbations for the combination therapy when compared to
ICS monotherapy (Szafranski et al., 2003). Pooled risk ratios from two meta-analyses,
showed no difference in the rate of exacerbations. Similar magnitudes of risk ratios were
noted in these studies; Sin et al. (Sin et al., 2003c): RR=0.90 (95% CI: 0.80 to 1.02) and
Cochrane review (Nannini et al., 2003): RR=0.91 (95% CI: 0.81 to 1.02). Another metaanalysis by Sin et al. however, found a significantly lower risk for exacerbations compared to
that of ICS alone (RR=0.74; 95% CI: 0.55 to 0.99) (Sin et al., 2004).
The data comparing the combination therapy to the long-acting beta-agonist component
however, shows significant differences. Two trials found that combination therapy (both
were budesonide/formoterol) had a significant risk reduction of 23 percent to 31 percent
compared to the long-acting beta-agonist (Szafranski et al., 2003; Calverley et al., 2003b).
Results from all three meta-analysis showed that combination therapy was significantly
better compared to long-acting beta-agonist alone. Pooled risk ratios reported were: Sin et al.
(Sin et al., 2003c), 0.8 (95% CI: 0.71 to 0.90); Sin et al. (Sin et al., 2004), 0.67 (95% CI: 0.51
to 0.89), and the Cochrane review (Nannini et al., 2003), 0.85 (95% CI: 0.77 to 0.95).
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Observational Studies:
Observational studies have assessed the impact of combination therapy on only severe
exacerbations requiring hospitalizations, and not moderate exacerbations. One study by
Soriano et al. assessed the impact of receiving a prescription for a combination therapy of
ICS and long-acting beta-agonist within 90 days of a hospitalization on a combined outcome
of re-hospitalization or death (Note: Separate risk ratios for these outcomes were not
reported). A 41 percent reduction in risk was found for this dual outcome (Soriano et al.,
2003). Two studies using similar cohort designs compared hospitalization risk of various
initial treatment regimens (Burney et al., 2003) relative to ipratropium. One study used the
Pharmetrics database, which is a collection of medical and prescription claims from several
managed care plans (Burney et al., 2003). The study results showed that compared to the
ipratropium therapy cohort, patients with the combination of ICS and salmeterol had the
greatest risk reduction (74%) in the 12-month follow-up period. The other study used a state
Medicaid database (Rascati et al., 2005), and found that the combination of ICS with
salmeterol had a significant risk reduction of 35 percent (HR=0.653; 95% CI = 0.43 to 0.99)
similar in magnitude to the study by Soriano et al. (Soriano et al., 2003). As can be noted,
this risk reduction was borderline significant. It is not clear why the magnitude of the risk
reduction seen in the Pharmetrics study was almost twice as high compared to that seen in
clinical trials and the other observational studies.
The observational studies do not provide results comparing the combination therapy with
ICS monotherapy or long-acting beta-agonist monotherapy. However, the presence of any
additive or synergistic effects can be ascertained by the magnitude of risk reduction relative
to the reference group using only short-acting bronchodilators. Two of the three
observational studies mentioned above found a significant risk reduction for the combination
therapy and ICS monotherapy compared to the reference group using only short-acting
bronchodilators. The risk reduction for combined outcome of re-hospitalization or death
relative to a reference group using short-acting bronchodilators in the Soriano study for the
combination therapy and ICS monotherapy was 41 percent and 16 percent (Soriano et al.,
2003). The Pharmetrics study also reported a higher risk reduction for the combination
therapy than that obtained with ICS monotherapy compared to ipratropium (74% vs. 29%,
respectively) (Burney et al., 2003). The Medicaid analysis found a significant risk reduction
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for the combination therapy, but an insignificant risk reduction of 16 percent for ICS
monotherapy compared to ipratropium (Rascati et al., 2005).
All the three observational studies found insignificant risk reductions for the long-acting
beta-agonist monotherapy (salmeterol) compared to the respective reference group. In the
study by Soriano et al., an insignificant effect was observed for salmeterol and a significant
effect for the combination therapy on the dual outcome of death or hospitalization compared
to a reference group using short-acting bronchodilators (Soriano et al., 2003). Thus, the
addition of ICS may be responsible for a survival advantage, where one may not be present
for long-acting beta-agonist monotherapy such as salmeterol. It should be noted that the
reference group in the other two observational studies was ipratropium, and the insignificant
reductions in those studies may reflect the fact that long-acting beta-agonists are as effective
as ipratropium (Burney et al., 2003; Rascati et al., 2005).
2. Mortality
Clinical Trials and Meta-Analyses:
In the second meta-analysis by Sin et al., mortality was also assessed as an outcome (Sin
et al., 2004). Three of six trials assessed mortality as a secondary outcome, and did not
provide information regarding the power to determine differences. However, pooling data
from these trials showed a trend towards lower mortality compared to placebo. (RR=0.66;
95% CI: 0.32 to 1.38). These findings are in contrast to that obtained from three
observational studies that contradict clinical trial findings.
Observational Studies:
Two studies by Soriano et al. assessed the impact of combination fluticasone and
salmeterol on mortality using two different study designs using the UK General Practice
Research Database (GPRD) (Soriano et al., 2002; Soriano et al., 2003). One study that
assessed the combined outcome of death and re-hospitalization was already discussed in the
section on the impact of the combination therapy on exacerbations, and will not be repeated
here (Soriano et al., 2003). The other study used physician-diagnosed patients with COPD,
and defined exposure based on the receipt of at least three prescriptions during an initial sixmonth period (Soriano et al., 2002). Treatment cohorts were defined based on the type of
drugs received during this period. Patients were followed after the six-month period until
69

three years or until the death of the patient. The adjusted survival analyses showed that the
combined use of fluticasone and salmeterol resulted in a 52 percent reduction in mortality
risk over a 3 year period compared to the reference group using only short-acting
bronchodilators. An additional analysis comparing the use of any ICS with salmeterol
demonstrated a class effect with an adjusted survival rate of 82.1 percent. A secondary
objective of the study assessed the presence of a dose-dependent effect on survival using a
nested case-control design. The total number of prescriptions during the entire period of
follow-up was used to calculate the cumulative amount of exposure to each treatment type,
and then assess a mean annual exposure to treatment. The use of each additional annual
combined prescription of fluticasone with salmeterol significantly reduced the risk of death
by 13 percent.
Two more studies assessing the impact of ICS and long-acting beta-agonists on mortality
were published as part of a paper from a symposium discussing the issues of observational
studies in COPD (Burney et al., 2003). A cohort study using claims data from two HMOs in
the U.S. defined a person using a combination of an ICS and long-acting beta-agonist as one
that had a total of at least 90 days (not necessarily consecutive) of overlapping prescription
fills of the two drugs, or of the combination product. Study results showed a significant
survival advantage for exposure to combination therapy similar to the findings of Soriano et
al. Furthermore, the magnitude of the hazard ratios for the combination therapy ranged from
0.34 to 0.11, which suggests a 66 percent to 89 percent reduction in mortality, substantially
higher compared to the Soriano et al. studies. The second study conducted by researchers in
Netherlands using data from the Integrated Primary Care Information (IPCI) database, used
the cohort design similar to that of Soriano et al.(Soriano et al., 2002). Exposure was defined
as having at least two prescriptions of the salmeterol, fluticasone, or a combination of
salmeterol and fluticasone after a COPD diagnosis. Study results showed that exposure to
fluticasone and salmeterol significantly reduced the risk of mortality by 63 percent
(HR=0.37; 95% CI: 0.21 to 0.67).
The combination therapy was shown to have a higher reduction in mortality risk
compared to using ICS alone in both the Soriano studies and the U.S. HMO study (Soriano et
al., 2003; Soriano et al., 2002; Burney et al., 2003). The IPCI study, however, reported
similar reductions in risk for both therapies. In one study by Soriano et al. the use of
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combination therapy reduced the risk of death by 52 percent while using ICS monotherapy
reduced the risk by 38 percent compared to the reference group using only short-acting
bronchodilators (Soriano et al., 2002). The dose-response analysis also showed higher risk
reduction for the combination therapy as seen in the Kaplan-Meier survival curve, however
no specific values were reported. The U.S. HMO study reported a risk reduction of 66
percent and 41 percent for the combination therapy and ICS monotherapy, respectively
(Burney et al., 2003). However, when the study population was restricted to those without a
prior diagnosis of asthma, the combination therapy remained significant with a risk ratio of
0.11 (89% reduction), while that of ICS alone was no longer significant (HR=0.74). The
IPCI study showed a significant risk reduction of approximately 64 percent for both groups
(Burney et al., 2003).
Both the cohort and the dose-response analyses in the study by Soriano et al., showed an
increased trend for survival, albeit insignificant for the use of salmeterol alone compared to
the reference group (Soriano et al., 2002). The U.S. HMO study was probably the only one
that showed the use of salmeterol alone significantly impacted mortality (HR=0.55; p=0.02)
compared to a reference group using short-acting bronchodilators and no ICS (Burney et al.,
2003). This effect however, disappeared when the study population was restricted to those
without a prior diagnosis of asthma (HR=0.57; p=0.1). The IPCI study did not report results
for salmeterol (Burney et al., 2003).
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CHAPTER 3: METHODOLOGY
Chapter 3 outlines the methodology used for conducting the three phases of the study.
The study sample, study design, and analyses are specific to each study objective, and are
individually detailed for each study objective. All phases of the study however, had a
common data source: paid medical and prescription claims from West Virginia and Kentucky
Medicaid. A description of the data source and the data cleaning procedures is provided
below. All raw claims data were manipulated through various processes in order to extract
relevant information using SAS v. 9.1.3. Statistical analyses were conducted using STATA
9.0 and SPSS 13.0.

DATA DESCRIPTION & VARIABLE EXTRACTION

Data Source
A list of raw claims data files used for the study in both states is provided in Table 6.
The Bureau for Medical Services of the West Virginia Department of Health and Human
Resources (WV-DHHR) provided the data for WV Medicaid. Similarly, the Kentucky
Department of Medicaid Services of the Kentucky Cabinet for Health and Family Services
(KY-CHFS) provided the data for KY Medicaid. Data are available from July 1, 1997 to
June 30, 2003 for WV Medicaid and from January 1, 1998 to December 31, 2003 for KY
Medicaid. Three main types of files were obtained for each state: medical claims, pharmacy
claims, and eligibility files. All claims data were linked by an encrypted identification
number to protect recipient confidentiality. Three types of medical claims were available:
UB-92, HCFA-1500 files, and Nursing home claims files. The first two types of files
included first and last dates of service, International Code of Diseases-Clinical Modification
(ICD-9 CM) diagnosis codes, Current Procedural Terminology (CPT) procedure codes, claim
(extract) indicator, and total amount paid. Additionally, the UB-92 file included revenue
codes, and Diagnosis Related Group (DRG). The nursing home claims files only included
first and last dates of service, and total amount paid. Each record of the prescription claims
data included details of a drug filled such as National Drug Codes (NDC), date dispensed,
quantity dispensed, days’ supply, and total amount paid. The eligibility files included
72

demographic information for recipients such as date of birth, gender, race, county, and dates
of enrollment. In addition to these three types of files, there were three files with provider
information, drug information, and procedure code information, details of which are provided
in Table 6.

TABLE 6: List of raw claims data files
File Name

Details

File Name

West Virginia

Details
Kentucky

UB-92 claims

July 1, 1997 to
June 30, 2003

UB-92 claims

January 1, 1998 to
December 31, 2003

HCFA-1500
claims

July 1, 1997 to
June 30, 2003

HCFA-1500 claims &
Homehealth care claims

January 1, 1998 to
December 31, 2003

Nursing home
claims

July 1, 1997 to
June 30, 2003

Nursing home claims

January 1, 1998 to
December 31, 2003

Prescription
claims

July 1, 1997 to
June 30, 2003

Prescription claims

January 1, 1998 to
December 31, 2003

Medicaid
eligibility file

Eligibility information
until June 30, 2003

Medicaid eligibility file

Eligibility information
until December 31,2003

Managed care
eligibility file

Eligibility information
until June 30, 2003

Managed care
eligibility file

Eligibility information
until December 31,2003

Provider file

Provider number
Provider specialty

Provider file

Provider number
Provider specialty

Procedure file

CPT code
Procedure name

Procedure file

CPT code
Procedure name

Drug file

NDC code
Generic code
Drug name

Drug file

NDC code
Generic code
Drug name
Therapeutic class code
Therapeutic class name

Data Cleaning
The UB-92 claims file contain facility claims for inpatient visits, emergency visits, and
outpatient encounters, whereas the HCFA-1500 claims file contain claims submitted by
health care professionals for services rendered in the outpatient (physician office or hospital
outpatient), emergency room, and home-healthcare settings. These two files were
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manipulated using the following algorithm to classify all claims for hospitalizations,
emergency room (ER) visits, and outpatient encounters:
For WV Medicaid:
1. Hospitalization claims in the UB92 file were identified by the presence of a DRG
code not equal to ‘000’. Also, some claims related to a hospitalization such as those
of professional services e.g. surgeon’s fees will be present in the HCFA1500 file.
These claims were identified by using recipient identification number (ID) and date of
admission information, and included in the “final hospitalization claims” file.
2. ER claims in the UB-92 file were identified by the presence of revenue codes 450459. It is important to note that not all of the claims occurring during an ER visit will
have this code since other line items will have revenue codes depending on the
service/procedure provided. Hence, all claims identified to be occurring for an
individual on the same date as that of claims with revenue code 450-459 will be
included in the final ER claims file. Similar to hospitalization scenario, all those
claims occurring on the same date for an individual for an ER visit in the HCFA1500
file will be included in the final ER claims file. ER visits for which no claim exists in
the UB92 file, but claims exist in the HCFA1500 file, were identified by the presence
of CPT procedure codes 99281-99285, 99288, and all claims occurring on the dates
of these claims are included in the ER file. The “final ER claims” file included all the
claims identified from both UB92 and HCFA1500 files.
3. Outpatient claims in the UB92 file were identified as those not classified as related to
either a hospitalization or ER visit, and constitute claims for services provided in an
outpatient setting (e.g. outpatient clinic, home-healthcare use, and physician office).
Similarly, outpatient claims in the HCFA1500 file were identified as those not
classified as related to either a hospitalization or ER visit. The “final outpatient
claims” file included all the claims identified from both UB92 and HCFA1500 files.
For each ID, the number of unique dates constituted the total number of outpatient
encounters for that ID. An outpatient encounter is defined as any service that
generated a CPT code other than 99281-99285, 99288. For outpatient claims, if all
the claims for an ID and date were for laboratory or transportation, then these were
excluded from the count of outpatient encounters.
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4. ER visits occurring on the same date as that of a hospitalization usually indicate that a
decision was made to hospitalize the person based on the ER visit. Hence, all claims
from the “final ER claims” file that met this criterion were transferred to the “final
hospitalization claims” file.
5. The WV Medicaid medical and prescription files had duplicate claims reflecting the
claim adjudication process (such as line items that reflect reversed claims), and were
appropriately deleted from the database.
For KY Medicaid:
1. Hospitalization claims in the UB92 file were identified using the INOUT
indicator=’IN’ (DRG not available in KY files). Also, some claims related to a
hospitalization such as those of professional services (e.g. surgeon’s fees) will be
present in the HCFA1500 file. These claims were identified by using ID and date of
admission information, and included in the “final hospitalization claims” file.
2. ER claims in the UB-92 file were identified using the ERIND indicator=’Y’. Similar
to hospitalization scenario, all those claims occurring on the same date for an
individual for an ER visit in the HCFA1500 file will be included in the final ER
claims file. ER visits for which no claim exists in the UB92 file, but claims exist in
the HCFA1500 file, were identified by the presence of CPT procedure codes 9928199285, 99288, and all claims occurring on the dates of these claims are included in
the ER file. The “final ER claims” file included all the claims identified from both
UB92 and HCFA1500 files.
3. ER visits occurring on the same date as that of a hospitalization usually indicate that a
decision was made to hospitalize the person based on the ER visit. Hence, all claims
from the “final ER claims” file that met this criterion were transferred to the “final
hospitalization claims” file.
4. Outpatient claims in the UB92 file were identified as those not classified as related to
either a hospitalization or ER visit, and constitute claims for services provided in an
outpatient setting (outpatient clinic, home-healthcare use, physician office, etc).
Similarly, outpatient claims in the HCFA1500 file were identified as those not
classified as related to either a hospitalization or ER visit. The “final outpatient
claims” file included all the claims identified from both UB92 and HCFA1500 files.
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For each ID, the number of unique dates constituted the total number of outpatient
encounters for that ID. An outpatient encounter is defined as any service that
generated a CPT code other than 99281-99285, 99288. For outpatient claims, if all
the claims for an ID and date were for laboratory or transportation, then these were
excluded from the count of outpatient encounters.

Measurement of Independent Variables
The multivariate analyses for all phases of the study controlled for several confounding
factors, and can be grouped into categories such as demographics, comorbidity, and COPD
severity. A description of these covariates follows, and use of these covariates as appropriate
is mentioned in the analyses section of each phase.
Demographics
1. Age: Calculated as the age at the index date for each phase of the study.
2. Gender: The field ‘recipient gender’ in the Medicaid eligibility file was used to identify
recipient’s gender.
3. Race: The field ‘recipient race’ in the Medicaid eligibility file was used to identify a
recipient’s race. Race was classified as ‘White’, ‘Black’, and ‘Other’.
4. County_smokerate: The county_smokerate is a dichotomous variable of the smoking
prevalence rate of each recipient’s county with values of 0 = < 31% and 1 = > 31%. The
cutoff of 31% was chosen based on the distribution of values in the data. The field
‘recipient county’ was obtained from the Medicaid eligibility file. County smoking
prevalence rates were obtained from statewide-county level Behavioral Risk Factor
Surveillance System (BRFSS) data (WVBPH, 2005; KYDPH, 2001; KYDPH, 2002;
KYDPH, 2003; KYDPH, 2004). The BRFSS is a telephone health survey sponsored by
the Centers for Disease Control and Prevention (CDC) and conducted by each state in the
U.S. every year. Current smoking prevalence was obtained in response to the BRFSS
question: “Have you smoked at least 100 cigarettes in lifetime and now smoke every day
or some days”?
5. State: Data were compiled from two state Medicaid programs: WV and KY for Phase II
and III of the study, and the variable denotes the residential state of each recipient.
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Comorbidity
1. COPD-related comorbid disorders: The presence of seven specific conditions found in
higher prevalence in recipients with COPD, and considered to increase healthcare costs
for recipients with COPD was determined by presence of a diagnosis on a medical claim
(Grasso et al., 1998; Ward et al., 2000). These conditions include upper respiratory tract
infections2, lower respiratory tract infections3, septicemia, allergic rhinitis, other diseases
of the lung4, congestive heart failure, and disorders of fluid, electrolyte, and acid-base
imbalance.
2. Charlson comorbidity index with D’Hoore modification (D’Hoore-CCI): The Charlson
index is a validated method of classifying comorbidity to predict short-term and longterm mortality from medical records (Charlson, Pompei, Ales, & MacKenzie, 1987). The
index, as computed, assigns weights (obtained empirically based on relative-risk
estimates for death) for 19 major conditions that an individual may have in addition to
COPD (see table 7 below). Thus, the index score is the total of assigned weights, and
represents a measure of burden of comorbid disease. Therefore, if a person has no
chronic conditions then the CCI index score will be 0. If a person has dementia, ulcer
disease, and metastatic solid tumor then the CCI index score will be 1+1+6=8. Thus, the
higher the index score, the more chronic conditions are present. The CCI is computed
using the ICD-9 CM codes which include the fourth and fifth digits (Deyo, Cherkin, &
Ciol, 1992). The D’Hoore modification on the other hand, uses the ICD-9 CM codes
with only the first three digits for these conditions(D'Hoore, Bouckaert, & Tilquin, 1996).
The D’Hoore-CCI was computed excluding diagnosis codes for COPD (491, 492,
496) for all analyses. Analyses in which the presence of asthma or CHF was included as
a separate variable excluded the codes for asthma and CHF when calculating the
D’Hoore CCI.

2

Includes influenza, acute bronchitis and bronchiolitis, bronchitis not specified as acute or chronic, acute
nasopharyngitis, acute laryngitis, acute tracheitis, acute laryngotracheitis, acute epiglottis, supraglottis, acute
laryngopharyngitis, acute upper respiratory infections of multiple and unspecified sites.
3
Includes pneumonia from bacterial, viral, other specified organisms, and organism unspecified.
4
Includes pleurisy, pneumothorax, abscess of lung and mediastinum, pulmonary congestion and hypostasis,
pulmonary collapse, interstitial emphysema, compensatory emphysema, pulmonary eosinophilia, acute edema
of lung, pulmonary insufficiency following trauma and surgery, allergic bronchopulmonary aspegillosis, and
acute and chronic respiratory failure.
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TABLE 7: Scoring algorithm for D’Hoore-Charlson comorbidity index
Weights
1

2

3
6

Conditions
Myocardial infarct
Congestive heart failure
Peripheral vascular disease
Dementia
Cerebrovascular disease
Chronic Pulmonary disease
Connective tissue disease
Ulcer disease
Mild liver disease
Hemiplegia
Moderate or severe renal disease
Diabetes
Any tumor
Leukemia
Lymphoma
Moderate or severe liver disease
Metastatic solid tumor

ICD-9 CM codes
410, 411
398, 402, 428
440-447
290, 291, 294
430-433, 435
491-493
710, 714, 725
531, 534
571, 573
342, 434, 436, 437
403, 404, 580-586
250
140-195
204-208
200, 202, 203
070, 570, 572
196-199

3. Number of other chronic conditions: The number of other chronic conditions not included
in the D’Hoore-CCI was also computed to comprehensively assess comorbid burden by
the presence of a diagnosis on a medical claim for these conditions. These conditions
include hypercholesterolemia, hypertension, other heart disease, AIDS, rheumatoid
arthritis, osteoarthritis, gall bladder disease, depression and anxiety, and schizophrenia.
COPD severity in pre-index period
1. Number of canisters of inhaled short-acting beta-agonists (SABA): A prescription claim
for an inhaled SABA can be for one or more than one canister. Accordingly, the number
of canisters was computed by dividing the quantity dispensed in mg by mg contained per
canister. SABAs included levalbuterol, albuterol, metaproterenol, bitolterol, and
terbutaline.
2. Number of canisters of inhaled ipratropium or ipratropium/albuterol: A prescription claim
for inhaled ipratropium can be for one or more than one canister. Accordingly, the
number of canisters was computed by dividing the quantity dispensed in mg by mg
contained per canister.
3. Number of prescriptions for other short-acting bronchodilators (SABD): The number of
prescription claims was computed for other SABD that includes theophylline and oral
and powder dosage forms of SABAs.
4. Number of prescriptions for oral corticosteroids (OCS): The number of prescription
claims was computed for OCS. OCS includes prednisone, prednisolone,
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methylprednisolone, cortisone, hydrocortisone, dexamethasone, betamethasone, oral
triamcinolone, and oral budesonide.
5. Use of nebulized short-acting bronchodilators (SABD): The use of nebulized dosage
forms of SABD was categorized as a binary variable (0=no use; 1=use)
6. Use of home oxygen therapy: The use of home oxygen therapy as determined from CPT
codes for home oxygen therapy on medical claims was categorized as a binary variable
(0=no use; 1=use).
7. Number of Hosp/ER visits for COPD or COPD-related comorbid disorders: The number
of hospitalizations and ER visit claims with a primary or secondary diagnosis for a
COPD-related comorbid disorder was determined. COPD-related comorbid disorders
included asthma, upper respiratory tract infections5, lower respiratory tract infections6,
septicemia, allergic rhinitis, other diseases of the lung7, congestive heart failure, and
disorders of fluid, electrolyte, and acid-base imbalance.
8. Number of physician visits for COPD or COPD-related comorbid disorders: The number
of physician visit claims with a primary or secondary diagnosis for a COPD-related
comorbid disorder was determined. COPD-related comorbid disorders included asthma,
upper respiratory tract infections8, lower respiratory tract infections9, septicemia, allergic
rhinitis, other diseases of the lung10, congestive heart failure, and disorders of fluid,
electrolyte, and acid-base imbalance.
9. Presence of asthma: Recipients were classified as having asthma if they had at least one
hospitalization, emergency room (ER) visit, or at least two outpatient encounters on
different dates in 2002 with a diagnosis code (primary or secondary) for asthma (493.xx).
5

Includes influenza, acute bronchitis and bronchiolitis, bronchitis not specified as acute or chronic, acute
nasopharyngitis, acute laryngitis, acute tracheitis, acute laryngotracheitis, acute epiglottis, supraglottis, acute
laryngopharyngitis, acute upper respiratory infections of multiple and unspecified sites.
6
Includes pneumonia from bacterial, viral, other specified organisms, and organism unspecified.
7
Includes pleurisy, pneumothorax, abscess of lung and mediastinum, pulmonary congestion and hypostasis,
pulmonary collapse, interstitial emphysema, compensatory emphysema, pulmonary eosinophilia, acute edema
of lung, pulmonary insufficiency following trauma and surgery, allergic bronchopulmonary aspegillosis, and
acute and chronic respiratory failure.
8
Includes influenza, acute bronchitis and bronchiolitis, bronchitis not specified as acute or chronic, acute
nasopharyngitis, acute laryngitis, acute tracheitis, acute laryngotracheitis, acute epiglottis, supraglottis, acute
laryngopharyngitis, acute upper respiratory infections of multiple and unspecified sites.
9
Includes pneumonia from bacterial, viral, other specified organisms, and organism unspecified.
10
Includes pleurisy, pneumothorax, abscess of lung and mediastinum, pulmonary congestion and hypostasis,
pulmonary collapse, interstitial emphysema, compensatory emphysema, pulmonary eosinophilia, acute edema
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Costs in the pre-index period have been used as a measure of severity in
pharmacoecnomic studies using retrospective databases in other disease states. However, the
same was not used in the present study for two reasons:
1. In other disease areas, severity measures using retrospective databases are generally
restricted to the presence of concomitant conditions/diseases. Prescription drug use is not
generally considered as a measure of severity. Hence, these studies include costs that
help to serve as a proxy measure of severity. In the case of COPD however, the presence
of concomitant conditions/diseases, as well as drugs used in the exacerbated state in
COPD serve as an adequate measure of severity in COPD, eliminating the need to
include costs in the pre-index period.
2. From an analytical perspective, inclusion of costs in the regression models may introduce
violations of assumption, particularly that of multicollinearity and linearity.

Measurement of Outcome Variables
1. Severe exacerbation: A severe exacerbation was defined as a hospitalization with a
primary diagnosis for COPD (ICD-9: 491.xx, 492.xx, 496.xx).
2. Moderate exacerbation: A moderate exacerbation was defined as the presence of an ER
visit or a physician visit with a primary diagnosis for COPD (ICD-9: 491.xx, 492.xx,
496.xx) and a prescription for an oral corticosteroid with or without an antibiotic within 3
days following the visit. An exacerbation occurring within 14 days of a previous
exacerbation was not counted as a separate exacerbation when computing number of
exacerbations (Burge et al., 2003)
3. Total healthcare costs: Total healthcare costs were computed using all the medical and
prescription claims of the study sample regardless of diagnoses code. Costs were
computed using the amounts reimbursed by Medicaid given on each medical and
prescription claim11.

of lung, pulmonary insufficiency following trauma and surgery, allergic bronchopulmonary aspegillosis, and
acute and chronic respiratory failure.
11
The hospitalizations claims for WV Medicaid did not include the amount reimbursed by Medicaid, and WV
Medicaid reimbursement rates for each DRG was used to calculate hospital costs. For a few DRG codes that
did not have a reimbursement value from WV Medicaid, the relative weight of the DRG was used to assign a
cost for the DRG.
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4. COPD-related costs: COPD-related costs were computed from the paid amounts of the
medical claims with a primary or secondary diagnosis of COPD11, and all the prescription
medications used for COPD. COPD-related prescription medications were classified into
the following categories: anticholinergics (ipratropium/combination product of
ipratropium and albuterol), short-acting beta-agonists (SABA), long-acting beta-agonists
(LABA), inhaled corticosteroids (ICS), inhaled corticosteroids/long-acting beta-agonists
combination, methylxanthines, oral corticosteroids (OCS), and antibiotics for respiratory
infections. COPD-related nursing home costs could not be calculated due to the absence
of diagnoses codes on nursing home claims.
5. Death: Death due to any cause except those resulting from an accident, homicide, suicide,
or due to injury at work was obtained from the death records from the Bureau of Vital
Statistics.
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Analyses of Cost Data
The following paragraph details the analytical approach used for multivariate analyses
when the dependent variable was the cost incurred by sample recipients. For cost data where
0% or less than 2% of the sample incurred costs (e.g. total healthcare costs or outpatient
costs), only one regression model was estimated. Since cost data were positively skewed,
costs were log-transformed, and consequently semi-logarithmic ordinary least squares (OLS)
regression was used (Manning WG & Mullahy J, 2001). Adjusted cost estimates were
computed by retransformation of the log-transformed costs using Duan’s smearing correction
factor (Duan N, 1983). The presence of heteroskedasticity in the regression models was
determined using the White’s test or the Breusch-Pagan/Cook-Weisburg test and also by
examining the graphical distribution of the residuals. If the semi-logarithmic OLS model
demonstrated heteroskedasticity, precluding retransformation without introducing bias
(Manning WG, 1998), a generalized linear model (GLM) using a gamma distribution with a
log link was used. The latter have the advantage of estimating the adjusted costs directly
without the need for retransformation while simultaneously using log-transformed costs in its
estimation, provided the log-scale error distribution is not kurtotic (Manning WG et al.,
2001). In a few instances where the GLM model was not found to be a good fit, the
heteroskedastic semi-log OLS model was used, since a bias would only be reflected in the
retransformed costs and not the impact of the primary independent variable. In all of these
instances, the heteroskedasticity was mild as depicted in a graph of the residuals versus the
fitted values.
Unlike total healthcare costs, where all recipients had some costs (because all recipients are
identified by presence of a medical claim), individual cost components like hospitalization
costs are not present for all recipients. Thus, these data have two primary characteristics: a
significant proportion with zero costs, and a positively skewed distribution for those with
costs. Therefore, a two-part model was used with a logistic model for the first part, and a
semi-log OLS model or a GLM model for the second part (Duan N, Manning WG, Morris
CN, & Newhouse JP, 1983). Adjusted costs estimated from two-part models were computed
by multiplying the adjusted probability obtained from the logistic regression model (part 1)
with the retransformed costs estimated from the semi-log OLS or the predicted cost from the
GLM model (part 2) (Duan N et al., 1983).
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The beta coefficients of all semi-log OLS and GLM models were interpreted using a
correction by Halverson and Palmquist with a modification by Kennedy (Halvorsen R &
Palmquist R, 1980; Kennedy P, 1981). Outliers were excluded as considered appropriate
using cutoff values for residuals and Cook’s distance. All regression models were tested for
multicollinearity using cutoff values of the variance inflation factor for each variable. None
of the models had multicollinearity issues. All statistical analyses were evaluated at α=0.05.
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DESIGN AND ANALYSIS OF STUDY GOALS AND OBJECTIVES

Phase I
Study design: A cross-sectional design was used for both objectives in phase I using data for
calendar year 2002 (most recent annual data available).

Research Objective 1: To estimate mean incremental costs incurred by recipients with
COPD enrolled in West Virginia and Kentucky Medicaid.
Study sample: Medicaid recipients having at least one hospitalization, emergency room (ER)
visit, or at least two outpatient encounters on different dates with a primary diagnosis code
for COPD (ICD-9: 491.xx, 492.xx, and 496.xx) in 2002 were identified as having COPD.
Prescription claims were not used for purposes of identifying the COPD population because
of the possibility of diagnostic misclassification with patients with bronchitis and asthma.
Only recipients between 35-64 years of age and those continuously eligible during 2002 were
included. Recipients without COPD were identified based on the absence of a claim with an
ICD-9 CM code for COPD in any diagnosis field. For each recipient with COPD, one nonCOPD recipient was matched on age and gender.
Outcome measure: Based on the type of medical care received, total healthcare costs were
classified into five main components: hospital, ER, outpatient, prescription, and nursing
home. Physician visit costs were also computed as a sub-component of outpatient costs.
Analyses: A description of the study sample by COPD status in terms of their demographic
and comorbidity characteristics was provided using means and proportions as considered
appropriate. Proportions of recipients with at least one hospitalization visit, ER visit,
outpatient encounter, physician visit, and any use of nursing home were reported by COPD
status. The number and cost of hospitalization visits, ER visits, outpatient encounters,
physician visits, and nursing home (number of nursing home visits per recipient could not be
calculated from data source) per recipient was compared between recipients with and without
COPD. The mean total healthcare cost incurred by recipients with COPD was calculated as
the difference in mean total healthcare costs between recipients with and without COPD.
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COPD-related utilization and costs in relation to total healthcare costs for recipients with
COPD was also analyzed. McNemar test was used to compare proportions of recipients with
and without COPD using different healthcare cost components, and the Wilcoxon signed
rank test was used for the number and cost per recipient of cost components. Multivariate
analyses were also conducted controlling for race, county_smokerate, D’Hoore-CCI, and
number of other chronic conditions to determine differences in total healthcare costs as well
as individual cost components between recipients with and without COPD.

Research Objective 2: To compare mean COPD-related costs among recipients with COPD
with and without concomitant asthma enrolled in West Virginia and Kentucky Medicaid.
Study sample: Recipients with COPD identified in objective 1 were classified as having
asthma if they had at least one hospitalization, emergency room (ER) visit, or at least two
outpatient encounters on different dates in 2002 with a diagnosis code (primary or secondary)
for asthma (493.xx).
Outcome measure: COPD-related total costs as well as for each component (hospital, ER,
outpatient, and prescription) were computed for recipients with COPD with and without a
concomitant diagnosis of asthma from the paid amounts of the medical claims with a primary
or secondary diagnosis of COPD, and all the prescription medications used for COPD.
COPD-related nursing home costs could not be calculated due to the absence of diagnoses
codes on nursing home claims.
Analyses: A description of the study sample by asthma status in terms of their demographic
and comorbidity characteristics was provided using means and proportions as considered
appropriate. Proportions of recipients with at least one COPD-related hospitalization visit,
ER visit, outpatient encounter, physician visit, and any use of nursing home were reported by
concomitant asthma status. The number and cost of COPD-related hospitalization visits, ER
visits, outpatient encounters, and physician visits per recipient was compared between
recipients with COPD with and without concomitant asthma (number of nursing home visits
per recipient could not be calculated from data source). The incremental cost per recipient
due to asthma for recipients with COPD was calculated as the difference in total COPD85

related costs per recipient between recipients with COPD with and without concomitant
asthma. Chi-square tests were used to compare proportions of recipients with and without
asthma using different healthcare cost components, and the Mann-Whitney U test or t-test (as
appropriate for the distribution) was used for the number and cost per recipient of cost
components. Multivariate analyses were also conducted controlling for age, gender, race,
county_smokerate, presence of upper respiratory tract infections, lower respiratory tract
infections, septicemia, allergic rhinitis, other diseases of the lung, congestive heart failure,
and disorders of fluid, electrolyte, and acid-base imbalance, D’Hoore-CCI excluding asthma
and CHF, and number of other chronic conditions to determine differences in total healthcare
costs as well as individual cost components between recipients with and without COPD.

Phase II
Phase II of the study compares costs and exacerbations of recipients initiating drug therapy.
Part 1 of phase II compares these outcomes between recipients initiating maintenance therapy
with ipratropium (i.e. use of combination product of ipratropium and albuterol, IPR/ALB) or
monotherapy with inhaled long-acting beta-agonist (LABA).
Part 1
Study sample: The study sample for both objectives in part 1 of Phase II was identified as
shown in figure 6. Sample recipients were identified as those having a prescription claim for
the combination product of ipratropium and albuterol (IPR/ALB) or inhaled long-acting betaagonist (LABA) between WV: July 1, 1998 to June 30, 2002 and KY: January 1, 1999 and
December 31, 2002. An index prescription was defined as the first chronologically occurring
prescription for which no other claims for these index drugs are found in the 12 months
preceding the date of the index prescription. This procedure identified an inception cohort of
new users of medication to indicate the start of drug therapy. The date of the index
prescription was termed as the index date, and the 12 months before the index date was
designated as the pre-index period. The follow-up period for outcome assessment was
defined as the 12 months after the index date. The study period spanned 24 months for each
recipient. An intent-to-treat approach, similar to that used in randomized controlled trials
was used for the analyses. Thus, recipients with COPD identified to be in a drug therapy
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group were considered as using that therapy during the entire follow-up periiod regardless of
therapy discontinuations that may occur beyond the index date.

FIGURE 6: Identification of study sample for Part 1 of Phase II

First day of available
data
WV: July 1, 1997
KY J 1 1998

12 month pre-index period

 No claims for index Rx
 No claims for ICS or

Index Rx identified during this period:
WV: Jul 1, 1998 to June 30, 2002
KY: Jan 1, 1999 to Dec 31, 2002

Index Rx date:
Date of first Rx
for study groups

End of available data
WV: Jun 30, 2003
KY: Dec 31, 2003

12 months post-index
Rx date = follow-up
period

ICS/LABA

 > 1 COPD-related ER


or > 2 COPD-related
outpatient encounters
No COPD-related
hospitalization or home
oxygen therapy

Drug therapy groups:


IPR/ALB: Recipients who fill a prescription for the combination product of
ipratropium/albuterol, and no claims for inhaled long-acting beta-agonists in the 30-day
post-index period. Additionally, recipients are required to have one more prescription
claim for IPR/ALB in the follow-up period.



LABA: Recipients with a prescription claim for inhaled long-acting beta-agonist and no
prescription claims for ipratropium or for the combination product of
ipratropium/albuterol in the post-index 30-day period. Additionally, recipients are
required to have one more prescription claim for LABA in the follow-up period.



Both drug therapy groups could have prescriptions claims for short-acting beta-agonists,
methylxanthines, and oral corticosteroids.

Inclusion criteria:


Recipients with at least one ER visit or at least two outpatient encounters on different
dates in the pre-index period with a primary or secondary diagnosis of COPD (ICD-9:
491.xx, 492.xx, 496.xx).



Recipients at least 35 years of age at the index date.
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Recipients continuously eligible one year before and one year after the index date.

Exclusion criteria:


Recipients with claims for a hospitalization with a primary or secondary diagnosis of
COPD (ICD-9: 491.xx, 492.xx, 496.xx) in the pre-index period.



Recipients with claims for home oxygen therapy in the pre-index period.



Recipients with claims for an inhaled corticosteroid (ICS) or a combination product of an
inhaled corticosteroid and a long-acting beta-agonist (ICS/LABA) in the pre-index
period, or in the 30 days following the index date.



Recipients with a diagnosis of respiratory cancer, cystic fibrosis, fibrosis due to
tuberculosis, and bronchiectasis during the study period were excluded to avoid
misdiagnosis.



Recipients over 64 years of age and those with Medicare eligibility were excluded
because of insufficient capture of claims.



Managed care recipients were excluded as they do not have all their utilization
information in the claims database.

Research Objective 3: To compare the risk and frequency of exacerbations between
recipients with COPD who initiated maintenance therapy with ipratropium or
monotherapy with inhaled long-acting beta-agonist.
Study design and outcome measure: A historical cohort design was used for objective 3. The
outcome was an exacerbation (moderate or severe) for COPD. Differences between groups
in risk of an exacerbation following the index date were determined as shown in figure 7.
Starting with the index date, recipients were followed until an exacerbation occurred or till
the end of the 12-month follow-up period, whichever occurred first.
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FIGURE 7: Historical cohort design to determine differences in time to first exacerbation (Phase
II – Part 1)
Exacerbation in
post-index period.
Yes
IPR/ALB

12-month pre-index period

No
Index date
Yes
LABA

No

A difference in frequency of exacerbations following the index date was determined as
shown in figure 8. Starting with the index date, each recipient was followed for a total of 12
months and the total number of exacerbations occurring in this period was calculated.

FIGURE 8: Historical cohort design to determine differences in number of exacerbations (Phase
II – Part 1)

IPR/ALB

Total exacerbations in
post-index period.

12-month pre-index period
Index date

LABA
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Total exacerbations in
post-index period.

Research Objective 4: To compare COPD-related costs between recipients with COPD who
initiated maintenance therapy with ipratropium or monotherapy with inhaled long-acting
beta-agonist.
Study design and outcome measure: A historical cohort design was used for objective 4 as
shown in figure 9. COPD-related costs accruing in the post-index period were computed for
each drug therapy group.
FIGURE 9: Historical cohort design to determine differences in COPD-related costs (Phase II –
Part 1)

IPR/ALB

COPD-related costs in
post-index period

12-month pre-index period
Index date

LABA

COPD-related costs in
post-index period.

Analyses for research objective 3 & 4:
Description of the study sample at baseline was done using descriptive statistics.
Univariate differences in proportion experiencing an exacerbation were analyzed using chisquare tests, and time to exacerbation was analyzed using the log-rank test. Differences in
total COPD-related costs and individual cost components were determined using MannWhitney tests. Multivariate analyses controlled for covariates in the pre-index period
including demographic characteristics (age, gender, race, state, county smoking prevalence
rate), overall comorbidity (D’Hoore CCI, number of other chronic conditions), and measures
of COPD severity (number of canisters of inhaled short-acting beta-agonists (SABA),
number of prescriptions of other short-acting bronchodilators (SABD), number of
prescriptions of oral corticosteroids (OCS), use of nebulized prescriptions of SABD, number
of hospitalizations/ER visits for COPD or COPD-related comorbid disorders, number of
physician visits for COPD or COPD-related comorbid disorders, and presence of asthma).
Survival analysis techniques were used to determine differences in time to an exacerbation.
The proportional hazards assumption was tested using the global test of proportional hazards,
and the assumption was satisfied. Consequently, a Cox-proportional hazards regression was
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used to determine differences in time to an exacerbation controlling for the above-mentioned
covariates. A logistic regression was used to determine differences in the probability of
experiencing an exacerbation controlling for the above-mentioned covariates.
The frequency of exacerbations represents count level data i.e. a non-negative integervalued random variable, and accordingly differences in the frequency of exacerbations can be
determined using the Poisson or the negative binomial regression model (depending on the
relationship between the variance and the mean) (Long JS, 1997). However, 84% of our
sample have no exacerbations (i.e. number of exacerbations=0). In such a situation, a zeroinflated Poisson or zero-inflated negative binomial regression model is appropriate (Greene
WH, 1994). The zero-inflated models allow overdispersion by changing the mean structure
to explicitly model the production of zero counts. The suitability of a zero-inflated model
was tested by the Vuong statistic. If it is positively significant, then it favors the zeroinflated models, while those that are significantly negative favor the original Poisson or
negative binomial regression model. Our model showed a significantly positive Vuong’s
statistic, and accordingly a zero-inflated model was used. The choice between Poisson and
negative binomial model was determined by the likelihood ratio test of α=0. Since the value
of α was found to be 0, and the p-value=1.00, the zero-inflated Poisson model was used to
determine differences in frequency of exacerbations. Multivariate differences in COPDrelated costs were analyzed using the approach mentioned for analyses of cost data.
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Part 2
The second part of phase II compares outcomes of exacerbations and costs between
recipients initiating combination therapy with an inhaled corticosteroid and long-acting betaagonist (ICS/LABA), inhaled corticosteroid monotherapy (ICS alone), long-acting betaagonist monotherapy (LABA alone), and those on short-acting bronchodilators (SABD).
Study sample: The study sample for objectives 5, 6 and 7 in part 2 of phase II, was identified
as shown in figure 10. Sample recipients were identified as those having a prescription claim
for a combination product of inhaled corticosteroid and long-acting beta-agonist
(ICS/LABA), inhaled corticosteroid (ICS), inhaled long-acting beta-agonist (LABA), or
short-acting bronchodilators (SABD) including anticholinergics (IPR or IPR/ALB), shortacting beta-agonists, and methylxanthines between WV: July 1, 1998 to June 30, 2002 and
KY: January 1, 1999 and December 31, 2002. An index prescription was defined as the first
chronologically occurring prescription for which no other claims for ICS/LABA, ICS, or
LABA are found in the 12 months preceding the date of the index prescription. This
procedure identified an inception cohort of new users of medication to indicate the start of
drug therapy. The date of the index prescription was termed as the index date, and the 12
months before the index date was designated as the pre-index period. The follow-up period
for outcome assessment was defined as the 12 months after the index date. The study period
spanned 24 months for each recipient. An intent-to-treat approach was used for the analyses.
Thus, recipients with COPD identified to be in a drug therapy group were considered to be
using that therapy during the entire follow-up period regardless of therapy discontinuations
that may occur beyond the index date.
FIGURE 10: Identification of study sample for Part 2 of Phase II

First day of available
data
WV: July 1, 1997
KY J 1 1998

12 month pre-index period

 No claims for ICS/LABA,

Index Rx identified during this period:
WV: Jul 1, 1998 to June 30, 2002
KY: Jan 1, 1999 to Dec 31, 2002

Index date: Date
of first Rx for
study groups

End of available data
WV: Jun 30, 2003
KY: Dec 31, 2003

12 months post-index
Rx date = follow-up
period

ICS, or LABA.

 > 1 COPD-related

hospitalization or ER visit
or > 2 COPD-related
outpatient encounters
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Drug therapy groups:


ICS/LABA: Recipients who filled a prescription for the combination product of an
ICS/LABA. Additionally, recipients are required to have one more prescription claim for
combination product of ICS/LABA in the follow-up period.



ICS: Recipients who filled a prescription for an ICS and no prescription for LABA or
combination product of ICS/LABA through the end of the follow-up period.
Additionally, recipients are required to have one more prescription claim for ICS in the
follow-up period.



LABA: Recipients who filled a prescription for LABA and no prescription for an ICS or
combination product of ICS/LABA through the end of the follow-up period.
Additionally, recipients are required to have one more prescription claim for LABA in
the follow-up period.



SABD: Recipients who filled a prescription for anticholinergics (IPR or IPR/ALB), shortacting beta-agonists, or methylxanthines but did not fill a prescription for ICS, LABA, or
combination product of ICS/LABA through the end of the follow-up period. The SABD
group was required to have at least two prescriptions of short-acting bronchodilators in
the pre-index period of which at least one was for ipratropium. This was done to avoid
the possibility of including recipients with mild COPD who use SABD on an as-needed
basis. Additionally, recipients are required to have one more prescription claim for
SABD in the follow-up period.



All therapy groups could also have prescriptions for short-acting bronchodilators.

Inclusion criteria:


Recipients with at least one hospitalization or ER visit or at least two outpatient
encounters on different dates in the pre-index period with a primary or secondary
diagnosis of COPD (ICD-9: 491.xx, 492.xx, 496.xx).



Recipients at least 35 years of age at the index date.



Recipients continuously eligible one year before and one year after the index date.

Exclusion criteria:


Recipients with prescription claims for ICS, LABA, or ICS/LABA combination product
in the pre-index period.
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Recipients with a diagnosis of respiratory cancer, cystic fibrosis, fibrosis due to
tuberculosis, and bronchiectasis during the study period were excluded to avoid
misdiagnosis.



Recipients over 64 years of age and those with Medicare eligibility were excluded
because of insufficient capture of claims.



Managed care recipients were excluded as managed care recipients do not have all their
utilization information in the claims database.

Research Objective 5: To compare the risk of a severe exacerbation among recipients with
COPD who initiate therapy with a combination of an inhaled corticosteroid and a longacting beta-agonist, inhaled corticosteroid alone, inhaled long-acting beta-agonist alone,
or only short-acting bronchodilators.
Study design and outcome measure: A historical cohort design was used for objective 5 as
shown in figure 11. The outcome was a severe exacerbation of COPD. Recipients were
followed for a period of 12 months until a severe exacerbation occurred or till the end of 12month follow-up period, whichever occurred first. Exacerbations were counted 14 days after
the index date to avoid protopathic bias i.e. the bias that results when the exposure occurs as
a direct result of the outcome. Thus, if an exacerbation was the reason that an ICS was
prescribed, this might inadvertently increase the number of exacerbations for the group being
prescribed a drug with an inhaled corticosteroid component.
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FIGURE 11: Historical cohort design to determine differences in time to first severe exacerbation
(Phase II – Part 2)
Severe exacerbation in
post-index period.
ICS/LABA

Yes

ICS

12-month pre-index period

No

Index date

LABA

Yes

SABD
No

Research Objective 6: To compare the frequency of moderate exacerbations among
recipients with COPD who initiate therapy with a combination of an inhaled corticosteroid
and a long-acting beta-agonist, inhaled corticosteroid alone, inhaled long-acting betaagonist alone, or only short-acting bronchodilators.
Study design and outcome measure: A historical cohort design was used for objective 6. The
outcome was a moderate exacerbation of COPD. Each recipient was followed for a period of
12 months after the index date and the total number of moderate exacerbations occurring in
this period was calculated for each individual group as shown in figure 12. Exacerbations
were counted 14 days after the index date to avoid protopathic bias i.e. the bias that results
when the exposure occurs as a direct result of the outcome. Thus, if an exacerbation was the
reason that an ICS was prescribed, this might inadvertently increase the number of
exacerbations for the group being prescribed a drug with an inhaled corticosteroid
component.
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FIGURE 12: Historical cohort design to determine differences in number of moderate
exacerbations (Phase II – Part 2)
ICS/LABA
ICS

Moderate exacerbations
in post-index period.
Moderate exacerbations in
post-index period.

12-month pre-index period
Index date

LABA

Moderate exacerbations
in post-index period.

SABD
Moderate exacerbations in
post-index period.

Research Objective 7: To compare COPD-related costs among recipients with COPD who
initiate therapy with a combination of an inhaled corticosteroid and a long-acting betaagonist, inhaled corticosteroid alone, inhaled long-acting beta-agonist alone, or only
short-acting bronchodilators.
Study design and outcome measure: A historical cohort design was used for objective 7 as
shown in figure 13. COPD-related costs accruing in the 12 months follow-up period were
computed for each drug therapy group.

FIGURE 13: Historical cohort design to determine differences in COPD-related costs (Phase II –
Part 2)
ICS/LABA
ICS

COPD-related costs in
post-index period.
COPD-related costs in
post-index period.

12-month pre-index period
Index date

LABA

COPD-related costs in
post-index period.

SABD

COPD-related costs in
post-index period.
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Analyses for research objective 5, 6, and 7:
Four drug therapy cohorts were formed for part 2 of Phase II. Three primary
comparisons were of interest:
1. ICS/LABA vs. SABD
2. ICS monotherapy vs. SABD
3. ICS/LABA vs. LABA
The first two comparisons assess whether therapy with ICS improves outcomes relative
to therapy with SABD. The third comparison assesses if addition of ICS to LABA
monotherapy improves outcomes.
Since the study is observational in nature, there is an inherent selection bias in the
creation of these drug therapy cohorts. Specifically, all three comparisons share a common
aspect with regard to the comparator groups: one group has been given an ICS. The
treatment algorithm for COPD reserves therapy with inhaled corticosteroids for those with
severe COPD. Hence, by definition there exist differences on observed characteristics
between the groups that might lead to biased estimates of the effect of treatment. Several
techniques exist to account for the impact of selection bias on treatment effects. The use of
propensity scores is one such technique that was used to account for selection bias when
analyzing outcomes for part 2 of Phase II (D'Agostino, Jr., 1998).
The propensity score for an individual is defined as the probability of being treated with
an ICS conditional on (or based only on) the individual’s covariate values. Thus, if two
persons, one found to be in the ICS group and the other in the non-ICS group, had the same
propensity score, then these two persons would have the same predicted probability of being
assigned to the ICS group (Rubin, 1997). Thus, it a measure of the likelihood that a person
would have been treated using only their covariate scores. It is obtained from a logistic
regression that predicts the probability of being in the ICS therapy group based on several
factors12. The propensity score so obtained provides a scalar summary of the covariate
12

Factors considered to predict the probability of being treated with an ICS included demographic
characteristics (age, gender, race, state, county smoking prevalence rate), overall comorbidity (D’Hoore CCI,
number of other chronic conditions), and measures of COPD severity (number of canisters of inhaled shortacting beta-agonists (SABA), number of prescriptions of other short-acting bronchodilators (SABD), number of
prescriptions of oral corticosteroids (OCS), use of nebulized prescriptions of SABD, use of hospitalizations/ER
visits for COPD or COPD-related comorbid disorders, number of physician visits for COPD or COPD-related
comorbid disorders, presence of asthma, and use of home oxygen therapy).
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information, and represents the probability of being treated. Using this probability to adjust
the estimated treatment effect has the advantage of creating a ‘quasi-randomized’
experiment. In observational studies, the propensity scores are used primarily to reduce bias
and increase precision, using three common techniques: matching, stratification, and
regression adjustment (D'Agostino, Jr., 1998).
For the two comparisons in part 2 of Phase II, matched samples were created using the
technique of nearest available matching on the estimated propensity score (Parsons L.S.,
2000). This matching method consists of randomly ordering the treated and control subjects,
then selecting the first treated subject and finding the control subject with the closest
propensity score. Both subjects are then removed from consideration for matching and the
next treated subject is selected. For both comparisons, The ICS comparator groups had a
larger number of people compared to those without ICS. Thus, each recipient in the non-ICS
groups (control) were matched to recipients from the ICS group (treated) based on the
propensity score using the nearest neighbor matching technique.
Before matching, baseline characteristics were compared between therapy groups using ttests or Mann-Whitney tests for continuous variables and chi-square tests for categorical
variables. After matching, baseline characteristics were compared between therapy groups
using Wilcoxon signed rank tests for continuous and McNemar’s test for categorical
variables. The ability of propensity scores to reduce bias was assessed by assessing the
balance in covariates after matching. Since a balance was found for all covariates, univariate
statistics was used to compare therapy groups on outcomes of exacerbations and costs.
Research objective 5 compares the risk of a severe exacerbation between therapy groups,
and McNemar’s test was used to assess statistical significance and obtain the odds ratio
estimate. Research objective 6 compares the frequency of moderate exacerbations between
therapy groups, and the Wilcoxon signed rank test was used to determine differences in
number of moderate exacerbations in the follow-up period. Similarly, for comparison of
COPD-related costs in research objective 7, the Wilcoxon signed rank test was used.
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Phase III
Phase III assesses the impact of ICS on mortality using two different study designs.
Objective 8 uses a case-control and Objective 9 uses a historical cohort study design to
ascertain this association. Objective 9 also attempts to test the hypothesis that any impact of
ICS on mortality is mediated by the impact of ICS on severe exacerbations.

Research Objective 8: To compare the odds of exposure to inhaled corticosteroids between
those who died and those who did not die during the study period (case-control study
design).
Study sample: The study sample for objective 8 of phase III was identified as shown in figure
14. An initial subset of recipients between 35-64 years of age having at least one medical
claim with a primary diagnosis code for COPD (ICD-9: 491.xx, 492.xx, and 496.xx) between
the period WV: July 1, 1997 to June 30, 2003 and KY: January 1, 1998 to December 31,
2003 were identified. Unique identification numbers of the recipients from this initial subset
were then linked to death records from the Bureau of Vital Statistics to determine recipients
who died between WV: July 1, 1998 to June 30, 2003 and KY: January 1, 1999 to December
31, 2003.
Recipients who died were designated as cases, and all other recipients were eligible to be
selected as controls, which are the comparators in a case-control study design. Inclusion and
exclusion criteria were applied to determine the number of cases and controls meeting study
eligibility criteria. Eligible controls were selected and matched to each case by age, gender,
and ethnicity to obtain the final study sample for objective 8. The index date is the date of
death for a case. The index date for each control is the date of death of its matched case.
The 12 month period prior to the index date is the pre-index period, and also represents the
study period for each recipient.
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FIGURE 14: Identification of study sample for research objective 8 of Phase III
First day of available data
WV: July 1, 1997
KY: Jan 1, 1998

End of available data
WV: Jun 30, 2003
KY: Dec 31, 2003

Recipients between 35-64 years of age having at least one medical claim with a
primary diagnosis code for COPD (ICD-9: 491.xx, 492.xx, and 496.xx)
between:
WV: July 1, 1997 to June 30, 2003
KY: January 1, 1998 to December 31, 2003

Link recipient IDs to
Bureau of Vital Statistics

Dead
(Cases)

Match by
age, sex,
race

Alive
(Eligible controls)

Final study sample
meeting inclusion
& exclusion criteria

Inclusion criteria:


Recipients with at least one hospitalization, emergency room (ER) visit, or at least two
outpatient encounters on different dates with a primary diagnosis code for COPD (ICD-9:
491.xx, 492.xx, and 496.xx) were identified as having COPD.



Recipients at least 35 years of age at the first day of available data.



Recipients continuously eligible for one year before the index date.

Exclusion criteria:


Recipients with a diagnosis of respiratory cancer, cystic fibrosis, fibrosis due to
tuberculosis, and bronchiectasis during the study period were excluded.



Recipients over 64 years of age and those with Medicare eligibility were excluded
because of insufficient capture of claims.



Managed care recipients were excluded as managed care recipients do not have all their
utilization information in the claims database.

Study design and outcome measure: A case-control design was used for objective 8 as
demonstrated in figure 15. In accordance with the case-control design, prescription claims in
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the 12 months prior to the index date were examined for cases and controls. Recipients with
at least two prescription claims for ICS in this retrospective period were classified as ICS
users, and those without any claims were classified as non-ICS users. Recipients with only
one prescription claim for ICS in the pre-index period were excluded to avoid the possibility
of misclassification.

FIGURE 15: Case-control design to determine impact of ICS on mortality
All-cause
mortality

ICS use

Yes
Death
(Cases)
No
Yes

No death
(Controls)

No

Analyses for Research Objective 8:
Description of the study sample in the pre-index period was done using descriptive
statistics. McNemar test was used to compare cases and controls on categorical variables,
and the Wilcoxon signed rank test was used for continuous variables. A conditional logistic
regression was used controlling for covariates in the pre-index period including county
smoking prevalence rate, overall comorbidity (D’Hoore CCI, number of other chronic
conditions), and measures of COPD severity (number of canisters of inhaled short-acting
beta-agonists (SABA), number of canisters of inhaled ipratropium (IPR), number of
prescriptions of other doseform short-acting bronchodilators (SABD), number of
prescriptions of oral corticosteroids (OCS), use of nebulized prescriptions of SABD, number
of hospitalizations/ER visits for COPD or COPD-related comorbid disorders, number of
physician visits for COPD or COPD-related comorbid disorders, presence of asthma, and use
of home oxygen therapy).
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Research Objective 9: To conduct a mediation analysis to examine the relationship
between use of ICS, severe exacerbations, and death (historical cohort study design).
Study sample: The study sample for objective 9 of phase III was identified as shown in figure
16. Sample recipients were identified as those having a prescription claim for an inhaled
corticosteroid (defined as a prescription claim for inhaled corticosteroid or for the
combination product of an inhaled corticosteroid and a long-acting beta-agonist), or use of
other COPD-related drugs (defined as a prescription claim for long-acting beta-agonists,
anticholinergics (ipratropium or combination product of ipratropium and albuterol), shortacting beta-agonists, or methylxanthines). An index prescription was defined as the first
chronologically occurring prescription for which no other claims for these index drugs are
found in the 12 months preceding the date of the index prescription. This procedure
identified an inception cohort of new users of medication to indicate the start of drug therapy.
The date of the index prescription was termed as the index date, and the 12 months before the
index date was designated as the pre-index period. The follow-up period was defined as 12
months after index date. The study period spanned 24 months for each recipient. An intentto-treat approach was used for the analyses. Thus, recipients with COPD identified to be in a
drug therapy group were considered to be using that therapy during the entire follow-up
period regardless of therapy discontinuations that may occur in the follow-up period.
FIGURE 16: Identification of study sample for research objective 9 of Phase III
First day of available
data
WV: July 1, 1997
KY: Jan 1, 1998

12 month pre-index period

 No claims for ICS/LABA,

Index Rx identified during this period:
WV: Jul 1, 1998 to June 31, 2002
KY: Jan 1, 1999 to Dec 31, 2002

Index date: Date
of first Rx for
study groups

End of available data
WV: Jun 30, 2003
KY: Dec 31, 2003

12 months post-index
Rx date = follow-up
period

or ICS

 > 1 COPD-related

hospitalization or ER visit
or > 2 COPD-related
outpatient encounters
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Drug therapy groups:


ICS: Recipients who filled a prescription for an ICS or a combination product of an
ICS/LABA. Additionally, recipients are required to have one more prescription claim for
ICS or the combination product of ICS/LABA in the follow-up period.



no ICS: Recipients who filled a prescription for other COPD-related drugs (inhaled longacting beta-agonists, anticholinergics (ipratropium or combination product of ipratropium
and albuterol), short-acting beta-agonists, or methylxanthines) but did not fill a
prescription for ICS during entire study period. Recipients in the non-ICS group without
long-acting beta-agonists were required to have at least two prescriptions of short-acting
bronchodilators in the pre-index period of which at least one was for ipratropium. This
was done to avoid the possibility of including recipients with mild COPD who use SABD
on an as-needed basis. Additionally, recipients were required to have one more
prescription claim for other COPD-related drugs in the follow-up period.

Inclusion criteria:


Recipients with at least one hospitalization, ER visit or at least two outpatient encounters
in the pre-index period with a primary or secondary diagnosis of COPD (ICD-9: 491.xx,
492.xx, 496.xx).



Recipients at least 35 years at the index date.



Recipients had to be continuously eligible during the year before the index date.
Additionally, recipients found to have died during the 12-month follow-up period were
required to be continuously eligible till the date of death, and recipients who did not die
during the 12-month follow-up were required to be continuously eligible till the end of
the 12-month follow-up period.

Exclusion criteria:


Recipients who died within 30 days post-index date were excluded to avoid recipients
with very severe COPD.



Recipients with a diagnosis of respiratory cancer, cystic fibrosis, fibrosis due to
tuberculosis, and bronchiectasis during the study period were excluded to avoid
misdiagnosis.
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Recipients over 64 years of age and those with Medicare eligibility were excluded
because of insufficient capture of claims.



Managed care recipients were excluded as managed care recipients do not have all their
utilization information in the claims database.

Study design and outcome measure: A historical cohort design was used for objective 9 as
demonstrated in figure 17. The outcome was death, and recipients were followed for a
period of 12 months until they died or till the end of 12-month follow-up period, whichever
occurred first. Additionally, the presence of a severe exacerbation before the date of death or
end of follow-up was assessed. Exacerbations were counted 14 days after the index date to
avoid protopathic bias i.e. the bias that results when the exposure occurs as a direct result of
the outcome. Thus, if an exacerbation was the reason that an ICS was prescribed, this might
inadvertently increase the number of exacerbations for the group being prescribed a drug
with an inhaled corticosteroid component.

FIGURE 17: Historical cohort design to determine differences in mortality
Death in
post-index period.
Yes
ICS use

12-month pre-index period

No
Index date

No ICS use

Yes

No
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Analyses for research objective 9:
Objective 9 attempts to understand if any relationship found between ICS use and
mortality may be mediated by the impact of ICS on severe exacerbations. Hence, the impact
of ICS on mortality as well as on severe exacerbations in the follow-up period was assessed.
Description of the study sample in the pre-index period was done using descriptive statistics.
Univariate differences in the proportion of those who died and those who experienced a
severe exacerbation were analyzed using chi-square tests, and time to death and time to
severe exacerbation was analyzed using the log-rank test.
Similar to the analytical approach for part 2 of Phase II, propensity scores were used to
account for selection bias in the analyses for research objective 9. However, the matching
technique was not used; rather the propensity score was used as a covariate in the regression
models (D'Agostino, Jr., 1998). There was a twofold reason for this approach: one was to
conserve sample size; and the second was to permit a mediation analysis that can only be
done by assessing changes in coefficients of the equations. The approach for regression
adjustment involves using the raw propensity score or the propensity score quintile as a
covariate in the model. The propensity score quintile for each person is obtained by dividing
the study sample into five equally sized strata based on quintiles of the propensity score
distribution. The quintile rather than the raw score was used since it permitted one to test
whether balance had been achieved in the covariates between the two groups. This was done
by conducting two-way ANOVAs using the drug therapy variable (ICS vs. no ICS),
propensity score quintile, and interaction of propensity score quintile and drug therapy
variable for the continuous variables, and Cochran-Mantel Haenzel tests for the categorical
variables (D'Agostino, Jr., 1998).
Survival analysis techniques were used to determine differences in time to death and time
to a severe exacerbation. The proportional hazards assumption was tested using the global
test of proportional hazards, and the assumption was satisfied. Consequently, a Coxproportional hazards regression was used to determine differences in time to death and time
to a severe exacerbation controlling for propensity score quintile and recipient’s state.
Although state was included in the propensity score models, it was included in the Cox
proportional hazards model due to differences in mortality rates between the two states
(Hoyert DL, Heron MP, Murphy SL, & Kung H, 2006). A mediation analysis as suggested
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by Baron and Kenny (MacKinnon, 1994) was originally proposed provided the above
analyses demonstrated that ICS impacted both risk of mortality and severe exacerbation.
However, as no relationship between use of ICS and severe exacerbation was found, no
mediation analysis was conducted.
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CHAPTER 4: RESULTS & DISCUSSION
Chapter 4 details the results and discussion of each objective of the study. As each phase
of the study involved different extraction criteria based on the study design, different subsets
of recipients were obtained for each objective. Accordingly, the results of each phase are
preceded by the resultant extraction process from the raw data.
Phase I
Phase I of the study involved the determination of costs incurred by recipients with COPD
during a year, and claims data for the year 2002 were used to achieve this goal. Table 8
outlines the sample extraction process depending on the study design mentioned in Chapter
3. The process follows the order in which the inclusion criteria were applied.

TABLE 8: Sample extraction for Phase I
Step

Outcome (WV)

Outcome (KY)

1. # of continuously eligible recipients in 2002

A = 200,068

A = 487,779

2. # of A between 35-63 years of age as of
January 1, 2002

B = 49,464

B = 111,355

3. # of B recipients not enrolled in managed
care at anytime during 2002

C = 47,245

C = 96,191

4. # of C recipients with COPD using
inclusion criteria

D = 5,572

D = 7,664

5. # of C recipients without COPD with no
ICD-9 CM code in any field for COPD

E = 39,260

E = 54,846

6. # of pairs after matching D to E by age and
gender

F = 5,120

F = 7,065

7. # of F recipients with COPD who have
asthma using criteria

H = 1,115 (21.8%)

H= 1,523 (21.5%)

Research Objective 1: To estimate mean incremental costs incurred due to COPD by
recipients enrolled in West Virginia Medicaid and Kentucky Medicaid.
The extraction process identified 5,572 and 7,664 recipients with COPD in WV and KY
Medicaid, respectively. Each of these recipients were matched by exact age and gender to a
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recipient identified as not having COPD. A total of 5,120 and 7,065 matched pairs were
obtained in WV and KY Medicaid, respectively (Table 8). Both states had a similar age and
gender distribution. The average age of a recipient with COPD was 52 years in WV and 51
years in KY, and both states had a majority of females (Table 9: 60% in WV and 64% in
KY). Table 9 presents the characteristics of recipients with and without COPD in WV and
KY Medicaid. Of recipients with race information, 95 percent were white in both states with
a slightly higher proportion for recipients with COPD compared to those without COPD
(Table 9_WV: 96.4% vs. 94.3%; Table 9_KY: 96.7% vs. 93.1%). A slightly higher but
significant proportion of recipients with COPD resided in counties with a smoking
prevalence rate of at least 31% compared to those without COPD in both states (Table
9_WV: 24.1% vs. 22.7%; Table 9_KY: 89.3% vs. 86.0%). Recipients with COPD in both
states had a significantly higher D’Hoore CCI index with 50% of the sample having an index
of 2.0 vs 1.0 for non-COPD recipients. Similar patterns were seen comparing the number of
chronic conditions.
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TABLE 9: Characteristics of recipients with and without COPD in WV and KY Medicaid
Characteristics

WV Medicaid
(N=10,240)

KY Medicaid
(N=14,130)

COPD
(N=5,120)

non-COPD
(N=5,120)

96.4%
(4,861)

94.3%
4,731)

1

24.1%
(1,236)

22.7%
(1,164)

1

Overall
comorbidity
D’Hoore-CCIa
Mean (SD)
Median

2.4 (2.4)
2.0

Number of other
chronic
conditionsb
Mean (SD)
Median

2.1 (1.4)
2.0

Demographic
Race, % (n)
White
Countysmokerate
>= 31%

Test
Statistic
(p-value)

COPD
(N=7,065)

non-COPD
(N=7,065)

Test
Statistic
(p-value)

(0.000)*

96.7%
(5,965)

93.1%
(5,778)

1

(0.000)*

(0.000)*

89.3%
(6,311)

86.0%
(6,076)

1

(0.000)*

1.4 (1.9)
1.0

-23.822
(0.000)*

2.2 (2.3)
2.0

1.2 (1.7)
1.0

-28.952
(0.000)*

1.6 (1.3)
1.0

-20.332
(0.000)*

2.0 (1.4)
2.0

1.4 (1.3)
0.0

-27.682
(0.000)*

* p<0.05
a
Excludes COPD
b
Includes hypercholesterolemia, hypertension, other heart disease, AIDS, rheumatoid arthritis, osteoarthritis,
gall bladder disease, depression and anxiety, and schizophrenia.
1
McNemar test, test statistic not available; 2Wilcoxon signed rank test statistic
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Comparison of mean total healthcare utilization and costs between recipients with and
without COPD in WV and KY Medicaid
Tables 10 and 11 compare the mean total healthcare use and costs of recipients with and
without COPD in WV and KY Medicaid, respectively. Almost half of the recipients with
COPD had at least one hospitalization visit compared to those without COPD in both states
(Table 10_WV: 47.7% vs. 16.3%; Table 11_KY: 46.3% vs. 13.0%). The number of visits
per recipient was also significantly higher in recipients with COPD (Table 10_WV: 0.98 vs.
0.28; Table 11_KY: 1.12 vs. 0.22). Similar trends were seen for proportions with versus
without COPD with at least one ER visit (Table 10_WV: 61.5% vs. 40.1%; Table 11_KY:
59.4% vs. 32.3%) and mean number of ER visits (Table 10_WV: 2.31 vs. 1.04; Table
11_KY: 2.33 vs. 0.81) in both states. A significantly higher proportion of recipients with
COPD had at least one physician visit in both states (Table 10_WV: 90.3% vs. 79.2%; Table
11_KY 94.0% vs. 77.4%) with a significantly higher mean number of physician visits (Table
10_WV: 9.08 vs. 5.53; Table 11_KY: 11.75 vs. 6.25) compared to those without COPD.
Recipients with COPD also had a significantly higher average number of prescription fills
compared to those without COPD in both states, with KY Medicaid recipients filling more
prescriptions than WV Medicaid recipients (Table 10_WV:78.91 vs. 50.27; Table 11_KY:
99.18 vs. 67.42). Overall, less than 5% of the sample used nursing home care in 2002.
Contrary to other healthcare cost components, recipients without COPD in both states
incurred significantly higher nursing home costs than recipients with COPD.
The mean incremental total healthcare cost incurred by recipients with COPD was
calculated as the difference in mean total healthcare costs incurred by recipients with and
without COPD. Thus, recipients with COPD incurred $6,589 per recipient in WV Medicaid
(Table 12). In multivariate analyses after controlling for confounders, recipients with COPD
were found to incur almost 74% higher total healthcare costs compared to recipients without
COPD with an incremental cost of $3,952 per recipient (Table 12). Recipients with COPD in
KY Medicaid incurred 53% higher total healthcare costs with an incremental cost of $4,979
per recipient with COPD (Table 13). For both states, adjusted analyses showed that a
majority of the costs for recipients with COPD was due to the higher cost of hospitalizations
for recipients with COPD, followed by costs for outpatient encounters, prescription drugs,
and ER visits. In both states, nursing home costs were found to be lower for recipients with
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COPD compared to those without COPD; however, this difference was statistically
significant only in the KY Medicaid sample. For both states, the maximum percentage
difference in costs between recipients with and without COPD was seen for hospitalization
and ER costs.

TABLE 10: Total healthcare utilization and costs for recipients with and without COPD in WV
Medicaid
Cost
Component

COPD
(N=5,120)

Non-COPD
(N=5,120)

Test Statistic
(p-value)

% (n) with use
1

Hosp

47.7% (2,443)

16.3% (836)

ER

61.5% (3,148)

40.1% (2,055)

Outpatient

99.7% (5,105)

95.1% (4,867)

1

(0.000)*

- Physiciana

90.3%a (4,622)

79.2%a (4,053)

1

(0.000)*

Prescription

92.8% (4,751)

89.2% (4,568)

1

(0.000)*

3.8% (195)

4.2% (215)

1

(0.000)*

Nursing homeb

(0.000)*

1

(0.196)

Amount of use per recipient, Mean (95% CI)
Number of
hosp visits

0.98
(0.94-1.03)

0.28
(0.24-0.31)

-31.202
(0.000)*

Number of ER
visits

2.31
(2.18-2.45)

1.04
(0.95-1.12)

-22.852
(0.000)*

Number of
Outpatient
encountersc

31.38
(30.67-32.08)

17.59
(17.04-18.13)

-34.302
(0.000)*

- Number of
physician
visitsa

9.08a
(8.84-9.31)

5.53a
(5.35-5.70)

-25.172
(0.000)*

Number of
prescription
fills

78.91
(77.50-80.32)

50.27
(49.14-51.40)

-30.032
(0.000)*

Cost per recipient, Mean (95% CI)
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$5,265
($4,978- $5,552)

$1,538
($1,370-$1,707)

Difference
$3,727
($3,392-$4,061)

$787
($737-$836)

$300
($275-$324)

$487
($431-$542)

-23.702
(0.000)*

Outpatient

$4,240
($4,004-$4,477)

$2,687
($2,461-$2,913)

$1,554
($1,226-$1,881)

-26.722
(0.000)*

- Physician
visita

$653a
($616-$691)

$362a
($336-$387)

$292
($246-$337)

-20.402
(0.000)*

Prescription
drugs

$4,058
($3,962-$4,154)

$2,528
($2,450-$2,606)

$1,531
($1,410-$1,652)

-26.452
(0.000)*

$1,000
($823-$1,178)

$1,709
($1,445-$1,972)

- $709
(-$1,029 - -$388)

-3.892
(0.000)*

$15,350
($14,839-$15,861)

$8,761
($8,328-$9,193)

$6,590
($5,916-$7,263)

-29.442
(0.000)*

Hosp
ER visit

Nursing home

Total costs

-28.852
(0.000)*

* p<0.05
a
Physician cost component is a sub-component of the Outpatient cost component.
b
Number of nursing home visits cannot be computed from data source
c
An outpatient encounter is defined as any service for a particular recipient on a unique date that generated a
CPT code other than 99281-99285, 99288.
1
McNemar test, test statistic not available; 2Wilcoxon signed rank test statistic
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TABLE 11: Total healthcare utilization and costs for recipients with and without COPD in KY
Medicaid
Cost
Component

COPD
(N=7,065)

Non-COPD
(N=7,065)

Test Statistic
(p-value)

% (n) with use
Hosp

46.3% (3,271)

13.0% (918)

1

(0.000)*

ER

59.4% (4,200)

32.3% (2,283)

1

(0.000)*

Outpatient

99.4% (7,024)

96.5% (6,817)

1

(0.000)*

- Physiciana

94.0%a (6,639)

77.4%a (5,468)

1

(0.000)*

Prescription

99.2% (7,006)

97.0% (6,855)

1

(0.000)*

3.4% (240)

3.0% (211)

1

(0.000)*

Nursing homeb

Amount of use per recipient, Mean (95% CI)
Number of
hosp visits

1.12
(1.08-1.17)

0.22
(0.20-0.24)

-38.812
(0.000)*

Number of ER
visits

2.33
(2.21-2.45)

0.81
(0.76-0.86)

-32.892
(0.000)*

Number of
Outpatient
encountersc

35.66
(34.66-36.66)

29.02
(27.64-30.41)

-27.622
(0.000)*

- Number of
physician
visitsa

11.75a
(11.54-11.97)

6.25a
(6.09-6.41)

-40.032
(0.000)*

Number of
prescription
fills

99.18
(97.69-100.67)

67.42
(66.16-68.68)

-31.742
(0.000)*

Cost per recipient, Mean (95% CI)
Hosp
ER visit
Outpatient

$4,495
($4,252-$4,738)

$922
($817-$1,028)

Difference
$3,573
($3,308-$3,837)

$858
($815-$900)

$274
($255-$293)

$584
($538-$630)

-33.782
(0.000)*

$7,283

$8,115

-$831

-34.092
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-37.142
(0.000)*

($6,986-$7,580)

($7,176-$9,053)

(-$1,816 - $153)

(0.000)*

- Physician
visita

$1,024a
($991-$1,056)

$491a
($471-$510)

$533
($495-$571)

-37.262
(0.000)*

Prescription
drugs

$5,303
($5,198-$5,408)

$3,529
($3,444-$3,614)

$1,774
($1,640-$1,909)

-28.452
(0.000)*

$631
($525-$737)

$1,240
($1,014-$1,467)

-$610
(-$859 - -$361)

-2.662
(0.008)*

$18,569
($18,041-$19,098)

$14,080
($13,091-$15,069)

$4,489
($3,368-$5,610)

-36.012
(0.000)*

Nursing home

Total costs

* p<0.05
a
Physician cost component is a sub-component of the Outpatient cost component.
b
Number of nursing home visits cannot be computed from data source
c
An outpatient encounter is defined as any service for a particular recipient on a unique date that generated a
CPT code other than 99281-99285, 99288.
1
McNemar test, test statistic not available; 2Wilcoxon signed rank test statistic
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TABLE 12: Mean incremental total healthcare costs incurred by recipients with COPD [Total
healthcare costs incurred by recipients with COPD – Total healthcare costs incurred by
recipients without COPD] in WV Medicaid
Cost
Component

Adjusteda

Unadjusted
Difference in
cost per recipient

Difference in
cost per recipient

Percentage difference
in costsb

Model
Details: see
Appendix
table

$3,727*

$2,424*

+178.2%*

A1

$487*

$218*

+80.7%*

A2

Outpatient

$1,554*

$1,111*

+63.8%*

A3

- Physician
visitc

$292c*

$127c*

+26.2%c*

A4

Prescription
drugs
Nursing home

$1,531*

$1,026*

+36.5%*

A5

- $709*

-$536

-35.7%

A6

Total costs

$6,590*

$3,952d*

73.5%*

A7

Hosp
ER visit

* p < 0.05
a
Covariates include race, countysmokingrate, D’Hoore-CCI, and number of other chronic conditions.
b
(Cost per COPD recipient – Cost per non-COPD recipient)/Cost per non-COPD recipient. + indicates that
COPD recipients have higher costs than those without COPD. * indicates that the difference was statistically
significant.
c
Physician cost component is a sub-component of the Outpatient cost component.
d
Total adjusted cost may not reflect the sum of individual cost components because estimates are obtained from
individual regression models for each component.
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TABLE 13: Mean incremental total healthcare costs incurred by recipients with COPD [Total
healthcare costs incurred by recipients with COPD – Total healthcare costs incurred by
recipients without COPD] in KY Medicaid
Cost
Component

Adjusteda

Unadjusted
Difference in
cost per recipient

Difference in
cost per recipient

Percentage difference
in costsb

$3,573*

$2,825*

+280.4%*

Details of
Model in
Appendix
A8

ER visit

$584*

$381*

+146.1%*

A9

Outpatient

-$831*

$1,785*

+52.9%*

A10

- Physician
visitc

$533c*

$304*

+57.9%*

A11

Prescription
drugs
Nursing home

$1,774*

$945*

+24.2%*

A12

-$610*

-$549*

-45.6%*

A13

Total costs

$4,489*

$4,979d

+53.1%

A14

Hosp

* p < 0.05
a
Covariates include race, countysmokingrate, D’Hoore-CCI, and number of other chronic conditions.
b
(Cost per COPD recipient – Cost per non-COPD recipient)/Cost per non-COPD recipient. + indicates that
COPD recipients have higher costs than those without COPD. * indicates that the difference was statistically
significant.
c
Physician cost component is a sub-component of the Outpatient cost component.
d
Total adjusted cost may not reflect the sum of individual cost components because estimates are obtained from
individual regression models for each component.
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Mean COPD-related utilization and costs in relation to mean total healthcare costs for

recipients with COPD in WV & KY Medicaid
Tables 14 and 15 compare the mean COPD-related utilization and costs for recipients
with COPD in relation to their mean total healthcare costs in WV and KY Medicaid,
respectively. Both states showed lower rates of COPD-related use and costs for recipients
with COPD compared to the recipients’ total healthcare use and costs. The mean COPDrelated costs for recipients with COPD in WV Medicaid was $4,999, and constituted
approximately 35 percent of total healthcare costs. The mean COPD related costs for
recipients with COPD in KY Medicaid was higher ($6,346) but the proportion of total
healthcare costs (35%) was similar to WV Medicaid. In both states, the average cost for a
COPD-related hospitalization consumed a greater proportion of the average cost for total
healthcare hospitalizations compared to other cost components. Recipients in KY Medicaid
had a higher mean number of COPD-related hospitalizations compared to those in WV
Medicaid.
Table 16 presents the proportion of Medicaid recipients with COPD in both states using
each of eight COPD-related drug classes. A higher proportion of recipients with COPD in
WV Medicaid had no COPD-related prescription drug use compared to recipients with
COPD in KY Medicaid (11% vs. 3%). The use of all drug categories was higher in KY
Medicaid than that in WV Medicaid. Anticholinergics, inhaled long-acting beta-agonists,
inhaled corticosteroids alone or in combination with long-acting beta-agonists, and
methylxanthines are used as maintenance drug therapy in COPD. The use of ipratropium, the
gold standard COPD drug treatment, alone or in combination with albuterol, occurred in 53
percent of recipients with COPD in KY Medicaid compared to 43 percent in WV Medicaid.
The use of the other maintenance drug therapies occurred in less than half of the study
sample in both states. Almost 80 to 90 percent were found to be using antibiotics indicated
for respiratory infections. Use of short-acting beta-agonists and oral corticosteroids was also
high.
The use and costs of home oxygen therapy were also calculated. Costs for home oxygen
therapy can be included in either the hospitalization, ER, or outpatient components based on
the nature of billing claims in the U.S. Hence, costs of home oxygen therapy were calculated
using all claims with HCPCS codes for oxygen therapy. Thirty-two percent of the recipients
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with COPD in WV Medicaid used home oxygen therapy incurring an average cost of $516.
Corresponding numbers in KY Medicaid were 26.2 percent and $622.
TABLE 14: Total healthcare and COPD-relateda utilization and cost per recipient for recipients
with COPD (N=5,120) in WV Medicaid
Cost Component

Total healthcare

COPD-related

% (n) with use
Hosp

47.7% (2,443)

16.5% (1,688)

ER

61.5% (3,148)

15.4% (1,266)

Outpatient

99.7% (5,105)

46.0% (4,713)

- Physicianb

90.3%b (4,622)

63.3%b(3,239)

Prescription

92.8% (4,751)

89.3% (4,572)

Amount of use per recipient, Mean (95% CI)
Number of hosp visits

0.98
(0.94-1.03)

0.16
(0.55-0.52)

Number of ER visits

2.31
(2.18-2.45)

0.54
(0.50-0.58)

Number of Outpatient
encountersc

31.38
(30.67-32.08)

8.52
(8.24-8.80)

- Number of physician
visitsb

9.08b
(8.84-9.31)

2.11b
(2.03-2.18)

Number of prescription
fills

78.91
(77.50-80.32)

16.16
(15.71-16.61)

Cost per recipient, Mean (95% CI)
% of total
healthcare related
to COPD
Hosp
ER visit

$5,265
($4,978- $5,552)

$2,860
($2,656-$3,064)

54.3%

$787
($737-$836)

$228
($208-$248)

29.0%
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Outpatient

$4,240
($4,004-$4,477)

$1,012
($964-$1,061)

23.9%

- Physician visitb

$653b
($616-$691)

$155 b
($144-$165)

23.7%b

Prescription drugs

$4,058
($3,962-$4,154)

$899
($869-$928)

22.2%

$14,350
($13,886$14,814)

$4,999
($4,761-$5,237)

34.8%

Total costs excluding
nursing home costs
a

COPD-related costs were computed from the paid amounts of the medical claims with a primary or secondary
diagnosis of COPD, and prescription claims of COPD-related drug classes. COPD-related drug classes
include: anticholinergics(ipratropium, ipratropium/albuterol), inhaled long-acting beta-agonists, short-acting
beta-agonists, inhaled corticosteroids, inhaled corticosteroid/long-acting beta-agonist combination,
methylxanthines, oral corticosteroids, and antibiotics for respiratory infections. COPD-related nursing home
costs could not be calculated due to the absence of diagnoses codes on nursing home claims.
b
Physician cost component is a sub-component of the Outpatient cost component.
c
An outpatient encounter is defined as any service for a particular recipient on a unique date that generated a
CPT code other than 99281-99285, 99288.
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TABLE 15: Total healthcare and COPD-relateda utilization and cost per recipient for recipients
with COPD (N=7,065) in KY Medicaid
Cost Component

Total healthcare

COPD-related

% (n) with use
Hosp

46.3% (3,271)

34.0% (2,404)

ER

59.4% (4,200)

29.6% (2,092)

Outpatient

99.4% (7,024)

83.7% (5,914)

- Physicianb

94.0%b (6,639)

75.2%b (5,315)

Prescription

99.2% (7,006)

96.7% (6,832)

Amount of use per recipient, Mean (95% CI)
Number of hosp visits

1.12
(1.08-1.17)

0.63
(0.60-0.67)

Number of ER visits

2.33
(2.21-2.45)

0.52
(0.49-0.56)

Number of Outpatient
encountersc

35.66
(34.66-36.66)

10.08
(9.46-10.69)

- Number of physician
visitsb

11.75b
(11.54-11.97)

3.05b
(2.97-3.13)

Number of prescription
fills

99.18
(97.69-100.67)

22.55
(22.08-23.01)

Cost per recipient, Mean (95% CI)
% of total
healthcare
related to
COPD
Hosp
ER visit
Outpatient

$4,495
($4,252-$4,738)

$2,404
($2,249-$2,560)

53.5%

$858
($815-$900)

$253
($234-$271)

29.5%

$7,283
($6,986-$7,580)

$2,368
($2,266-$2,469)

32.5%
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- Physician visitb

$1,024b
($991-$1,056)

$287b
($275-$299)

28.0%b

Prescription drugs

$5,303
($5,198-$5,408)

$1,321
($1,289-$1,354)

24.9%

$17,939
($17,435-$18,442)

$6,346
($6,110-$6,580)

35.4%

Total costs excluding
nursing home costs
a

COPD-related costs were computed from the paid amounts of the medical claims with a primary or secondary
diagnosis of COPD, and prescription claims of COPD-related drug classes. COPD-related drug classes
include: anticholinergics(ipratropium, ipratropium/albuterol), inhaled long-acting beta-agonists, short-acting
beta-agonists, inhaled corticosteroids, inhaled corticosteroid/long-acting beta-agonist combination,
methylxanthines, oral corticosteroids, and antibiotics for respiratory infections. COPD-related nursing home
costs could not be calculated due to the absence of diagnoses codes on nursing home claims.
b
Physician cost component is a sub-component of the Outpatient cost component.
c
An outpatient encounter is defined as any service for a particular recipient on a unique date that generated a
CPT code other than 99281-99285, 99288.
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TABLE 16: Utilization of COPD-related prescription drugs and home oxygen therapy for
recipients with COPD in WV (N=5,120) and KY (N=7,065) Medicaid
WV Medicaid
% (n)

KY Medicaid
% (n)

1. Any drug use

92.8% (4,751)

99.2% (7,006)

2. Non-COPD related prescription drug use

92.3% (4,724)

98.8% (5,108)

3. COPD-related prescription drug use

89.3% (4,572)

96.7% (6,832)

43.6% (2,233)

53.4% (3,775)

16.5% (845)

22.0% (1,554)

c. Short-acting beta-agonists (all doseforms)

58.9% (3,017)

70.1% (4,952)

d. Inhaled corticosteroids

27.9% (1,430)

35.0% (2,473)

e. Inhaled corticosteroids/Long-acting beta-agonist
combination (Fluticasone/Salmeterol)

25.6% (1,312)

24.7% (1,744)

f.

Methylxanthines

21.1% (1,084)

27.1% (1,916)

g. Oral corticosteroids

42.2% (2,160)

49.5% (3,494)

h. Antibiotics for respiratory infections

79.0% (4,047)

88.6% (6,258)

32.0% (1,640)

26.2% (1,851)

Prescription drug category

a. Anticholinergics (Ipratropium,
Ipratropium/Albuterol combination)
b. Inhaled Long-acting beta-agonists

4. Use of home oxygen therapy
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Discussion for Research Objective 1:
Objective 1 estimated three annual cost estimates for recipients with COPD: the total
healthcare costs, the COPD-related costs, and the incremental cost due to COPD. The three
provide different pieces of information that can be used by policymakers. The total
healthcare cost provides the annual average cost incurred by a recipient with COPD for any
healthcare use. The COPD-related costs are computed using only claims with a primary and
secondary diagnosis of COPD, and prescription drugs indicated for treating COPD. The total
healthcare cost is obviously not an accurate representation of how much a recipient with
COPD incurs due to COPD. The estimate of COPD-related costs as obtained from claims
data may under-estimate the costs incurred due to COPD. The reason is that costs incurred
by conditions resulting from a consequence of COPD are not captured. For instance,
congestive heart failure can be considered a COPD-related comorbidity, and may be
exacerbated in the presence of COPD or could also result from COPD. However, attributing
costs to different conditions as a result of COPD runs the risk of making untenable
assumptions, and consequently misestimating costs. Therefore, an incremental approach that
compares the costs incurred by recipients with COPD versus without COPD provides a better
representation of the costs incurred due to COPD. However, the difference in costs between
these two groups should be adjusted for other comorbid conditions and relevant
characteristics in multivariate analyses.
The results of objective 1 showed recipients with COPD to incur $15,350 to $18,569 per
person in total healthcare costs in the year 2002 using Medicaid claims data from two states.
Only two published studies have computed the total healthcare costs for recipients with
COPD. A study conducted by Strassels et al. estimated a person with COPD to cost $6,500
in 1987 (Strassels et al., 2001). At that time, hospitalizations accounted for the majority
(70%) of the total mean cost followed by that for outpatient (22%), while prescription drugs
accounted for a mere 8 percent of the total mean COPD expenditures. The other more recent
study by Mapel et al. in 1997 estimated an average of $11,678 with hospitalizations and
outpatient encounters accounting for an equivalent proportion of the total mean cost (~43%),
and prescription drugs accounting for 13.2 percent of the total mean cost (Mapel et al.,
2000a). Similar results were seen in the present study with hospitalizations (WV: 34.2% &
KY: 24.2%) and outpatient encounters (WV: 27.6% & KY: 39.2%) accounting for the
123

majority of costs in both states. Prescription drugs accounted for approximately 26-28
percent of the total healthcare costs in both states. The increase since the 1987 study in the
proportion accounted by prescription drugs this study can be explained by two reasons. For
one, at least 50 percent of recipients with COPD have at least one chronic condition and a
higher D’Hoore CCI. Several new prescription drugs have been approved since the past
decade for most therapeutic categories indicated for chronic conditions, and could explain the
increase in non-COPD related prescription drug use. Also, the pharmacological alternatives
for treating COPD have increased considerably in the past 5 years with the introduction of
long-acting beta-agonists and inhaled corticosteroids for COPD. This is in contrast to
Strassels’ 1987 study, where only ipratropium was primarily used for COPD.
It is of interest to note that in the two studies by Strassels et al. and Mapel et al., the
proportion of costs related to COPD was only ~25% of the total healthcare costs incurred by
recipients with COPD (Strassels et al., 2001; Mapel et al., 2000a). In the present study,
COPD-related costs represented 35 percent of the total healthcare costs incurred by recipients
with COPD (WV: $4,999 & KY: $6,346). For most cost components, the proportion of the
COPD-related cost to the total cost component ranged from 25 percent to 32 percent.
However, in the case of hospitalizations, costs for COPD-related hospitalizations comprised
almost 50 percent of the costs for all hospitalizations for recipients with COPD. This finding
emphasizes the impact that COPD can have on the hospitalization cost component compared
to other cost components.
In the present study, home oxygen therapy was used by 32 percent of the WV Medicaid
sample, and by 26 percent of the KY Medicaid sample. The mean cost computed represented
approximately 10 percent of the total COPD-related cost in both states. Three studies
conducted in the U.S. have provided information on the cost of home oxygen therapy. Ward
et al. determined home oxygen therapy to account for 35 percent of total COPD-related direct
medical costs in the U.S. in 1996 (Ward et al., 2000). Their exceedingly high estimate may
be due to the fact that it is based on the prevalence estimate of 616,000 persons receiving
home oxygen therapy in the U.S. in 1996, with the assumption that all have COPD. A recent
survey in the U.S. (Confronting COPD survey) found 26 percent of the sample to be using
home oxygen therapy, similar to our sample proportions, however, unlike our cost estimates,
home oxygen therapy was only 1% of the total direct medical costs (Halpern et al., 2003).
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The discrepancy maybe attributed to the fact that oxygen use was adjusted by the number of
days of use of oxygen therapy (Halpern, Musin, & Sondhi, 2003). Our estimates are similar
to a study by Hilleman et al. where oxygen therapy accounted for 15 to 20 percent of total
costs for patients with moderate and severe COPD, respectively (Hilleman et al., 2000).
In the present study, the incremental cost due to COPD was $3,952 per recipient in WV
Medicaid, and $4,979 per recipient in KY Medicaid after controlling for demographic
characteristics and other comorbid chronic conditions. Our estimates are very similar to the
recent cost of COPD study done in the U.S- the Confronting COPD survey, in which the
mean direct medical cost was $4,120 per patient (Halpern et al., 2003). This study is
considered the most comprehensive of all cost-of-illness studies in COPD since it also
included undiagnosed patients with COPD whose data are frequently not available in other
cost of illness studies including ours. The Confronting COPD survey found hospitalizations
to comprise 70 percent of the total direct medical costs with less than 17 percent and 1
percent accounted for by outpatient and prescription drug costs (Halpern et al., 2003). In our
study, hospitalizations still comprised the majority (~50%), however, outpatient and
prescription drugs comprised ~30 percent and ~20 percent, respectively of the total
incremental cost. The inclusion of undiagnosed patients in the Confronting COPD survey
may have reduced the proportion seeking treatment, and consequently the costs of the latter
components.
Our study showed that a recipient with COPD cost almost 1.5 to 1.7 times more than a
recipient without COPD. Similar estimates were found by Mapel et al. (ratio of 2.0) and
Grasso et al. (ratio of 2.4) (Mapel et al., 2000a; Grasso et al., 1998). The greatest difference
in costs was due to differences in costs for hospitalizations and ER costs emphasizing the
severe nature of the condition. In our study, nursing home costs was the only component
where recipients with COPD were found to incur lower costs than non-COPD recipients.
Available studies in the literature have not incorporated this cost component, and
consequently we have no studies to which we can compare our results. However, the lower
cost can probably be attributed to a policy initiative by Medicaid of reducing costs by
shifting to home-based care from nursing home care (Wiener, Tilly, & Alecxih, 2002).
Kentucky was one of seven states in the U.S. to participate in a home and community based
waiver system for older people and younger adults with physical disabilities, and might
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explain why a significant difference was found in the nursing home cost component as
opposed to that seen in the West Virginia sample (Wiener et al., 2002).
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Research Objective 2: To compare mean COPD-related costs among recipients with COPD
with and without a concomitant diagnosis of asthma enrolled in West Virginia and Kentucky
Medicaid.
Of the recipients with COPD identified in objective 1, 22 percent had concomitant
asthma in both states. A demographic distribution of these recipients with COPD by
concomitant asthma status is given in Table 17. Recipients with COPD with asthma in both
states were on average three years younger than those without asthma. Although statistically
significant, this difference is of no practical significance. Recipients with COPD with
asthma had a significantly higher proportion of females compared to those without asthma in
both states. In WV Medicaid, recipients with COPD with asthma were also significantly
more likely to be white compared to those without asthma. No differences were seen by race
in KY Medicaid. In terms of overall comorbidity, the two groups had similar D’Hoore CCI
(excluding asthma and CHF) and number of chronic conditions. In terms of COPD-related
comorbid disorders however, a significantly higher proportion of recipients with COPD with
asthma in both states were found to have upper respiratory tract infections, lower respiratory
tract infections, allergic rhinitis, other disease of the lung, and disorders of fluid, electrolyte,
and acid-base balance compared to recipients with COPD without asthma. The groups did
not differ in the proportions having septicemia and CHF, although in KY Medicaid, there
was a slightly higher proportion of recipients with COPD with asthma having CHF.
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TABLE 17: Characteristics of recipients with COPD with and without concomitant asthma in
WV and KY Medicaid
Characteristics

WV Medicaid
(N=5,120)

KY Medicaid
(N=7,065)

COPD
with
asthma
(N=1,115)

COPD
without
asthma
(N=4,005)

Test
Statistic
(p-value)

COPD
with
asthma
(N=1,523)

COPD
without
asthma
(N=5,542)

Test
Statistic
(p-value)

49 (8.0)

52 (7.7)

11.431
(0.000)*

49 (7.3)

51 (7.5)

11.201
(0.000)*

74.2 %
(809)

56.6%
(2,235)

109.972
(0.000)*

79.0%
(1,203)

60.2%
(3,335)

184.032
(0.000)*

95.1%
(1,051)

96.7%
(3,810)

6.192
(0.013)*

96.5%
(1,282)

96.8%
(4,683)

0.412
(0.521)

24.9%
(278)

23.9%
(958)

0.489
(0.485)

88.6%
(1,350)

89.5%
(4,961)

0.962
(0.327)

Overall
comorbidity
D’Hoore-CCIa
Mean (SD)
Median

1.9 (2.1)
2.0

1.8 (2.2)
1.0

-1.170
(0.242)

1.8 (2.0)
2.0

1.6 (2.1)
1.0

-4.213
(0.000)*

Number of other
chronic
conditionsb
Mean (SD)
Median

2.4 (1.4)
2.0

2.1 (1.4)
2.0

-6.839
(0.000)*

2.3 (1.4)
2.0

2.0 (1.4)
2.0

-7.23
(0.000)*

COPD-related
comorbid
disorders
Upper respiratory
tract infectionsc

67.1%
(748)

47.3%
(1,896)

136.151
(0.000)*

77.8%
(1,185)

57.8%
(3,203)

203.301
(0.000)*

Lower respiratory
tract infectionsd

27.1%
(302)

19.5%
(780)

30.301
(0.000)*

32.8%
(499)

19.4%
(1,074)

123.671
(0.000)*

1.3% (15)

2.0% (82)

2.311
(0.128)

2.6% (39)

2.1% (117)

1.118
(0.290)

19.5%

10.0%

73.871

22.1%

11.8%

105.64

Demographic
Age,
mean years (SD)
Female, % (n)
Race, % (n)
White
Countysmokerate
>= 31%

Septicimia
Allergic rhinitis
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(217)

(400)

(0.000)*

(337)

(654)

(0.000)*

Other diseases of
the lunge

37.0%
(413)

28.0%
(1,120)

34.251
(0.000)*

35.8%
(545)

27.5%
(1,523)

39.791
(0.000)*

Congestive heart
failure

22.2%
(248)

21.8%
(873)

0.1011
(0.751)

24.8%
(377)

20.7%
(1,149)

11.411
(0.001)*

Disorders of fluid,
electrolyte, and
acid-base balance

24.0%
(268)

19.1%
(764)

13.331
(0.000)*

23.0%
(350)

17.4%
(964)

24.631
(0.000)*

* p<0.05
a
Excludes asthma and congestive heart failure
b
Includes hypercholesterolemia, hypertension, other heart disease, AIDS, rheumatoid arthritis, osteoarthritis,
gall bladder disease, depression and anxiety, and schizophrenia.
c
Includes influenza, acute bronchitis and bronchiolitis, bronchitis not specified as acute or chronic, acute
nasopharyngitis, acute laryngitis, acute tracheitis, acute laryngotracheitis, acute epiglottis, supraglottis, acute
laryngopharyngitis, acute upper respiratory infections of multiple and unspecified sites.
d
Includes pneumonia from bacterial, viral, other specified organisms, and organism unspecified.
e
Includes pleurisy, pneumothorax, abscess of lung and mediastinum, pulmonary congestion and hypostasis,
pulmonary collapse, interstitial emphysema, compensatory emphysema, pulmonary eosinophilia, acute edema
of lung, pulmonary insufficiency following trauma and surgery, allergic bronchopulmonary aspegillosis, and
acute and chronic respiratory failure.
1
t-test statistic 2Chi-square test statistic 3Mann-Whitney U-statistic

Tables 18 and 19 compare the COPD-related utilization and costs for recipients with
COPD with and without concomitant asthma in WV and KY Medicaid, respectively. A
significantly higher proportion of recipients with COPD with concomitant asthma in both
states had at least one COPD-related hospitalization compared to those without asthma
(Table 18_WV: 42.8% vs. 30.2%; Table 19_KY: 46.5% vs. 30.6%) together with a higher
mean number of COPD-related hospitalizations per recipient. Similar trends were seen for
ER visits in both states (Table 18_WV: 42.5% vs. 27.7%; Table 19_KY: 40.1% vs. 26.7%).
Similar proportions of recipients with COPD with and without asthma had at least one
physician visit in WV Medicaid; however the mean number of COPD-related physician visits
was significantly higher for those with asthma (Table 18_WV: 2.32 vs. 2.05). These
measures were both significantly higher for KY Medicaid recipients with COPD with asthma
compared to those without asthma. Recipients with COPD with concomitant asthma had a
significantly higher mean number of fills in both states. On average, recipients with COPD
with asthma were prescribed one additional COPD-related drug class compared to those
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without asthma in both states (Table 18_WV: 4 vs. 3; Table 19_KY: 5 vs. 4). This difference
was statistically significant.
Tables 20 and 21 present the proportion of recipients with COPD using each of eight
COPD-related drug classes and home oxygen therapy in WV and KY Medicaid, respectively.
A higher proportion of recipients with COPD with concomitant asthma were found to be
using drugs for COPD in all classes of COPD-related drugs in both states (Table 20 and
Table 21). Of note, the maximum difference in proportion between the two groups was seen
for the use of short-acting beta-agonists (Table 20_WV: 74.7% vs. 54.5%; Table 21_KY:
86.1% vs. 65.7%) and oral corticosteroids (Table 20_WV: 63.7% vs. 36.2%; Table 21_KY:
71.8% vs. 43.3%). Another interesting observation was that at least 50 percent of recipients
with COPD with asthma were found to be using inhaled corticosteroids in KY Medicaid
compared to 39 percent in WV Medicaid. Additionally, the difference in proportions using
inhaled corticosteroids between recipients with COPD with and without asthma was
comparable to that for short-acting beta-agonists and oral corticosteorids (Table 21_KY:
50.5% vs. 30.7%). This difference in proportion was lower in WV Medicaid (Table 20_WV:
38.9% vs. 24.9%). In WV Medicaid, similar proportions of recipients with COPD with and
without concomitant asthma were found to be using home oxygen therapy. In KY Medicaid,
however, a significantly higher proportion of recipients with COPD with asthma were using
home oxygen therapy (Table 21_KY: 31.7% vs. 24.6%) compared to those without asthma.
The presence of an asthma diagnosis significantly increased the average COPD-related
cost of a recipient with COPD by $2,271 in WV Medicaid (Table 22) and by $3,518 (Table
23) in KY Medicaid. For both states, univariate analyses showed statistically significant
higher cost for all COPD-related cost components for recipients with COPD with asthma
compared to those without asthma. In multivariate analyses, recipients with COPD with
asthma had a higher cost for all COPD-related cost components. However, the cost
difference per recipient was statistically significant only for prescription drugs in both states.
Recipients with COPD with asthma were found to incur almost 50% higher costs in COPDrelated prescription drug costs compared to those without asthma (Table 22_WV: 48.5%;
Table 23_KY: 50.7%). No difference was seen in both states between recipients with COPD
with and without asthma in costs for physician visits. Contrary to the results found for the
WV Medicaid sample, costs for hospitalization, ER, and outpatient was found to be
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statistically significantly higher for recipients with COPD with asthma compared to those
without asthma (Table 22_WV & Table 23_KY). However, it is interesting to note that
asthma significantly increased the odds of a COPD-related hospitalization in both states, as
noted in part 1 of the two-part cost model (See Appendix A: Table A15_WV: OR=1.561 &
Table A21_KY: OR=1.633). A similar pattern was seen for a COPD-related ER visit (See
Appendix A: Table A16_WV: OR=1.608 & Table A22_KY: OR=1.448).
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TABLE 18: COPD-relateda utilization and costs per recipient for recipients with COPD with and
without concomitant asthma in WV Medicaid
COPDRelateda Cost
Component
(unit of use)

COPD with
asthma
(N=1,115)

COPD without
asthma
(N=4,005)

Test Statistic
(p-value)

% (n) with use
Hosp

42.8% (477)

30.2% (1,211)

62.091 (0.000)*

ER

42.5% (474)

27.7% (1,108)

90.031 (0.000)*

Outpatient

91.3% (1,018)

92.3% (3,695)

1.101 (0.295)

- Physicianb

65.6%b (731)

62.6%b (2,508)

3.241 (0.07)

Prescription

93.2% (1,039)

88.2% (3,533)

22.531 (0.000)*

Amount of use, Mean per recipient (95% CI)
Number of
hosp visits

0.80
(0.72-0.89)

0.48
(0.45-0.51)

1923298.52
(0.000)*

Number of ER
visits

0.86
(0.76-0.97)

0.45
(0.40-0.49)

1859533.52
(0.000)*

Number of
Outpatient
encountersc

9.14
(8.53-9.75)

8.35
(8.04-8.66)

2148398.02
(0.052)

- Number of
physician
visitsb

2.32b
(2.15-2.49)

2.05b
(1.97-2.13)

2120443.02
(0.008)*

Number of
prescription
fills

21.33
(20.31-22.36)

14.72
(14.23-15.21)

1626838.02
(0.000)*

4.04
(3.93-4.14)

2.90
(2.85-2.96)

-18.073
(0.000)*

- Number of
unique COPDrelated drug
classes

Costs, Mean per recipient (95% CI)
Hosp

$4,041
($3,492-$4,590)

$2,531
($2,321-$2,741)
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Difference
$1,510

1941964.52
(0.000)*

$365
($314-$417)

$190
($169-$211)

$175

1875579.52
(0.000)*

Outpatient

$1,114
($1,012-$1,216)

$984
($929-$1,039)

$130

2095245.52
(0.000)*

- Physician
visitb

$187b
($161-$212)

$146b
($134-$157)

$41b

2045981.52
(0.000)*

Prescription
drugs

$1,227
($1,154-$1,299)

$807
($776-$839)

$420

1635821.52
(0.000)*

Total costs

$6,747
($6,122-$7,372)

$4,513
($4,265-$4,761)

$2,234

1725798.02
(0.000)*

ER visit

* p<0.05
a
COPD-related costs were computed from the paid amounts of the medical claims with a primary or secondary
diagnosis of COPD, and prescription claims of COPD-related drug classes. COPD-related drug classes
include: anticholinergics(ipratropium, ipratropium/albuterol), inhaled long-acting beta-agonists, short-acting
beta-agonists, inhaled corticosteroids, inhaled corticosteroid/long-acting beta-agonist combination,
methylxanthines, oral corticosteroids, and antibiotics for respiratory infections. COPD-related nursing home
costs could not be calculated due to the absence of diagnoses codes on nursing home claims.
b
Physician cost component is a sub-component of the Outpatient cost component.
c
An outpatient encounter is defined as any service for a particular recipient on a unique date that generated a
CPT code other than 99281-99285, 99288.
1
Chi-square test statistic; 2Mann-Whitney U-statistic; 3t statistic
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TABLE 19: COPD-relateda utilization and costs per recipient for recipients with COPD with and
without concomitant asthma in KY Medicaid
COPDRelateda Cost
Component
(unit of use)

COPD with
asthma
(N=1,523)

COPD without
asthma
(N=5,542)

Test Statistic
(p-value)

% (n) with use
Hosp

46.5% (708)

30.6% (1,696)

134.281 (0.000)*

ER

40.1% (610)

26.7% (1,482)

101.561 (0.000)*

Outpatient

83.7% (1,274)

83.7% (4,640)

0.0051 (0.945)

- Physicianb

77.8%b (1,185)

74.5%b (4,130)

6.921 (0.009)*

Prescription

99.0% (1,508)

96.1% (5,324)

32.571 (0.000)*

Amount of use, Mean per recipient (95% CI)
Number of
hosp visits

0.98
(0.89-1.07)

0.54
(0.51-0.57)

3494277.02
(0.000)*

Number of ER
visits

0.88
(0.78-0.98)

0.42
(0.39-0.45)

3587644.52
(0.000)*

Number of
Outpatient
encountersc

8.60
(7.58-9.62)

10.48
(9.75-11.22)

3971016.02
(0.000)*

- Number of
physician
visitsb

3.53b
(3.33-3.74)

2.92b
(2.83-3.00)

3880827.52
(0.000)*

Number of
prescription
fills

30.74
(29.64-31.83)

20.30
(19.80-20.79)

2846350.02
(0.000)*

4.70
(4.62-4.78)

3.43
(3.39-3.48)

2545424.52
(0.000)*

- Number of
unique COPDrelated drug
classes

Costs, Mean per recipient (95% CI)
Hosp

$3,737
($3,306-$4,167)

$2,038
($1,881-$2,196)
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Difference
$1,699

34383331.52
(0.000)*

$402
($349-$454)

$212
($193-$231)

$190

3603196.52
(0.000)*

Outpatient

$2,653
($2,411-$2,896)

$2,289
($2,178-$2,400)

$364

3870278.02
(0.000)*

- Physician
visitb

$343b
($313-$374)

$271b
($259-$284)

$72b

3896708.02
(0.000)*

Prescription
drugs

$1,826
($1,749-$1,902)

$1,182
($1,148-$1,217)

$644

2875742.02
(0.000)*

Total costs

$8,617
($7,982-$9,253)

$5,721
($5,480-$5,963)

$2,896

3151009.52
(0.000)*

ER visit

* p<0.05
a
COPD-related costs were computed from the paid amounts of the medical claims with a primary or secondary
diagnosis of COPD, and prescription claims of COPD-related drug classes. COPD-related drug classes
include: anticholinergics(ipratropium, ipratropium/albuterol), inhaled long-acting beta-agonists, short-acting
beta-agonists, inhaled corticosteroids, inhaled corticosteroid/long-acting beta-agonist combination,
methylxanthines, oral corticosteroids, and antibiotics for respiratory infections. COPD-related nursing home
costs could not be calculated due to the absence of diagnoses codes on nursing home claims.
b
Physician cost component is a sub-component of the Outpatient cost component.
c
An outpatient encounter is defined as any service for a particular recipient on a unique date that generated a
CPT code other than 99281-99285, 99288.
1
Chi-square test statistic; 2Mann-Whitney U-statistic; 3t statistic
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TABLE 20: Utilization of COPD-related prescription drugs and home oxygen therapy for
recipients with COPD with and without concomitant asthma in WV Medicaid
Prescription drug category

COPD with
asthma
(N=1,115)

COPD
without
asthma
(N=4,005)

% (n)

% (n)

93.2% (1,039)

88.2% (3,533)

22.531
(0.000)*

a. Anticholinergics (Ipratropium,
Ipratropium/Albuterol combination)

53.1% (592)

41.0% (1,641)

52.101
(0.000)*

b. Long-acting beta-agonists

22.6% (252)

14.8% (593)

38.451
(0.000)*

c. Short-acting beta-agonists

74.7% (833)

54.5% (2,184)

146.701
(0.000)*

d. Inhaled corticosteroids

38.9% (434)

24.9% (996)

85.591
(0.000)*

e. Inhaled corticosteroids/Long-acting
beta-agonist combination
(Fluticasone/Salmeterol)

36.9% (411)

22.5% (901)

94.421
(0.000)*

f.

Methylxanthines

27.4% (305)

19.5% (779)

32.651
(0.000)*

g. Oral corticosteroids

63.7% (710)

36.2% (1,450)

269.901
(0.000)*

h. Antibiotics for respiratory
infections

86.4% (963)

77.0% (3,084)

46.171
(0.000)*

31.5% (351)

29.5% (1,181)

1.651
(0.199)

1. COPD-related prescription drug use

2. Use of home oxygen therapy
* P < 0.05
1
Chi-square test statistic
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Test Statistic
(p-value)

TABLE 21: Utilization of COPD-related prescription drugs and home oxygen therapy for
recipients with COPD with and without concomitant asthma in KY Medicaid
Prescription drug category

COPD with
asthma
(N=1,523)

COPD without
asthma
(N=5,542)

% (n)

% (n)

100.0% (1,523)

96.6% (4,894)

3.621
(0.06)

a. Anticholinergics (Ipratropium,
Ipratropium/Albuterol combination)

62.3% (949)

51.0% (2,826)

61.511
(0.000)*

b. Long-acting beta-agonists

30.5% (464)

19.7% (1,090)

81.191
(0.000)*

c. Short-acting beta-agonists

86.1% (1,312)

65.7% (3,640)

238.71
(0.000)*

d. Inhaled corticosteroids

50.5% (769)

30.7% (1,704)

204.71
(0.000)*

e. Inhaled corticosteroids/Long-acting
beta-agonist combination
(Fluticasone/Salmeterol)

38.1% (581)

21.0% (1,163)

189.21
(0.000)*

f.

Methylxanthines

35.9% (547)

24.7% (1,369)

76.011
(0.000)*

g. Oral corticosteroids

71.8% (1,094)

43.3% (2,400)

388.91
(0.000)*

h. Antibiotics for respiratory infections

94.6% (1,440)

86.9% (4,818)

68.461
(0.000)*

31.7% (483)

24.6% (1,365)

34.041
(0.000)*

1. COPD-related prescription drug use

2. Use of home oxygen therapy
* P < 0.05
1
Chi-square test statistic
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Test
Statistic (pvalue)

TABLE 22: Mean incremental COPD-related cost per recipient for recipients with COPD with
and without concomitant asthma in WV Medicaid
COPD-related
Cost
Component

Adjusteda

Unadjusted
Difference in
cost per recipient

Difference in
cost per recipient

Percentage difference
in costsb

$1,510*

$994

+42.4%

Model
Details in
Appendix
table
A15

ER visit

$175*

$104

+52.6%

A16

Outpatient

$130*

$82

+7.6%

A17

- Physician
visitc

$41c*

$13c

+9.3%

A18

Prescription
drugs
Total costs

$420*

$407*

+48.5%*

A19

$2,234*

$2,271d*

+47.9%*

A20

Hosp

* p < 0.05
a
Covariates include age, gender, race, countysmokingrate, D’Hoore-CCI excluding asthma & CHF, number of
other chronic conditions, presence of asthma, upper respiratory tract infections, lower respiratory tract
infections, septicemia, allergic rhinitis, other diseases of the lung, congestive heart failure, and disorders of
fluid, electrolyte, and acid-base imbalance.
b
(Cost per COPD recipient – Cost per non-COPD recipient) / Cost per non-COPD recipient. + indicates that
COPD recipients have higher costs than those without COPD. * indicates that the difference was statistically
significant.
c
Physician cost component is a sub-component of the Outpatient cost component.
d
Total adjusted cost may not reflect the sum of individual cost components because estimates are obtained from
individual regression models for each component.
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TABLE 23: Mean incremental COPD-related costs per recipient for recipients with COPD with
and without concomitant asthma in KY Medicaid
COPD-related
Cost
Component

Adjusteda

Unadjusted
Difference in
cost per recipient

Difference in
cost per recipient

Percentage difference
in costsb

$1,699*

$1,146*

+61.0%*

Model
Details in
Appendix
table
A21

ER visit

$190*

$105*

+58.2%*

A22

Outpatient

$364*

$334*

+13.8%*

A23

- Physician
visitc

$72c*

$15

+6.6%

A24

Prescription
drugs
Total costs

$644*

$611*

+50.7%*

A25

$2,896*

$3,518*

+60.3%*

A26

Hosp

* p < 0.05
a
Covariates include age, gender, race, countysmokingrate, D’Hoore-CCI excluding asthma & CHF, number of
other chronic conditions, presence of asthma, upper respiratory tract infections, lower respiratory tract
infections, septicemia, allergic rhinitis, other diseases of the lung, congestive heart failure, and disorders of
fluid, electrolyte, and acid-base imbalance.
b
(Cost per COPD recipient – Cost per non-COPD recipient) / Cost per non-COPD recipient. + indicates that
COPD recipients have higher costs than those without COPD. * indicates that the difference was statistically
significant.
c
Physician cost component is a sub-component of the Outpatient cost component.
d
Total adjusted cost may not reflect the sum of individual cost components because estimates are obtained from
individual regression models for each component.
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Discussion for Research Objective 2
The airflow limitation in COPD was initially thought to be completely irreversible while
that in asthma was thought to be completely reversible. However, studies conducted in the
past few years that have shown the presence of significant reversibility or partial reversibility
in patients with COPD, and of non-reversible airflow obstruction in patients with asthma
demonstrate that these conditions can coexist (Mannino, 2002). In our study, 22 percent of
the total recipients identified as having COPD also had a concomitant diagnosis of asthma
similar to the 21 percent found in the 1996 National Health Interview Survey (NHIS)
(Mannino, 2002). A higher proportion was found in another study that analyzed data from
medical records of patients with COPD with almost half of all patients with COPD having
asthma (Mapel, 2004).
There are no studies in the literature that have determined if the presence of asthma
increases the economic burden for patients with COPD although some preliminary
comparisons from the 1996 NHIS data provides some indication (Mannino, 2002). In that
study, the lung function, respiratory symptoms, and activity limitation was compared among
patients with COPD with asthma versus those without asthma. A total of 29.9 percent
reportedly had low lung function compared to 17.4 percent of patients with COPD without
asthma. Additionally, differences were seen in almost all characteristic COPD symptoms of
cough, phlegm, wheeze, and shortness of breath with at least 95 percent versus 84 percent
experiencing any symptom for those with and without asthma, respectively. The
significantly increased prevalence of other respiratory conditions found in our study for
recipients with COPD with concomitant asthma may explain the higher proportions
experiencing symptoms in the NHIS. The NHIS only documented indicators of indirect costs
between COPD patients with and without asthma, and found significantly more days of
restricted activity, bed confinement, and work loss.
Our study documented only direct medical costs and showed that recipients with COPD
with asthma have increased use of COPD-related healthcare resources than those without
asthma. The marginal cost of asthma was quite substantial, and ranged from $2,200 in WV
Medicaid to $3,500 in KY Medicaid, reflecting a percentage difference of 50 to 60 percent.
Of note, asthma significantly increased the odds of having a COPD-related hospitalization
and ER visit for recipients with COPD in both states. Although the cost differences for
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hospitalization, ER, and outpatient cost components were found to be higher for those with a
concomitant diagnosis of asthma in both states, this difference was statistically significant
only in the KY Medicaid sample. This discrepancy may point to a difference in treatment
approaches of recipients with COPD with asthma versus without asthma in the two states.
An indication of this differential approach can be seen in the use of inhaled corticosteroids
and home oxygen therapy in the two states. Specifically, in KY Medicaid, at least 50 percent
of the recipients with COPD with asthma were found to be using inhaled corticosteroids
compared to 39 percent in WV Medicaid. Additionally, the difference in proportions using
inhaled corticosteroids between recipients with COPD with and without asthma in KY
Medicaid (Table 21_KY: 50.5% vs. 30.7%) was lower to the difference in proportion in WV
Medicaid (Table 20_WV: 38.9% vs. 24.9%). Also, the proportion using home oxygen
therapy was significantly higher for the recipients with COPD with concomitant asthma in
the KY Medicaid sample contrary to the WV Medicaid sample where similar proportions
were found. Thus, it is probable that recipients with COPD in KY Medicaid with
concomitant asthma are treated using more resources compared to those in WV Medicaid,
and may explain the statistically significant higher COPD-related cost components found in
the former sample.
Another interesting finding was that after controlling for demographic characteristics and
comorbid conditions, the presence of asthma significantly increased the costs of prescription
drugs by 50 percent. It should be noted that a higher proportion of recipients with COPD
with asthma were using all COPD-related drug classes, and not solely those that are more
commonly used for asthma (e.g. an increase was seen for both ipratropium (primarily
indicated for COPD) and inhaled corticosteroid (primarily indicated for asthma). This may
indicate that the drug treatment is not specifically targeted to treating asthma but treating the
respiratory syndrome as a whole.
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Phase II
Part 1
Phase II of the study compares costs and exacerbations of recipients initiating drug therapy.
Part 1 of phase II compares these outcomes between recipients initiating therapy with a
combination product of ipratropium and albuterol (IPR/ALB) or monotherapy with inhaled
long-acting beta-agonist (LABA). Table 24 outlines the extraction process from raw data to
obtain the study sample.

TABLE 24: Sample extraction for Phase II – Part 1
Step
1. # with a Rx claim for IPR/ALB or LABA
during: WV- Jul 1, 1998 to Jun 30, 2002
and KY-Jan 1, 1999 to Dec 31, 2002

Outcome WV

Outcome KY

A = 19,257
-IPR/ALB = 8,204
-LABA = 11,053

A = 43,256
-IPR/ALB = 21,265
-LABA = 21,991

2. The date of first chronologically occurring prescription claim was defined as an index
date for each person
3. # of A between 35-64 years, continuously
eligible for Medicaid and not enrolled in
managed care at anytime during study
period

B = 6,646
-IPR/ALB = 3,012
-LABA = 3,634

B = 14,533
-IPR/ALB = 7,727
-LABA = 6,806

4. # of B without a Rx claim for IPR/ALB or
IPR, LABA, or ICS in the pre-index period
and those without a Rx claim for LABA
(IPR/ALB group), IPR/ALB or IPR (LABA
group) or ICS in the 30 days post-index
period

C = 2,505
-IPR/ALB = 1,696
-LABA = 809

C = 5,364
-IPR/ALB = 4,136
-LABA = 1,228

5. # of C without Home O2 therapy in preindex period

D = 2,401
-IPR/ALB = 1,618
-LABA = 783

D = 5,230
-IPR/ALB = 4,030
-LABA = 1,200

6. # of D without diagnosis of cystic fibrosis,
fibrosis due to tuberculosis, respiratory
cancer, and bronchiectasis during study
period

E = 2,345
-IPR/ALB = 1,581
-LABA = 764

E = 5,132
-IPR/ALB = 3,952
-LABA = 1,180

7. # of E with at least one ER visit or at least
two outpatient encounters on different dates
with a primary or secondary diagnosis of
COPD but do not have a hospitalization
with a primary or secondary diagnosis of
COPD in pre-index period

F = 374
-IPR/ALB = 250
-LABA = 124

F = 780
-IPR/ALB = 624
-LABA = 156
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8. # of F with at least 1 additional Rx claim of
index drug therapy in follow-up period.

G = 213
-IPR/ALB = 130
-LABA = 83

9. Final study sample size

Total
= 691
-IPR/ALB = 506
-LABA
= 185

G = 478
-IPR/ALB = 376
-LABA = 102

A total of 691 recipients met the inclusion criteria for the study design of Part 1 of Phase
II. A majority of the recipients were initiated on combination ipratropium/albuterol (73.2%).
The majority of the long-acting beta-agonist group was initiated on salmeterol, and only 11
people had formoterol as their index LABA as formoterol was introduced in 2002. The study
design selected recipients with relatively less severe COPD by excluding those with a
hospitalization for COPD and home oxygen therapy in the pre-index period. The design
ensured almost comparable drug therapy groups at baseline. As can be seen in table 25,
which outlines the baseline characteristics of the study sample, the groups were similar in
terms of demographic characteristics except in the smoking prevalence rate of their
residential county. A significantly higher proportion of recipients initiated on combination
ipratropium/albuterol resided in counties with a smoking prevalence rate of at least 31%. No
differences were observed in overall comorbidity burden. The groups differed on two
measures of COPD severity: the use and number of canisters of inhaled short-acting betaagonists (SABA), and in the use and number of prescriptions of nebulized short-acting
bronchodilators (SABD). In particular, the LABA group was found to have a significantly
higher proportion of recipients using inhaled SABA and nebulized SABD. No differences
were seen for other measures.
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TABLE 25: Baseline characteristics of study sample by drug therapy status (IPR/ALB vs.
LABA: Phase II – Part 1)
Characteristic

IPR/ALB
(N= 506)

LABA
(N= 185)

Test Statistic
(p-value)
* = values <0.05

Demographic
52 (7.5)

51 (7.6)

1.5931 (0.112)

Female, % (n)

56.8% (287)

55.4% (102)

0.1072 (0.744)

White, % (n)

96.5% (440)

97.7% (171)

0.6162 (0.432)

WV

25.7% (130)

44.9% (83)

23.3552 (0.000)*

KY

74.3% (376)

55.1% (102)

72.3% (366)

63.2% (117)

5.3192 (0.021)*

Mean (SD)
Median

1.2 (1.7)
0.0

1.1 (1.8)
0.0

1.2573 (0.209)

Number of other chronic conditionsb
Mean (SD)
Median

1.8 (1.3)
2.0

1.9 (1.4)
2.0

-0.5803 (0.562)

Use of inhaled SABAc canisters, % (n)
Mean # of canisters (SD)
Median

51.4% (260)
2.9 (5.1)

63.2% (117)
4.4 (6.5)

7.6862 (0.006)*
-3.3303 (0.001)*

Use of other doseform SABDd, % (n)
Mean # of Rx (SD)
Median

25.3% (128)
1.3 (3.2)

28.7% (53)
1.7 (4.0)

0.7872 (0.375)
-0.9223 (0.357)

Use of OCSe, % (n)

29.1% (147)
0.6 (1.6)

23.8% (44)
0.6 (1.7)

1.8792 (0.170)
1.3473 (0.178)

Use of nebulized SABDd, % (n)
Mean # of Rx (SD)
Median

10.1% (51)
0.3 (1.4)
0.0

18.9% (35)
0.4 (1.4)
0.0

9.7152 (0.002)*
-2.9233 (0.004)*

Use of Hosp/ER for COPD-related

43.7% (221)

42.2% (78)

0.1272 (0.722)

Age, mean years (SD)

State, % (n)

Countysmokerate >=31%
Overall Comorbidity
D’Hoore-CCIa

COPD severity

Mean # of Rx (SD)
Median
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comorbid disordersf, % (n)
Mean (SD)
Median
Use of Physician visits for COPDrelated comorbid disordersf, % (n)
Mean (SD)
Median
Presence of asthma, % (n)

0.8 (1.3)
0.0

0.7 (1.0)
0.0

0.7393 (0.460)

85.3% (432)

85.4% (158)

0.0012 (0.992)

3.5 (2.9)
3.0

3.5 (3.2)
3.0

0.4133 (0.680)

8.9% (45)

11.9% (22)

1.3912 (0.238)

*p < 0.05
a
Excludes asthma
b
Includes hypercholesterolemia, hypertension, other heart disease, AIDS, rheumatoid arthritis, osteoarthritis,
gall bladder disease, depression and anxiety, and schizophrenia.
c
Short-acting beta-agonist: includes levalbuterol, albuterol, metaproterenol, bitolterol, terbutaline.
d
Short-acting bronchodilators: includes levalbuterol, albuterol, metaproterenol, bitolterol, terbutaline, and
theophylline
e
Oral corticosteroids: includes prednisone, prednisolone, methylprednisolone, cortisone, hydrocortisone,
dexamethasone, betamethasone, oral triamcinolone, oral budesonide.
f
Includes COPD, asthma, upper respiratory tract infections, lower respiratory tract infections, septicemia,
allergic rhinitis, other diseases of the lung, congestive heart failure, and disorders of fluid, electrolyte, and acidbase imbalance.
1
t statistic; 2Chi-square test statistic; 3Mann-Whitney U-statistic
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Research Objective 3: To compare the risk and frequency of exacerbations between
recipients with COPD who initiated therapy with ipratropium/albuterol or monotherapy with
inhaled long-acting beta-agonist.
A total of 141 (20.4%) recipients experienced at least one exacerbation in the follow-up
period, with a majority of the exacerbations being moderate in nature. The chi-square test
and the log-rank test showed no differences between the drug therapy groups in the
proportion experiencing an exacerbation or in the time to exacerbation, respectively, as seen
in table 26. Similar results were seen in the multivariate analyses. Following no violation of
the proportional hazards assumption, the Cox-proportional hazards regression model was
used to determine differences between drug therapy groups in their time to exacerbation
(Table 27). Similar to findings from univariate analyses, those initiated on a LABA had a
lower hazard of experiencing an exacerbation compared to the IPR/ALB group, but this
difference was not statistically significant (Figure 18 and Table 27). A logistic regression
analyses was also conducted that determined differences in the probability of experiencing an
exacerbation, and similar results were seen (Table 28). The zero-inflated Poisson model
showed no differences in the frequency of exacerbations between drug therapy groups (Table
29)
Research Objective 4: To compare COPD-related costs between recipients with COPD who
initiated therapy with ipratropium/albuterol or monotherapy with inhaled long-acting betaagonist.
Table 26 also lists the total COPD-related costs incurred by recipients in the two drug
therapy groups. No differences were observed in total COPD-related costs, as well as in
individual COPD-related cost components except for COPD-related prescription drug costs.
In univariate analyses, recipients initiated on a long-acting beta-agonist were found to incur
$140 in incremental COPD-related prescription drug costs compared to those initiated on
combination IPR/ALB. Multivariate semi-log OLS models were run to determine
differences in total COPD-related costs, and no differences were seen (Table 30). Following
the significant difference found between drug therapy groups for COPD-related prescription
drug costs in univariate analyses, multivariate analyses were done only for the COPD-related
prescription drug cost component, and again recipients initiated on LABA therapy were
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found to incur 23.7 percent higher costs with an adjusted incremental cost of $163 (Table
31).

TABLE 26: Exacerbations and costs in follow-up period by drug therapy status (IPR/ALB vs.
LABA: Phase II – Part 1)
Characteristic

IPR/ALB
(N=506)

LABA
(N=185)

Test Statistic
(p-value)
* = values <0.05

Mean
Median

20.8% (105)
0.3 (0.8)
0.0

19.5% (36)
0.3 (0.8)
0.0

0.1391 (0.709)
0.5222 (0.602)

Mean
Median

6.1% (35)
0.1 (0.3)
0.0

8.1% (15)
0.1 (0.5)
0.0

0.2861 (0.593)
-0.5922 (0.554)

Mean
Median

16.6% (84)
0.3 (0.6)
0.0

14.1% (26)
0.2(0.5)
0.0

0.6561 (0.418)
0.9772 (0.328)

Mean (SD)

319 (100.5)

331 (85)

0.8003 (0.370)

Mean (SD)

$2,093
(3446.5)

$2,657
(5393.8)

-1.6232 (0.105)

$831
(2525.4)

$1,214
(4569.7)

0.6512 (0.515)

Mean (SD)

$120
(356.6)

$108
(299.0)

0.5862 (0.558)

Mean (SD)

$461
(1140.0)

$514
(1100.5)

0.9492 (0.342)

$681
(622.7)

$821
(552.1)

-3.9112 (0.000)*

Total exacerbations (%, n)

Severe exacerbations (%, n)

Moderate exacerbations (%, n)

Time to exacerbation (days)

Total COPD-related costs

COPD-related hospitalization costs
Mean (SD)
COPD-related ER costs

COPD-related Outpatient costs

COPD-related Prescription drug costs
Mean (SD)

*p < 0.05
1
Chi-square test statistic; 2Mann-Whitney U-statistic; 3Log-rank test statistic
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TABLE 27: Cox-Proportional hazards regression of the impact of drug therapy (IPR/ALB or
LABA) on time to exacerbation
DV: Time to exacerbation
Hazard ratio (SE)

Variable

95% CI

p
value

Drug therapy (Ref: IPR/ALB)
LABA

0.871 (0.212)

0.541 - 1.403

0.570

Age (years)

1.015 (0.014)

0.987 - 1.044

0.281

Gender (Ref: Male)
Female

1.771 (0.393)

1.146 - 2.738

0.010*

Race (Ref: non-White)
White

1.225 (0.883)

0.298 - 5.034

0.779

State (Ref: WV )
KY

1.166 (0.311)

0.692 - 1.965

0.564

County_Smokerate (Ref: <31%)
>=31%

1.324 (0.357)

0.781 - 2.245

0.297

D’Hoore-CCI

0.931 (0.066)

0.810 - 1.070

0.313

Number of other chronic conditions

0.788 (0.071)

0.660 - 0.941

0.008*

# of inhaled SABA canisters

1.017 (0.020)

0.979 - 1.057

0.389

# of other doseform SABD prescriptions

0.993 (0.032)

0.931 - 1.059

0.826

# of OCS prescriptions

1.071 (0.048)

0.981 - 1.059

0.127

Use of nebulized SABD

1.140 (0.333)

0.643 - 2.021

0.653

# of Hosp/ER visits for COPD-related
comorbid disorders

1.373 (0.091)

1.205 - 1.564

0.000*

# of Physician visits for COPD-related
comorbid disorders

1.016 (0.035)

0.951 - 1.086

0.632

Presence of asthma

1.218 (0.393)

0.646 - 2.294

0.542

Demographic

Overall comorbidity

COPD severity

*p < 0.05
Log likelihood = -609.04; χ2 = 49.74; p=0.000*
Global test of proportional hazards assumption: χ2 = 19.34; p=0.245
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FIGURE 18: Adjusted Kaplan-Meier survival curve of time to exacerbation by drug therapy
group (IPR/ALB vs. LABA: Phase II – Part 1)
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TABLE 28: Logistic regression of the impact of drug therapy (IPR/ALB or LABA) on
probability of exacerbation
DV: Probability of exacerbation
Odds ratio (SE)

Variable

95% CI

p
value

Drug therapy (Ref: IPR/ALB)
LABA

0.844 (0.232)

0.493 – 1.446

0.538

Age (years)

1.017 (0.016)

0.986 – 1.049

0.299

Gender (Ref: Male)
Female

1.920 (0.478)

1.179 – 3.127

0.009*

Race (Ref: non-White)
White

1.697 (1.385)

0.343 – 8.401

0.517

State (Ref: WV )
KY

1.125 (0.331)

0.632 – 2.002

0.689

County_Smokerate (Ref: <31%)
>=31%

1.381 (0.413)

0.768 – 2.482

0.281

D’Hoore-CCI

0.926 (0.074)

0.792 – 1.083

0.334

Number of other chronic conditions

0.762 (0.077)

0.625 – 0.930

0.007*

# of inhaled SABA canisters

1.025 (0.022)

0.983 – 1.069

0.252

# of other SABD prescriptions

0.994 (0.036)

0.926 – 1.068

0.878

# of OCS prescriptions

1.082 (0.062)

0.967 – 1.210

0.168

Use of nebulized SABD

1.194 (0.404)

0.615 – 2.318

0.601

# of Hosp/ER visits for COPD-related
comorbid disorders

1.500 (0.144)

1.242 – 1.812

0.000*

# of Physician visits for COPD-related
comorbid disorders

1.021 (0.041)

0.944 – 1.105

0.599

Presence of asthma

1.167 (0.443)

0.555 – 2.455

0.684

Demographic

Overall comorbidity

COPD severity

*p < 0.05
Log likelihood = -250.56; χ2 = 49.86; p=0.000*
Pseudo R2: 9.1%
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TABLE 29: Zero-inflated Poisson regression model of the impact of drug therapy (IPR/ALB or
LABA) on the frequency of exacerbations
DV: Number of exacerbations
Coeff (SE)

Variable

95% CI

p
value

Drug therapy (Ref: IPR/ALB)
LABA

0.209 (0.284)

-0.347 – 0.766

0.461

Age (years)

0.049 (0.017)

0.016 – 0.081

0.003*

Gender (Ref: Male)
Female

0.254 (0.321)

-0.375 – 0.884

0.428

Race (Ref: non-White)
White

0.818 (0.482)

-0.126 – 1.762

0.090

State (Ref: WV )
KY

0.446 (0.269)

-0.082 – 0.973

0.098

-0.774 (0.275)

-1.313 - -0.235

0.005*

0.020 (0.088)

-0.152 – 0.192

0.817

-0.251 (0.091)

-0.429 - -0.073

0.006*

0.034 (0.016)

0.004 – 0.065

0.029*

# of other SABD prescriptions

-0.010 (0.031)

-0.072 – 0.051

0.445

# of OCS prescriptions

-0.091 (0.047)

-0.183 – 0.001

0.748

Use of nebulized SABD

-0.211 (0.277)

-0.754 – 0.331

0.054

# of Hosp/ER visits for COPD-related
comorbid disorders

0.262 (0.072)

0.120 – 0.403

0.000*

# of Physician visits for COPD-related
comorbid disorders

0.056 (0.040)

0.162 – -0.022

0.162

Presence of asthma

0.207 (0.349)

-0.477 – 0.892

0.552

Demographic

County_Smokerate (Ref: <31%)
>=31%
Overall comorbidity
D’Hoore-CCI
Number of other chronic conditions
COPD severity
# of inhaled SABA canisters

*p < 0.05
Log likelihood = -412.25; χ2 = 49.86; p=0.002*
Value of alpha=0.00; χ2 = 0.00; p=1.000
Vuong test: z=3.55 p=0.000
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TABLE 30: Two part semi-logarithmic regression of the impact of drug therapy (IPR/ALB or
LABA) on total COPD-related costs
DV: Total COPD-related costs
β coefficient
(SE)

Variable

p
value

Drug therapy (Ref: IPR/ALB)
LABA

0.124 (0.098)

0.206

Age (years)

0.018 (0.006)

0.002*

Gender (Ref: Male)
Female

0.105 (0.088)

0.230

Race (Ref: non-White)
White

0.058 (0.244)

0.811

State (Ref: WV )
KY

0.101 (0.107)

0.344

County_Smokerate (Ref: <31%)
>=31%

0.057 (0.107)

0.592

0.030 (0.028)

0.286

-0.034 (0.036)

0.314

# of inhaled SABA canisters

0.025 (0.008)

0.003*

# of other SABD prescriptions

0.032 (0.013)

0.016*

# of OCS prescriptions

-0.002 (0.026)

0.952

Use of nebulized SABD

0.392 (0.133)

0.003*

# of Hosp/ER visits for COPD-related comorbid
disorders

0.130 (0.040)

0.001*

# of Physician visits for COPD-related
comorbid disorders

0.041 (0.016)

0.010*

Presence of asthma

0.077 (0.155)

0.617

Demographic

Overall comorbidity
D’Hoore-CCI
Number of other chronic conditions
COPD severity

*p < 0.05
Semi-log OLS: R2=11.92%; p=0.000*; Test for heteroskedasticity (χ2 =0.06, p=0.801)
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TABLE 31: Two part semi-logarithmic regression of the impact of drug therapy (IPR/ALB or
LABA) on COPD-related prescription drug costs
DV: COPD-related
prescription drug costs
β coefficient
(SE)

Variable

p
value

Drug therapy (Ref: IPR/ALB)
LABA

0.216 (0.062)

0.001*

Age (years)

0.005 (0.004)

0.183

Gender (Ref: Male)
Female

0.045 (0.055)

0.411

Race (Ref: non-White)
White

0.145 (0.154)

0.346

State (Ref: WV )
KY

0.196 (0.067)

0.004*

County_Smokerate (Ref: <31%)
>=31%

0.058 (0.067)

0.389

0.017 (0.017)

0.335

-0.009 (0.022)

0.695

# of inhaled SABA canisters

0.036 (0.005)

0.000*

# of other SABD prescriptions

0.034 (0.008)

0.000*

# of OCS prescriptions

0.015 (0.016)

0.374

Use of nebulized SABD

0.272 (0.084)

0.001*

-0.008 (0.025)

0.742

# of Physician visits for COPD-related
comorbid disorders

0.023 (0.010)

0.019*

Presence of asthma

0.122 (0.098)

0.214

Demographic

Overall comorbidity
D’Hoore-CCI
Number of other chronic conditions
COPD severity

# of Hosp/ER visits for COPD-related comorbid
disorders

*p < 0.05
Semi-log OLS: R2=23.19%; p=0.000; Test for heteroskedasticity (χ2 =120.27, p=0.674)
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Discussion for Research Objectives 3 and 4
The 2004 update to the GOLD guidelines suggested that long-acting beta-agonists were
more effective and convenient for maintenance therapy than the short-acting anti-cholinergic,
ipratropium (GOLD, 2004). However, a review of the literature showed the evidence for
long-acting beta-agonists relative to ipratropium to be inconsistent. Therefore, Part 1 of
Phase II compared initiation of monotherapy with long-acting beta-agonist relative to therapy
with a combination of ipratropium/albuterol. The combination therapy with
ipratropium/albuterol has been demonstrated to be comparable to using ipratropium alone for
maintenance therapy in terms of both costs and effects. The former was chosen as the
comparator in this study because of the difficulty in designating use of ipratropium alone as
maintenance therapy from claims data.
The results of objective 3 showed that ipratropium was as effective as LABA in the
proportions of recipients experiencing an exacerbation. These results are similar to results
from Rennard et al. and Dahl et al. in which there were no differences in the proportion of
patients with exacerbations requiring oral corticosteroids, but contrast those from a trial by
Mahler et al. which showed a significantly longer time to an exacerbation relative to
ipratropium (Rennard et al., 2001; Dahl et al., 2001; Mahler et al., 1999). In two studies
using observational data such as the present study, a trend towards a lower hazard for a
severe exacerbation (hospitalization) was seen for patients initiating therapy on salmeterol
compared to those on ipratropium (Burney et al., 2003; Rascati et al., 2005). In both studies,
the hazard ratio ranged from 0.76 to 0.82. In our study, the hazard ratio was 0.87. However,
these results are not comparable as our study population was a relatively less severe
population, while those in the other observational studies were at different severity levels.
Additionally, our results assessed the impact not only on severe exacerbations but also on
moderate exacerbations. There are no observational studies that have seen the effect of a
long-acting beta-agonist relative to ipratropium in a moderately severe COPD population. In
contrast to the above studies and our study, another study using the Pharmetrics database
found ipratropium to have a significantly higher risk for a COPD-related ER (OR=1.9) or
hospitalization (OR=1.5) visit compared to salmeterol (Howard KB et al., 2001). However,
the authors do mention the possibility that the ipratropium group was probably sicker.
Neither the study design nor the analyses attempted to control the selection bias.
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The data source for the current study precluded relevant clinical measures of symptom
scores, dyspnea scores, quality of life, and lung function. However, the data do provide
information on COPD-related costs. Research has shown that those with poorer quality of
life, and low lung function incur higher costs (Fan et al., 2002; Hilleman et al., 2000), and it
is plausible that patients who incur higher costs have higher symptom and dyspnea scores.
Hence, COPD-related costs, which can be considered as a summative measure representing
these outcomes, were compared between the drug therapy groups. Results of objective 4
showed that both therapy groups incurred similar total COPD-related costs in the follow-up
period. Although total COPD-related costs were not statistically different, recipients initiated
on long-acting beta-agonists were found to incur 24% higher COPD-related prescription drug
costs.
The literature cites three pharmacoeconomic studies comparing COPD-related costs
between patients using salmeterol versus ipratropium. One of the studies by Howard et al.
mentioned above, which found ipratropium to have a higher risk of a COPD-related
hospitalization or ER visit, found no difference in total COPD-related costs between the
groups (Howard KB et al., 2001). Friedman et al. conducted a hypothetical analysis based on
data from two different trials of ipratropium and salmeterol (Friedman et al., 2001). The
trials found similar reductions in exacerbations for salmeterol and ipratropium (37% vs. 33%,
respectively). The authors did not empirically assess, but estimated that salmeterol would
have higher annual costs ($1,059) compared to ipratropium ($788). In our study, recipients
initiated on long-acting beta-agonists had an annual cost of $2,291 compared to $2,023 for
those on ipratropium. None of the aforementioned two studies individually examined cost
components. A study by Hogan et al. used information from a clinical trial comparing
ipratropium to formoterol on measures of FEV1 and quality of life to conduct a
pharmacoeconomic analysis (Hogan et al., 2003). The major limitation of this analysis was
that no a priori economic data were collected during the trial. Instead, only the cost of the
study drugs and rescue medications were considered. The results showed those on
formoterol to have incremental costs of $1,611 per additional change in FEV1 and $25 per
additional change in units of the quality of life instrument. The results imply that patients on
formoterol incurred higher COPD-related prescription drug costs compared to those on
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ipratropium. However, our study included other COPD-related drug classes when computing
the cost for COPD-related prescription drugs.
As was mentioned earlier, COPD-related costs can be considered a summative measure
representing outcomes of lung function, exercise capacity, dyspnea, symptom scores, and
health-related quality of life. The result of no difference in total COPD-related costs can be
explained by the equal efficacy of long-acting beta-agonists to ipratropium found on these
measures in four clinical trials. Of the four trials, only one trial found significant differences
on lung function. Salmeterol was shown to be statistically different from ipratropium at 4
and 6 hours after bronchodilator administration at the end of 12 weeks in change in
FEV1AUC (area under curve) (Mahler et al., 1999). Another trial found a statistical but not a
clinically relevant difference in normalized FEV1AUC (area under the curve) at 12 weeks
between ipratropium and formoterol (Dahl et al., 2001).
A timed walking test is a measure of functional exercise capacity that indicates the level
of dyspnea. Both salmeterol trials have found no differences between salmeterol and
ipratropium in either the distance walked or the post-walk dyspnea scores using the 6 minute
walking test (Mahler et al., 1999; Rennard et al., 2001). Formoterol also showed similar
results on exercise capacity as measured using the shuttle walking test, with 41 percent in the
formoterol group and 38 percent of patients in the ipratropium group reaching a clinically
significant improvement of >30 m after 12 weeks (difference between groups not statistically
significant) (Wadbo et al., 2002). Dyspnea scores using the Baseline Dyspnea Index (BDI)
and the Transitional Dyspnea Index (TDI) did not differ significantly between salmeterol and
ipratropium groups in both trials. Only one formoterol trial assessed daytime and nighttime
dyspnea scores using a symptom scale, and also found insignificant differences compared
with ipratropium (Wadbo et al., 2002).
In terms of HRQol, no differences were seen in the total Chronic Respiratory
Questionnaire (CRQ) score between salmeterol and ipratropium (Mahler et al., 1999;
Rennard et al., 2001). Formoterol again showed inconsistent results on the St. George’s
Respiratory Questionnaire (SGRQ). The trial conducted by Dahl et al. found that formoterol
differed statistically from ipratropium by -3.79 units on total SGRQ score, less than the
minimum clinically important difference of four units (Dahl et al., 2001). The other
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formoterol trial reported no statistically significant differences between groups (Wadbo et al.,
2002).
Patients on ipratropium and long-acting beta-agonists reported similar symptom scores at
the end of 12 weeks in 3 trials (Mahler et al., 1999; Rennard et al., 2001; Wadbo et al., 2002).
In one trial, the daily symptom score was 0.3 units lower in the formoterol group (only for
12µg and not 24µg) compared to the ipratropium group that was statistically significant
(Dahl et al., 2001). Increase in symptoms necessitates increased use of rescue medications,
measured as daily number of puffs or inhalations. Therefore, the trials that showed no
differences in symptom scores also showed no differences in daily number of puffs or
inhalations of rescue medication required (Mahler et al., 1999; Rennard et al., 2001; Wadbo
et al., 2002), while the formoterol trial showed significant differences (Dahl et al., 2001).
Dahl et al. showed the mean daily number of puffs of inhaled albuterol during the treatment
period to be 1.2, 1.7, 2.5, and 2.0 in the 12µg, 24µg formoterol, ipratropium and placebo
group, respectively (Dahl et al., 2001). Both doses of formoterol produced a significant
reduction in the need for rescue medication versus ipratropium (p< 0.014).
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Part 2
The second part of phase II compares outcomes of exacerbations and costs between
recipients initiating combination therapy with an inhaled corticosteroid and long-acting betaagonist (ICS/LABA), inhaled corticosteroid monotherapy (ICS alone), inhaled long-acting
beta-agonist monotherapy (LABA alone), and those on short-acting bronchodilators (SABD).
Table 32 outlines the extraction process from raw data to obtain the study sample.

TABLE 32: Sample extraction for Phase II – Part 2
Step

Outcome WV

Outcome KY

1. # with a Rx claim for combination
product of ICS/LABA, ICS, LABA, or
SABD during: WV- Jul 1, 1998 to Jun 30,
2002 and KY-Jan 1, 1999 to Dec 31, 2002

A = 159,514
-ICS/LABA = 6,328
-ICS alone = 26,620
-LABA alone = 11,053
-SABD = 115,513

A = 323,567
-ICS/LABA = 16,938
-ICS alone = 60,407
-LABA alone = 21,991
-SABD = 224,231

2. The date of first chronologically occurring prescription claim was defined as an index date for
each person. The drug therapy groups represent numbers with respective prescription claim at
index date.
3. # of A between 35-64 years, continuously
eligible for Medicaid and not enrolled in
managed care at anytime during study
period

B = 29,281
-ICS/LABA = 2,307
-ICS alone = 6,703
-LABA alone = 3,634
-SABD = 16,637

B = 56,128
-ICS/LABA = 5,500
-ICS alone = 12,460
-LABA alone = 6,806
-SABD = 31,362

4. # of B with prescription drug patterns
specified in study criteria.

C = 14,477
-ICS/LABA = 962
-ICS alone = 3,298
-LABA alone = 853
-SABD = 9,364

C = 27,450
-ICS/LABA = 2,439
-ICS alone = 5,771
-LABA alone = 1,436
-SABD = 17,804

5. # of C without diagnosis of cystic fibrosis,
fibrosis due to tuberculosis, respiratory
cancer, and bronchiectasis during study
period

D = 14,153
-ICS/LABA = 922
-ICS alone = 3,210
-LABA alone = 824
-SABD = 9,197

D = 26,961
-ICS/LABA = 2,393
-ICS alone = 5,645
-LABA alone =1,404
-SABD = 17,519

6. # of D with at least one hospitalization or
ER visit or at least two outpatient
encounters on different dates with a
primary or secondary diagnosis of COPD
in pre-index period

E = 2,869
-ICS/LABA = 331
-ICS alone = 1,060
-LABA alone = 248
-SABD = 1,230

E = 5,246
-ICS/LABA = 654
-ICS alone = 1,709
-LABA alone = 394
-SABD = 2,489
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7. # of E who had at least one additional
prescription claim of index drug therapy
in follow-up period.

F = 1,184
-ICS/LABA = 236
-ICS alone = 645
-LABA alone = 150
-SABD = 153

8. Final study sample size

I = 3,458
-ICS/LABA = 730
-ICS alone = 1,819
-LABA alone = 414
-SABD = 495

F = 2,274
-ICS/LABA = 494
-ICS alone = 1,174
-LABA alone = 264
-SABD = 342

Four drug therapy cohorts were formed for Part 2 of Phase II. Three primary
comparisons were of interest:
1. ICS/LABA vs. SABD
2. ICS monotherapy vs. SABD
3. ICS/LABA vs. LABA
Two combination ICS/LABA products are now available: combination
fluticasone/salmeterol commonly called Advair®, and combination budesonide/formoterol
commonly called Symbicort®. In the present study, only Advair® was available during the
the study time period, and consequently ICS/LABA refers to the combination of
fluticasone/salmeterol.
Since the study is observational in nature, there is an inherent selection bias in the creation
of these drug therapy cohorts. Hence, propensity scores were used to account for selection
bias. The logistic regression model predicting the probability of being in the drug cohort
with an ICS is presented in table B1, B2, and B3 in appendix B for comparison 1, 2, and 3
respectively. The results for objective 5, 6, and 7 are presented for each of the three above
comparisons.
ICS/LABA vs. SABD: Table 33 outlines the comparison of characteristics of the study
sample before and after matching for the analyses comparing ICS/LABA vs. SABD. A total
of 173 matched pairs were obtained. Before matching, the groups differed significantly on
demographic and comorbid characteristics. Recipients who were prescribed ICS/LABA
were more likely to be younger females, and reside in counties with a lower prevalence of
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smoking. Although the D’Hoore Charlson comorbidity index showed no differences,
recipients in the ICS/LABA group had a higher mean number of other chronic conditions
(1.9 vs. 1.6). Recipients with ICS/LABA were also more likely to have a hospitalization or
ER visit for COPD or a COPD-related disorder in the pre-index period compared to the
SABD group (52.9% vs. 44.2%), and had a slightly higher but significant number of
prescriptions of oral corticosteroids (1.2 vs. 1.1). As expected, recipients with concomitant
asthma were also more likely to have been prescribed ICS/LABA (23.0% vs. 14.6%).
Recipients in the SABD group had a higher number of canisters of SABA and IPR, and a
higher number of prescriptions of other dose forms of short-acting bronchodilators.
However, this increased use may be a reflection of the study design, since those in the SABD
group were required to have at least two SABD prescriptions in the pre-index period of
which one was for IPR. This was done in order to avoid including a relatively mild COPD
population who use SABD on an acute as-needed basis. The matching process was
successful in balancing the covariates at baseline as can be seen from the significance tests
after matching.
ICS alone vs. SABD: Table 34 outlines the comparison of characteristics of the study sample
before and after matching for the analyses comparing ICS alone vs. SABD. A total of 335
matched pairs were obtained. Recipients using ICS alone were more likely to be younger
females, and reside in counties with a lower prevalence of smoking. Recipients with ICS
alone also had a significantly higher D’Hoore CCI as well as number of other chronic
conditions. Also, a significantly higher proportion of those using ICS alone had a
hospitalization or ER visit for COPD or COPD-related comorbid disorders (53.6% vs.
44.2%), and were found to have asthma (21.8% vs. 14.6%). Similar to the comparison of
ICS/LABA vs. SABD, recipients in the SABD group had a higher number of canisters of
SABA and IPR, and a higher number of prescriptions of other dose forms of short-acting
bronchodilators compared to those using ICS alone. Of note however, a significantly higher
proportion of recipients in the SABD group used home oxygen therapy (18.4% vs. 13.3%).
The matching process was not completely successful in balancing the covariates at baseline
as can be seen from the significance tests after matching. Specifically, recipients in the
SABD group still had a significantly higher number of canisters of SABA (4.7 vs. 3.9) and
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IPR (4.2 vs. 3.5) after matching. However, the use of home oxygen therapy was balanced
between the groups. Hence, the difference in the use of SABA and IPR canisters was
considered an artifact of the study design rather than to any differences in severity between
the groups. However, the researcher conducted a separate analysis on the full sample
(1819+495) using the propensity score quintile, and number of canisters of SABA and IPR in
the regression model (data not shown). Since the results were no different from that of the
analysis of the matched sample, only the analysis of the matched sample is shown.
ICS/LABA vs. LABA alone: Table 35 outlines the comparison of characteristics of the study
sample before and after matching for the analyses comparing ICS/LABA vs. LABA alone. A
total of 240 matched pairs were obtained. Recipients prescribed combination ICS/LABA
were more likely to be younger females, and have asthma. However, few differences in
COPD severity measures were seen between therapy groups. Specifically, recipients being
prescribed ICS/LABA had a slightly higher mean number of prescriptions for oral
corticosteroids (1.2 vs. 1.1), and were more likely to have used nebulized SABD (29.3% vs.
20.5%) compared to those using LABA alone. No differences were seen in the use of
hospitalization/ER visit for COPD or a COPD related comorbid disorder (52.9% vs. 48.6%).
However, recipients using ICS/LABA had a significantly higher mean number of physician
visits for COPD or COPD-related disorders (4.0 vs. 3.6). The matching process was
successful in balancing the covariates at baseline as can be seen from the significance tests
after matching.
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TABLE 33: Baseline characteristics of study sample by drug therapy status
(ICS/LABA vs. SABD: Phase II-Part 2)
Before Matching
Characteristic

After Matching

ICS/LABA
(N=730)

SABD
(N=495)

Test
Statistic
(p-value)

ICS/LABA
(N=173)

SABD
(N=173)

Test
Statistic
(p-value)

Age, mean years
(SD)

51 (7.9)

53 (7.4)

5.4491
(0.000)*

52 (7.2)

52 (8.1)

0.1524
(0.879)

Female, % (n)

66.9%
(486)

58.0%
(286)

9.8752
(0.002)*

60.7%
(105)

60.7%
(105)

0.0005
(1.000)

White, % (n)

96.6%
(627)

98.2%
(439)

2.5462
(0.111)

96.5%
(167)

96.5%
(167)

0.0005
(1.000)

State (KY), % (n)

67.7%
(494)

69.1%
(342)

0.2742
(0.600)

62.4%
(108)

65.9%
(114)

0.4305
(0.586)

Countysmokerate
>=31%, % (n)

60.6%
(442)

70.9%
(351)

13.8722
(0.000)*

65.9%
(114)

65.9%
(114)

0.0005
(1.000)

D’Hoore-CCIa ,
mean (SD)

1.5 (1.8)

1.3 (1.8)

-1.3153
(0.189)

1.2 (1.8)

1.4 (1.9)

-1.053
(0.293)

Number of other
chronic
conditionsb,
mean (SD)

1.9 (1.3)

1.6 (1.3)

-7.0293
(0.000)*

1.8 (1.3)

1.9 (1.3)

-0.352
(0.725)

# of inhaled
SABAc canisters,
mean (SD)

3.9 (7.4)

5.4 (6.9)

6.2501
(0.006)*

3.6 (6.8)

3.8 (5.0)

-1.9324
(0.053)

# of inhaled IPR
canisters,
mean (SD)

2.3 (5.0)

5.9 (6.6)

16.1211
(0.000)*

2.9 (5.3)

3.2 (3.6)

-2.4044
(0.016)*

# of Rx of other
doseform
SABDc,

2.0 (4.2)

3.8 (5.1)

7.897
(0.000)*

2.3 (4.3)

2.5 (4.4)

-0.9194
(0.358)

Demographic

Overall
Comorbidity

COPD severity
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mean (SD)
# of Rx of OCSd,
mean (SD)

1.2 (2.4)

1.1 (2.6)

-2.4211
(0.016)*

1.0 (2.2)

1.1 (2.3)

0.0954
(0.924)

Use of nebulized
SABDc, % (n)

29.3%
(214)

29.3%
(145)

0.0002
(0.993)

23.7%
(41)

31.2%
(54)

2.7705
(0.124)

Use of Hosp/ER
for COPD or
COPD-related
comorbid
disorderse, % (n)

52.9%
(386)

44.2%
(219)

8.7802
(0.003)*

50.9%
(88)

50.3%
(87)

0.0105
(1.000)

# of Physician
visits for COPD
or COPD-related
comorbid
disorderse,
mean (SD)

4.0 (3.9)

3.8 (3.5)

-1.0162
(0.310)

3.8 (3.9)

3.8 (3.7)

-0.0524
(0.959)

Presence of
asthma, % (n)

23.0%
(168)

14.6%
(72)

13.4282
(0.000)*

15.0%
(26)

16.8%
(29)

0.2305
(0.749)

Use of Home
oxygen therapy,
%(n)

17.1%
(125)

18.4%
(91)

0.3232
(0.570)

16.8%
(29)

15.6%
(27)

0.0105
(0.878)

*p < 0.05
a
Excludes asthma
b
Includes hypercholesterolemia, hypertension, other heart disease, AIDS, rheumatoid arthritis, osteoarthritis,
gall bladder disease, depression and anxiety, and schizophrenia.
c
Short-acting beta-agonist: includes levalbuterol, albuterol, metaproterenol, bitolterol, terbutaline.
d
Short-acting bronchodilators: includes levalbuterol, albuterol, metaproterenol, bitolterol, terbutaline,
theophylline, and ipratropium.
d
Oral corticosteroids: includes prednisone, prednisolone, methylprednisolone, cortisone, hydrocortisone,
dexamethasone, betamethasone, oral triamcinolone, oral budesonide.
e
Includes COPD, asthma, upper respiratory tract infections, lower respiratory tract infections, septicemia,
allergic rhinitis, other diseases of the lung, congestive heart failure, and disorders of fluid, electrolyte, and acidbase imbalance.
1
t statistic; 2Chi-square test statistic; 3Mann-Whitney U-statistic; 4Wilcoxon signed rank test statistic; 5McNemar
test statistic.
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TABLE 34: Baseline characteristics of study sample by drug therapy status
(ICS vs. SABD: Phase II-Part 2)
Before Matching
Characteristic

After Matching

ICS
(N=1,819)

SABD
(N=495)

Test
Statistic
(p-value)

ICS
(N=335)

SABD
(N=335)

Test
Statistic
(p-value)

Age, mean years
(SD)

52 (7.5)

53 (7.4)

4.0281
(0.000)*

53 (7.1)

53 (7.7)

0.5894
(0.556)

Female, % (n)

64.0%
(1,159)

58.0%
(286)

6.0092
(0.014)*

59.7%
(200)

58.5%
(196)

0.0105
(0.816)

White, % (n)

96.4%
(1,585)

98.2%
(439)

3.6682
(0.055)

96.5%
(167)

96.5%
(167)

0.3305
(0.774)

State (KY), % (n)

64.5%
(1,174)

69.1%
(342)

0.2742
(0.600)

63.9%
(214)

65.1%
(218)

0.1205
(0.796)

Countysmokerate
>=31%, % (n)

64.9%
(1,180)

70.9%
(351)

13.8722
(0.000)*

66.5%
(223)

69.3%
(232)

0.5705
(0.504)

D’Hoore-CCIa ,
mean (SD)

1.5 (1.8)

1.3 (1.8)

-2.0513
(0.040)*

1.4 (1.8)

1.4 (1.8)

-1.200
(0.841)

Number of other
chronic conditionsb,
mean (SD)

1.9 (1.3)

1.6 (1.3)

-5.5433
(0.000)*

1.6 (1.3)

1.7 (1.3)

-0.952
(0.341)

# of inhaled SABAc
canisters, mean (SD)

4.2 (6.9)

5.4 (6.9)

5.1071
(0.000)*

3.9 (6.0)

4.7 (5.7)

-2.4904
(0.012)*

# of inhaled IPR
canisters, mean (SD)

2.7 (5.7)

5.9 (6.6)

16.7681
(0.000)*

3.5 (5.5)

4.2 (4.6)

-3.9044
(0.001)*

# of Rx of other
doseform SABDc,
mean (SD)

2.3 (4.4)

3.8 (5.1)

7.286
(0.000)*

3.1 (5.0)

3.1 (4.7)

0.2204
(0.826)

# of Rx of OCSd,
mean (SD)

1.0 (2.1)

1.1 (2.6)

-1.9011
(0.057)

1.2 (2.6)

1.1 (2.6)

2.0284
(0.053)

Demographic

Overall Comorbidity

COPD severity
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Use of nebulized
SABDc, % (n)

26.5%
(214)

29.3%
(145)

1.5392
(0.215)

28.7%
(96)

26.9%
(90)

0.2705
(0.664)

Use of Hosp/ER for
COPD or COPDrelated comorbid
disorderse, % (n)

53.6%
(974)

44.2%
(219)

13.4842
(0.000)*

47.2%
(158)

46.6%
(156)

0.0305
(0.930)

3.8 (3.6)

3.8 (3.5)

0.1482
(0.883)

3.8 (3.3)

3.7 (3.4)

0.5594
(0.576)

Presence of asthma,
% (n)

21.8%
(396)

14.6%
(72)

12.5882
(0.000)*

14.6%
(49)

17.3%
(58)

0.8905
(0.402)

Use of Home oxygen
therapy, %(n)

13.3%
(242)

18.4%
(91)

8.1502
(0.004)*

17.6%
(59)

15.5%
(52)

0.5205
(0.538)

# of Physician visits
for COPD or COPDrelated comorbid
disorderse, mean (SD)

*p < 0.05
a
Excludes asthma
b
Includes hypercholesterolemia, hypertension, other heart disease, AIDS, rheumatoid arthritis, osteoarthritis,
gall bladder disease, depression and anxiety, and schizophrenia.
c
Short-acting beta-agonist: includes levalbuterol, albuterol, metaproterenol, bitolterol, terbutaline.
d
Short-acting bronchodilators: includes levalbuterol, albuterol, metaproterenol, bitolterol, terbutaline,
theophylline, and ipratropium.
d
Oral corticosteroids: includes prednisone, prednisolone, methylprednisolone, cortisone, hydrocortisone,
dexamethasone, betamethasone, oral triamcinolone, oral budesonide.
e
Includes COPD, asthma, upper respiratory tract infections, lower respiratory tract infections, septicemia,
allergic rhinitis, other diseases of the lung, congestive heart failure, and disorders of fluid, electrolyte, and acidbase imbalance.
1
t statistic; 2Chi-square test statistic; 3Mann-Whitney U-statistic; 4Wilcoxon signed rank test statistic; 5McNemar
test statistic.
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TABLE 35: Baseline characteristics of study sample by drug therapy status
(ICS/LABA vs. LABA: Phase II-Part 2)
Before Matching
Characteristic

After Matching

ICS/LABA
(N=730)

LABA
(N=414 )

Test
Statistic
(p-value)

ICS/LABA
(N=240 )

LABA
(N=240)

Test
Statistic
(p-value)

Age, mean years
(SD)

51 (7.9)

52 (7.5)

2.5571
(0.011)*

52 (7.6)

52 (7.4)

-0.0644
(0.949)

Female, % (n)

66.9%
(486)

59.8%
(247)

5.6932
(0.017)*

61.7%
(148)

58.3%
(140)

0.6805
(0.471)

White, % (n)

96.6%
(627)

97.4%
(368)

0.4382
(0.508)

97.9%
(235)

98.3%
(236)

0.1105
(1.000)

State (KY), % (n)

67.7%
(494)

63.8%
(264)

1.8002
(0.180)

60.0%
(144)

63.8%
(153)

0.7705
(0.435)

Countysmokerate
>=31%, % (n)

60.6%
(442)

64.3%
(266)

1.5362
(0.215)

58.8%
(141)

62.1%
(149)

0.5705
(0.509)

D’Hoore-CCIa ,
mean (SD)

1.5 (1.8)

1.5 (1.8)

0.0533
(0.958)

1.5 (1.8)

1.4 (1.8)

0.490
(0.624)

Number of other
chronic
conditionsb,
mean (SD)

2.1 (1.4)

2.0 (1.4)

-1.5993
(0.110)

2.2 (1.3)

1.9 (1.3)

1.147
(0.252)

# of inhaled
SABAc canisters,
mean (SD)

3.9 (7.4)

3.9 (8.5)

-0.7033
(0.482)

2.9 (5.8)

3.3 (6.3)

-0.0024
(0.999)

# of inhaled IPR
canisters,
mean (SD)

2.3 (5.0)

2.6 (6.1)

0.3563
(0.722)

1.9 (4.2)

2.4 (5.4)

-0.4884
(0.625)

# of Rx of other
doseform
SABDc,

2.0 (4.3)

2.0 (4.2)

-0.2253
(0.822)

1.8 (4.1)

2.3 (4.5)

-1.6904
(0.091)

Demographic

Overall
Comorbidity

COPD severity
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mean (SD)
# of Rx of OCSd,
mean (SD)

1.2 (2.4)

1.1 (2.7)

-3.2153
(0.001)*

1.2 (2.5)

1.2 (2.9)

1.7154
(0.086)

Use of nebulized
SABDc, % (n)

29.3%
(214)

20.5%
(85)

10.5582
(0.001)*

17.1%
(41)

20.8%
(50)

1.5305
(0.272)

Use of Hosp/ER
for COPD or
COPD-related
comorbid
disorderse, % (n)

52.9%
(386)

48.6%
(201)

1.9792
(0.160)

51.7%
(124)

47.9%
(115)

0.7405
(0.444)

# of Physician
visits for COPD
or COPD-related
comorbid
disorderse,
mean (SD)

4.0 (3.9)

3.6 (3.6)

-2.2073
(0.027)*

3.6 (3.4)

3.6 (3.5)

-0.3674
(0.713)

Presence of
asthma, % (n)

23.0%
(168)

15.9%
(66)

8.1201
(0.004)*

18.3%
(44)

16.3%
(39)

0.4105
(0.609)

Use of Home
oxygen therapy,
%(n)

17.1%
(125)

15.2%
(63)

0.6991
(0.403)

15.4%
(37)

14.6%
(35)

0.0605
(0.902)

*p < 0.05
a
Excludes asthma
b
Includes hypercholesterolemia, hypertension, other heart disease, AIDS, rheumatoid arthritis, osteoarthritis,
gall bladder disease, depression and anxiety, and schizophrenia.
c
Short-acting beta-agonist: includes levalbuterol, albuterol, metaproterenol, bitolterol, terbutaline.
d
Short-acting bronchodilators: includes levalbuterol, albuterol, metaproterenol, bitolterol, terbutaline,
theophylline, and ipratropium.
d
Oral corticosteroids: includes prednisone, prednisolone, methylprednisolone, cortisone, hydrocortisone,
dexamethasone, betamethasone, oral triamcinolone, oral budesonide.
e
Includes COPD, asthma, upper respiratory tract infections, lower respiratory tract infections, septicemia,
allergic rhinitis, other diseases of the lung, congestive heart failure, and disorders of fluid, electrolyte, and acidbase imbalance.
1
t statistic; 2Chi-square test statistic; 3Mann-Whitney U-statistic; 4Wilcoxon signed rank test statistic; 5McNemar
test statistic.
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Research Objective 5: To compare the risk of a severe exacerbation among recipients with
COPD who initiate therapy with a combination of an inhaled corticosteroid and a longacting beta-agonist, inhaled corticosteroid alone, inhaled long-acting beta-agonist alone,
or only short-acting bronchodilators.
Table 36 shows the proportion experiencing an exacerbation between drug therapy
cohorts for each of the three comparisons. Compared to those using SABD, inhaled
corticosteroids alone or in combination with LABA did not appear to impact the risk of a
severe exacerbation. In the comparison of ICS/LABA with SABD, the direction of the effect
favored the combination product with an odds ratio of 0.75 (95% CI: 0.384-1.441).
However, in the comparison of ICS alone with SABD, the direction of the effect favored
SABD with an odds ratio of 1.256 (95% CI: 0.826-1.920). The addition of ICS to LABA
monotherapy also did not have any effect on the risk of a severe exacerbation with an odds
ratio of 1.261 (95% CI 0.704-2.282).

Research Objective 6: To compare the frequency of moderate exacerbations among
recipients with COPD who initiate therapy with a combination of an inhaled corticosteroid
and a long-acting beta-agonist, inhaled corticosteroid alone, inhaled long-acting betaagonist alone, or only short-acting bronchodilators.
Table 37 compares the frequency of moderate exacerbations between the drug therapy
cohorts for each of the three comparisons. There was no difference in the frequency of
exacerbations between those using ICS/LABA vs. those using SABD or those using LABA
monotherapy. However, in the comparison of ICS vs. SABD, a slightly higher but
significant number of moderate exacerbations were found for those using ICS alone (0.28 vs.
0.18, p=0.003).

Research Objective 7: To compare COPD-related costs among recipients with COPD who
initiate therapy with a combination of an inhaled corticosteroid and a long-acting betaagonist, inhaled corticosteroid alone, inhaled long-acting beta-agonist alone, or only
short-acting bronchodilators.
Table 38 compares COPD-related costs in the follow-up period between the drug therapy
cohorts for each of the three comparisons. Inhaled corticosteroids either alone (ICS) or in
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combination (ICS/LABA) increased the total COPD-related costs relative to those using
SABD by approximately $200 to $300. This increase was primarily driven by a difference in
the prescription drug cost component. In the comparison of ICS/LABA vs. LABA alone, no
differences were seen in overall COPD costs. However, COPD-related prescription drug
costs were higher in the ICS/LABA group.
TABLE 36: Risk of a severe exacerbation in the follow-up period by drug therapy status (Phase
II-Part 2)
Outcome§

Test Statistic
(p-value)
* = values <0.05

Severe exacerbations (%, n)
Risk of a severe exacerbation

Severe exacerbations (%, n)
Risk of a severe exacerbation

Severe exacerbations (%, n)
Risk of a severe exacerbation

ICS/LABA
(N=173)

SABD
(N= 173)

12.1%
(21)

15.6%
(27)

0.8601 (0.441)

OR = 0.750 (0.384-1.441)
ICS
(N=335)

SABD
(N=335)

19.1%
(53)

15.8%
(64)

1.2501 (0.339)

OR = 1.256 (0.826-1.920)
ICS/LABA
(N=240 )

LABA
(N=240)

15.4% (37)

12.9% (31)

0.6901 (0.489)

OR = 1.261 (0.704-2.282)

*p < 0.05
§
Analysis of difference in outcome controlled for variables included in the propensity score model: age, gender,
race, countysmokerate, state, D’Hoore-CCI, number of other chronic conditions, number of inhaled SABA
canisters, number of inhaled IPR canisters, number of other doseforms of SABD, use of nebulized SABD, use
of Hosp/ER for COPD or COPD-related comorbid disorders, # of physician visits for COPD or COPD-related
comorbid disorders, presence of asthma, and use of home oxygen therapy.
1
McNemar test statistic
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TABLE 37: Frequency of moderate exacerbations in follow-up period by drug therapy status
(Phase II-Part 2)
Outcome§

Test Statistic
(p-value)
* = values <0.05

Moderate exacerbations, mean (SD)

Moderate exacerbations, mean (SD)

Moderate exacerbations, mean (SD)

ICS/LABA
(N=173)

SABD
(N= 173)

0.31 (0.9)

0.18 (0.6)

ICS
(N=335)

SABD
(N=335)

0.28 (0.7)

0.18 (0.6)

ICS/LABA
(N=240 )

LABA
(N=240)

0.2 (0.5)

0.3 (0.7)

1.6921 (0.091)

2.9621 (0.003)*

-0.5131 (0.608)

*p < 0.05
§
Analysis of difference in outcome controlled for variables included in the propensity score model: age, gender,
race, countysmokerate, state, D’Hoore-CCI, number of other chronic conditions, number of inhaled SABA
canisters, number of inhaled IPR canisters, number of other doseforms of SABD, use of nebulized SABD, use
of Hosp/ER for COPD or COPD-related comorbid disorders, # of physician visits for COPD or COPD-related
comorbid disorders, presence of asthma, and use of home oxygen therapy.
1
Wilcoxon signed rank test statistic
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TABLE 38: COPD-related costs in follow-up period by drug therapy status (Phase II-Part 2)
Outcome§

Test Statistic
(p-value)
* = values <0.05

ICS/LABA
(N=173)

SABD
(N= 173)

$4,848
(9,989)

$4,639
(9,976)

2.6551 (0.008)*

$1,731
(6,487)

$2,374
(7,721)

-0.4831 (0.629)

Mean (SD)

$195
(764)

$198
(1,032)

0.4381 (0.662)

Mean (SD)

$1,392
(3,466)

$1,326
(2,626)

1.8241 (0.068)

$1,530
(1045)

$740
(765)

7.8801 (0.000)*

ICS
(N=335)

SABD
(N=335)

$4,672
(6,309)

$4,340
(8,941)

2.6711 (0.008)*

$2,012
(4,563)

$1,977
(6,057)

0.6381 (0.523)

Mean (SD)

$191
(536)

$258
(1,555)

1.1151 (0.265)

Mean (SD)

$1,313
(2,189)

$1,388
(3,237)

1.7951 (0.073)

$1,155
(879)

$717
(695)

8.2581 (0.000)*

ICS/LABA
(N=240 )

LABA
(N=240)

$5,546
(14,632)

$4,951
(10,661)

Total COPD-related costs
Mean (SD)
COPD-related hospitalization costs
Mean (SD)
COPD-related ER costs
COPD-related Outpatient costs
COPD-related Prescription drug costs
Mean (SD)

Total COPD-related costs
Mean (SD)
COPD-related hospitalization costs
Mean (SD)
COPD-related ER costs
COPD-related Outpatient costs
COPD-related Prescription drug costs
Mean (SD)

Total COPD-related costs
Mean (SD)
COPD-related hospitalization costs
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1.0781 (0.281)

Mean (SD)

$2,763
(11,688)

$1,889
(6,255)

0.9771 (0.329)

Mean (SD)

$129 (483)

$254 (890)

-0.7731 (0.440)

Mean (SD)

$1,259
(3,499)

$1,720
(4,843)

-0.1651 (0.869)

$1,394
(986)

$1,088
(980)

4.3921 (0.000)*

COPD-related ER costs
COPD-related Outpatient costs
COPD-related Prescription drug costs
Mean (SD)

*p < 0.05
§
Analysis of difference in outcome controlled for variables included in the propensity score model: age, gender,
race, countysmokerate, state, D’Hoore-CCI, number of other chronic conditions, number of inhaled SABA
canisters, number of inhaled IPR canisters, number of other doseforms of SABD, use of nebulized SABD, use
of Hosp/ER for COPD or COPD-related comorbid disorders, # of physician visits for COPD or COPD-related
comorbid disorders, presence of asthma, and use of home oxygen therapy.
1
Wilcoxon signed rank test statistic
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Discussion for Research Objectives 5, 6, and 7
Research objective 5 assessed the impact of ICS either alone or in combination with an
inhaled long-acting beta-agonist on risk of a severe exacerbation in comparison to recipients
with COPD using short-acting bronchodilators alone or using an inhaled long-acting betaagonist. The results showed that ICS either alone or in combination with an inhaled longacting beta-agonist did not reduce the risk of severe exacerbation.
Six randomized trials have reported the impact of ICS alone on exacerbations, but have
not specifically differentiated between moderate and severe exacerbations. Of the six trials
that reported ICS use and exacerbations, four did not show any significant difference (Weir
et al., 1999) (Bourbeau et al., 1998) (Lung Health Study Group, 2000) (Vestbo et al., 1999)
in reducing exacerbations. The lack of a significant difference in two of the four trials can be
attributed to lower sample size (n=79 and n=98) (Weir et al., 1999) (Bourbeau et al., 1998),
and in the other two to the COPD severity level of the patients (Lung Health Study Group,
2000) (Vestbo et al., 1999). Specifically, the mean FEV1 of the patients in the latter two
trials ranged from 68% to 85% of the predicted value. This is in contrast to the mean FEV1
of less than 50% of the predicted value in patients in the two trials that showed significant
differences (Burge et al., 2000; Paggiaro et al., 1998). In the present study, data on FEV1
were not available, and hence it is not possible to determine the severity level based on FEV1.
However, other measures of COPD severity were assessed at baseline such as use of home
oxygen therapy, use of nebulized short-acting bronchodilators, and presence of
hospitalization or ER visit for COPD or a COPD-related disorder. In the present study, home
oxygen therapy was used by at least 15% of the cohort, nebulized short-acting
bronchodilators were used by at least 20% of the cohort, and approximately 45% had at least
one hospitalization or ER visit for COPD or a COPD-related comorbid disorder. Thus, the
cohort in the present study was more likely to have moderate to severe COPD than mild
COPD. However, within this group varying levels of severity can exist, and it was not
possible to isolate a population with a higher severity level in which a beneficial effect of
ICS may have been identified.
Observational studies have provided conflicting evidence regarding the impact of ICS on
the risk of severe exacerbations. The impact of ICS on the risk of severe exacerbations in the
present study is similar to the findings of two other observational studies. Fan et al. used a
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cohort study design, and found a risk ratio of 0.85 (95% CI: 0.67 – 1.06) (Fan et al., 2003).
Bourbeau et al. used a nested case-control study design, and found a risk ratio of 1.07 (95%
CI: 0.91 – 1.27) (Bourbeau et al., 2003). However, Sin et al. and Soriano et al. have found
ICS to reduce the risk of a severe exacerbation by 24 percent and 16 percent, respectively
(Sin et al., 2001; Soriano et al., 2003). Similarly, a study using the Pharmetrics database
showed that patients treated with ICS alone reduced the risk of a COPD-related
hospitalization by 29 percent (Burney et al., 2003).
The discrepancy in the findings from observational studies has been considered by some
researchers to be a result of creation of immortal time bias (Suissa, 2003). This reasoning
has been further debated since studies that took specific measures to account for immortal
time bias found a null effect of the impact of ICS on severe exacerbations (Fan et al., 2003;
Bourbeau et al., 2003). Other studies where immortal time bias was found to exist were
reanalyzed to eliminate this bias without any change in the study findings (Sin, Man, & Tu,
2003b). In the present study, exposure status was defined based on the prescription received
on the index date. There was no period of time where exposure status and outcome
assessment were simultaneously determined, thus excluding the creation of immortal time
bias.
Of two randomized trials that have assessed the effect of combination ICS/LABA on the
risk of a severe exacerbation, one did not show any differences in the number of hospital
admissions experienced by patients compared to a placebo group (Calverley et al., 2003a).
In the other trial, a 24 percent reduction was found for severe exacerbations which was
defined as the presence of hospitalizations or the requirement of oral steroids and/or
antibiotics (Szafranski et al., 2003). Only three observational studies have specifically
assessed the impact of combination ICS/LABA compared to the use of short-acting
bronchodilators alone. One study was similar to the present study in that it used a similar
cohort study design and Medicaid data from another state and found a risk reduction of 35
percent (HR=0.653; 95% CI=0.43 to 0.99) (Rascati et al., 2005). The only difference
between two studies was the definition of combination therapy, which in the present study
referred to initiating on the combination product of ICS/LABA (Advair®), while in the
Rascati et al. study, the receipt of concomitant prescriptions of ICS and LABA during a 60
day period was designated as combination therapy.
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Research objective 6 assessed the impact of ICS either alone or in combination with an
inhaled long-acting beta-agonist on the frequency of moderate exacerbations in comparison
to recipients with COPD using short-acting bronchodilators alone or using a long-acting betaagonist. In the present study, recipients initiated on ICS alone had a significantly higher
number of moderate exacerbations (0.28 vs. 0.18; p=0.003). Only two observational studies
have assessed the impact of ICS alone on the risk of a moderate exacerbation. Fan et al.
found a null effect of HR=1.13 (95% CI=0.94-1.36) (Fan et al., 2003). On the other hand, a
study by de Melo et al. using the Saskatechewan database found a significantly increased risk
of exacerbations with an odds ratio of 1.27 (95% CI: 1.08 to 1.48) (de Melo et al., 2004a).
The authors attributed the increased risk to residual confounding due to a selection bias rather
than to a detrimental effect of ICS. In the present study, propensity scores were used to
account for the selection bias in those receiving ICS. However, propensity scores cannot
account for unobserved factors (D'Agostino, Jr., 1998). It is well known that acute
exacerbations of COPD have a heterogenous etiology and pathophysiology, and are the result
of a variety of causes including bacterial and viral infections, cold weather, and interruption
of regular treatment (Burge et al., 2003). Thus, it is possible that unobservable factors
affecting exacerbations were not captured in the propensity score leading to residual
confounding.
In one randomized trial, combination ICS/LABA (fluticasone/salmeterol) was shown to
reduce the number and risk of exacerbations requiring oral corticosteroid courses (moderate
exacerbations) compared to a placebo group (Calverley et al., 2003a). No observational
studies have been conducted of the impact of ICS/LABA on the frequency of moderate
exacerbations. In the present study, no difference was seen in the rate of moderate
exacerbations between those initiated on combination ICS/LABA versus those on shortacting bronchodilators alone.
In the present study, the combination ICS/LABA (fluticasone/salmeterol) did not
significantly reduce exacerbations compared to LABA (salmeterol) monotherapy. This
finding is similar to a large randomized trial comparing combination ICS/LABA
(fluticasone/salmeterol) to the LABA (salmeterol) component (Calverley et al., 2003a). No
observational study has specifically compared the combination of ICS/LABA to the LABA
component, but three observational studies found a significant risk reduction for combination
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ICS/LABA compared to an insignificant risk reduction for the LABA (salmeterol)
monotherapy component in comparison to the reference short-acting bronchodilator group
(Soriano et al., 2003; Burney et al., 2003; Rascati et al., 2005).
Research objective 7 compared direct costs between those initiated on ICS either alone or
in combination with an inhaled long-acting beta-agonist compared to those using short-acting
bronchodilators alone or an inhaled long-acting beta-agonist. The results of the economic
evaluation mirrored the results of the objective 5 and 6. Since no difference was seen in the
risk of severe exacerbations and the frequency of moderate exacerbations, no differences
were observed in the hospitalization, ER, or outpatient cost components. Those using ICS
either alone or in combination incurred $200 to $300 higher COPD-related total costs
compared to those using short-acting bronchodilators alone. This difference was primarily
driven by differences in the prescription drug cost component. Two studies have conducted a
cost-analysis of using ICS either alone or in combination with an inhaled long-acting betaagonist compared to using only short-acting bronchodilators. One study empirically
determined costs in a clinical trial, and found those using ICS alone incurred lower total cost
per day compared to those in a placebo group, but with no difference in the prescription drug
cost component between groups (Ayres et al., 2003). The lower cost found among the ICS
group was driven by a lower mean cost for hospitalizations and outpatient visits, since the
ICS group was found to have a reduced risk of moderate to severe exacerbations. Another
study using claims data from an HMO had similar findings to the present study (Gagnon et
al., 2005). Patients using ICS either alone or in combination with an inhaled long-acting
beta-agonist incurred higher costs during a 3 year period than those using short-acting
bronchodilators. Also, patients using combination ICS/LABA incurred higher costs
compared to those using LABA monotherapy. Statistical significance tests were not
computed, and differences in cost components were not identified.
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Phase III
Phase III assesses the impact of ICS on mortality using two different study designs.
Objective 8 uses a case-control study design and Objective 9 uses a historical cohort study
design to ascertain this association.

TABLE 39: Sample extraction for Phase III – Objective 8
Step

Outcome (WV)

Outcome (KY)

1. # 35-64 years of age with at least one
medical claim with a primary diagnosis of
COPD between WV: Jul 1, 1997 to Jun 30,
2003 and KY: Jan 1, 1998 to Dec 31, 2003.

A = 20,193

A = 27,901

2. # of A who died between WV: Jul 1, 1998
and Jun 30, 2003 and KY: Jan 1, 1999 and
Dec 31, 2003

B = 1,942

B = 2,728

3. # of controls available for matching to cases

C = A-B = 18,251

C = A-B = 25,173

4. # of B+C continuously eligible for
Medicaid and not enrolled in managed care
at anytime 1 year before index date.

D = 2,563

D = 3,773

5. # of D with at least one hospitalization or
ER visit or at least two outpatient claims on
different dates with a primary diagnosis of
COPD in 1 year before index date

E = 1,277
-Cases = 910
-Controls = 367

E = 1,905
-Cases = 1,285
-Controls = 620

6. # of E without diagnosis of cystic fibrosis,
fibrosis due to tuberculosis, respiratory
cancer, and bronchiectasis during study
period

F = 1,042
-Cases = 691
-Controls = 351

F = 1,529
-Cases = 927
-Controls = 602

7. # of matched pairs

G = 101
-Cases = 101
-Controls = 101

G = 175
-Cases = 175
-Controls = 175

8. Total sample size

H = 552
-Cases = 276
-Controls = 276
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Table 39 shows that there were more cases than controls that met the study inclusion
criteria for objective 8. Accordingly, a 1:1 match was done by age, gender, and race to
obtain a final sample size of 276 matched pairs. The average age was 51 years with a
majority of women (61%) and whites (95%). Table 40 outlines overall comorbidity and
COPD severity of the cases and controls in the year before the index date. As expected,
cases (those who died) were more likely to have been sicker with a mean D’Hoore Charlson
comorbidity index of 4.6 versus 1.7 for controls. Additionally, cases had greater COPD
severity as measured by the proportion using oral corticosteroids (55.7% vs. 48.9%),
nebulized short-acting bronchodilators (59.8% vs. 38.4%), and home oxygen therapy (44.2%
vs. 28.3%). Of note, cases were significantly more likely to have a hospitalization or ER
visit (82.6% vs. 49.6%), and significantly less likely to have a physician visit for COPD or
COPD-related comorbid disorder (73.2% vs. 85.6%) compared to controls. Although cases
were more likely to have asthma, this difference was not statistically significant (20.7% vs.
15.5%).
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TABLE 40: Characteristics of study sample by case-control status in pre-index period (Phase IIIObjective 8)
Characteristic

Cases
(N= 276)

Controls
(N= 276)

Test Statistic
(p-value)

Demographic
Age, mean years (SD)

51 (0.34)

NA

Female, % (n)

61.0% (167)

NA

White, % (n)

95.1% (234)

NA

53.6% (148)

62.0% (171)

4.9401 (0.033)*

Mean (SD)
Median

4.6 (3.8)
4.0

1.7 (2.0)
1.0

-9.3862 (0.000)*

Number of other chronic conditionsb
Mean (SD)
Median

2.2 (1.5)
2.0

2.2 (1.4)
2.0

-0.8092 (0.419)

Use of inhaled SABAc canisters, % (n)
Mean # of canisters (SD)
Median

47.4% (131)
4.3 (8.9)
0.0

55.0% (152)
3.6 (6.0)
1.0

3.2701 (0.085)
-0.0572 (0.954)

Use of inhaled IPR canisters, % (n)
Mean # of canisters (SD)
Median

46.4% (128)
3.6 (5.9)
0.0

48.9% (135)
3.0 (4.4)
0.0

0.3501 (0.556)
-0.3682 (0.713)

Use of other doseform SABDc, % (n)
Mean # of Rx (SD)
Median

37.3% (103)
3.0 (5.1)
0.0

39.1% (173)
3.2 (5.1)
0.0

0.1801 (0.736)
-0.5472 (0.584)

Use of OCSd, % (n)
Mean # of Rx (SD)
Median

55.7% (154)
3.0 (4.4)
1.0

48.9% (135)
1.4 (2.5)
0.0

2.6001 (0.127)
-4.0042 (0.000)*

Use of nebulized SABDc, % (n)
Mean # of Rx (SD)
Median

59.8% (165)
6.0 (9.6)
2.0

38.4% (106)
2.5 (5.2)
0.0

27.4101 (0.000)*
-5.5562(0.000)*

Use of Hosp/ER for COPD or COPDrelated comorbid disorderse, % (n)

82.6% (228)

49.6% (137)

58.7301 (0.000)*

Countysmokerate >=31%
Overall Comorbidity
D’Hoore-CCIa

COPD severity
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4.0 (4.1)
3.0

1.3 (3.2)
0.0

-9.7852 (0.000)*

Use of Physician visits for COPD or
COPD-related comorbid disorderse, %
(n)
Mean (SD)
Median

73.2% (202)

85.6% (236)

12.5701 (0.000)*

3.4 (4.8)
2.0

4.6 (4.1)
4.0

4.3962 (0.000)*

Presence of asthma, % (n)

20.7% (57)

15.5% (43)

3.0601 (0.103)

Use of Home oxygen therapy

44.2% (122)

28.3% (78)

15.3702 (0.000)*

Mean (SD)
Median

*p < 0.05
a
Excludes asthma
b
Includes hypercholesterolemia, hypertension, other heart disease, AIDS, rheumatoid arthritis, osteoarthritis,
gall bladder disease, depression and anxiety, and schizophrenia.
c
Short-acting beta-agonist: includes levalbuterol, albuterol, metaproterenol, bitolterol, terbutaline.
d
Short-acting bronchodilators: includes levalbuterol, albuterol, metaproterenol, bitolterol, terbutaline,
theophylline, and ipratropium.
d
Oral corticosteroids: includes prednisone, prednisolone, methylprednisolone, cortisone, hydrocortisone,
dexamethasone, betamethasone, oral triamcinolone, oral budesonide.
e
Includes COPD, asthma, upper respiratory tract infections, lower respiratory tract infections, septicemia,
allergic rhinitis, other diseases of the lung, congestive heart failure, and disorders of fluid, electrolyte, and acidbase imbalance.
1
McNemar test statistic; 2Wilcoxon signed rank test statistic

Research Objective 8: To compare the odds of exposure to inhaled corticosteroids between
those who died and those who did not die during the study period (case-control study
design).
A lower proportion of cases were found to have at least two prescriptions of inhaled
corticosteroids in the pre-index period compared to controls (39.1% vs. 46.0%) with a crude
odds ratio of 0.768 (0.544-1.080) (Table 41). In adjusted analyses (Table 42) controlling for
all possible confounders, recipients exposed to inhaled corticosteroids had a 40 percent lower
probability of death compared to those who did not use inhaled corticosteroids (OR=0.605).
However, this effect was not significant. A power analysis was conducted using Dupont’s
methodology for calculating power in matched case-control designs (Dupont, 1988). This
method computes power or sample size based on the alternative odds ratio, the correlation of
exposure between pairs in the case-control set, and the probability of exposure in the
controls. Based on the study inputs, the analysis computed a power of 46%.
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TABLE 41: Exposure to inhaled corticosteroids in pre-index period by case-control status
(Phase III – Objective 8)
Cases
Controls
Crude Odds
Test Statistic
(N= 276)
(N= 276)
Ratio (95% CI)
(p-value)
39.1%
(108)

Exposure to ICS (%, n)

46.0%
(127)

0.768
(0.544-1.080)

2.49 (0.135)

TABLE 42: Conditional logistic regression of the impact of inhaled corticosteroids on mortality
(Phase III – Objective 8)
DV: Probability of death
Odds ratio (SE)

Variable

95% CI

p
value

Exposure to ICS (Ref: No)
Yes

0.605 (0.179)

0.338-1.080

0.089

County_Smokerate(Ref: <31%)
>=31%

0.702 (0.216)

0.385-1.281

0.249

D’Hoore-CCI

1.465 (0.096)

1.288-1.666

0.000*

Number of other chronic conditions

0.719 (0.078)

0.580-0.889

0.002*

# of inhaled SABA canisters

1.014 (0.016)

0.982-1.048

0.398

# of inhaled IPR canisters

1.063 (0.029)

1.007-1.122

0.026*

# of other SABD prescriptions

1.011 (0.027)

0.959-1.065

0.693

# of OCS prescriptions

1.107 (0.049)

1.015-1.208

0.022*

Use of nebulized SABD

1.619 (0.469)

0.920-2.857

0.096

# of Hosp/ER visits for COPD or COPDrelated comorbid disorders

3.160 (0.976)

1.725-5.787

0.000*

# of Physician visits for COPD or COPDrelated comorbid disorders

0.302 (0.103)

0.154-0.591

0.000*

Presence of asthma

0.632 (0.261)

0.282-1.421

0.267

Use of Home oxygen therapy

1.740 (0.530)

0.957-3.163

0.069

Demographic

Overall comorbidity

COPD severity

*p < 0.05
Log likelihood = -98.34; χ2 = 185.93; p=0.000*
Pseudo R2: 48.6%
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TABLE 43: Sample extraction for Phase III – Objective 9
Step

Outcome WV
A = 159,514
ICS = 32,948
no ICS = 126,566

1. # with a Rx claim for combination product
of ICS/LABA or ICS, or other COPDrelated drugs during: WV- Jul 1, 1998 to
Mar 31, 2002 and KY-Jan 1, 1999 to Sep
30, 2002

Outcome KY
A = 101,967
ICS = 77,345
no ICS = 246,222

2. The date of first chronologically occurring prescription claim was defined as an index date for
each person. The drug therapy groups represent number with respective prescription claim at
index date.
3. # of A between 35-64 years, continuously
eligible for Medicaid and not enrolled in
managed care at anytime 1 year before
index date

B = 33,010
ICS = 10,058
no ICS = 22,952

B = 62,408
ICS = 19,810
no ICS = 42,598

4. # of B with prescription drug patterns
specified in study criteria

C = 16,576
ICS = 4,797
no ICS = 11,779

C = 30,937
ICS = 9,152
no ICS = 21,785

5. # of C without diagnosis of cystic fibrosis,
fibrosis due to tuberculosis, respiratory
cancer, and bronchiectasis during study
period

D = 16,103
ICS = 4,622
no ICS = 11,481

D = 30,219
ICS = 8,909
no ICS = 21,310

6. # of D with at least one hospitalization or
ER visit or at least two outpatient claims on
different dates with a primary or secondary
diagnosis of COPD

E = 3,237
ICS = 1,534
no ICS = 1,703

E= 5,808
ICS = 2,610
no ICS = 3,198

7. # of E who did not die during 30 days
following index date

F= 3,220
ICS = 1,532
no ICS = 1,688

F = 5,790
ICS = 2,602
no ICS = 3,188

8. # of F continuously eligible for Medicaid
and not enrolled in managed care at anytime
till date of death for those who died or till
end of follow-up for those who did not die

G = 2,928
ICS = 1,420
no ICS = 1,508

G = 5,341
ICS = 2,420
no ICS = 2,921

1. # of G who had at least one additional
prescription claim of index drug therapy
in follow-up period.

H = 1,209
ICS = 901
no ICS = 308

H = 2,308
ICS = 1,696
no ICS = 616

2. Final study sample size

J = 3,517
ICS = 2,594
no ICS = 923
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A total of 3,517 recipients met the inclusion criteria for objective 9 of Phase III, the
majority of which were prescribed an inhaled corticosteroid (ICS) (Table 43). Table 44
outlines the baseline characteristics of the study sample. Recipients who were prescribed
inhaled corticosteroids were more likely to be younger females. Although the D’Hoore
Charlson comorbidity index showed no differences, recipients in the ICS group had a higher
mean number of other chronic conditions (2.0 vs. 1.8). Recipients with ICS were also more
likely to have used oral corticosteroids (41.9% vs. 35.4%) and home oxygen therapy (18.1%
vs. 14.6%) in the pre-index period, and have a hospitalization or ER visit for COPD or a
COPD-related disorder in the pre-index period compared to those not prescribed an ICS
(53.8% vs. 46.8%). As expected, recipients with concomitant asthma were also more likely
to have been prescribed an ICS (22.1% vs. 14.8%). Recipients who were not prescribed an
ICS had a higher number of canisters of SABA and IPR, and a higher number of
prescriptions of other dose forms of short-acting bronchodilators. However, this increased
use may be a reflection of the study design, since those in the non-ICS group having a shortacting bronchodilator as the index prescription were required to have at least two
prescriptions for a short-acting bronchodilator in the pre-index period of which one was for
ipratropium. This was done in order to avoid including a relatively mild COPD population
who use short-acting bronchodilators on an acute as-needed basis.
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TABLE 44: Baseline characteristics of study sample by drug therapy status (ICS vs. no ICS:
Phase III-Objective 9)
Characteristic

ICS
(N= 2,594)

No ICS
(N= 923)

Test Statistic
(p-value)

51 (7.6)

53 (7.4)

4.2891 (0.000)*

Female, % (n)

64.9% (1,675)

58.3% (537)

12.5762 (0.000)*

White, % (n)

96.4% (2,246)

97.7% (818)

3.4892 (0.062)

WV

34.7% (901)

33.4% (308)

0.5622 (0.453)

KY

65.3% (1,693)

66.6% (615)

63.4% (1,644)

67.2% (620)

4.2762 (0.039)*

Mean (SD)
Median

1.5 (1.8)
1.0

1.5 (2.0)
1.0

-1.0923 (0.275)

Number of other chronic conditionsb
Mean (SD)
Median

2.0 (1.3)
2.0

1.8 (1.3)
2.0

-4.3773 (0.000)*

Use of inhaled SABAc canisters, % (n)
Mean # of canisters (SD)
Median

59.3% (1,538)
4.1 (7.2)
1.0

63.8% (589)
4.8 (7.8)
2.0

5.8272 (0.016)*
2.8183 (0.005)*

Use of inhaled IPR canisters, % (n)
Mean # of canisters (SD)
Median

43.9% (1,138)
2.6 (5.5)
0.0

67.4% (622)
4.3 (6.5)
2.0

150.6182 (0.000)*
12.1983 (0.000)*

Use of other doseform SABDc, % (n)
Mean # of Rx (SD)
Median

31.7% (821)
2.3 (4.4)
0.0

40.3% (372)
2.9 (4.8)
0.0

22.7432 (0.000)*
4.8333 (0.000)*

41.9% (1,087)
1.2 (2.3)
0.0

35.4% (327)
1.1 (2.6)
0.0

11.8781 (0.001)*
-3.4273 (0.001)*

27.5% (713)

25.7% (237)

1.1301 (0.288)

Demographic
Age, mean years (SD)

State, % (n)

Countysmokerate >=31%
Overall Comorbidity
D’Hoore-CCIa

COPD severity

Use of OCSd, % (n)
Mean # of Rx (SD)
Median
Use of nebulized SABDc, % (n)
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1.8 (4.8)
0.0

2.1 (5.7)
0.0

-0.5273 (0.580)

Use of Hosp/ER for COPD or COPDrelated comorbid disorderse, % (n)
Mean (SD)
Median

53.8% (1,398)

46.8% (432)

13.6791 (0.000)*

0.5 (0.5)
1.0

0.5 (0.5)
0.0

-3.6983 (0.000)*

Use of Physician visits for COPD or
COPD-related comorbid disorderse, % (n)
Mean (SD)
Median

85.1% (2,210)

84.2% (778)

0.4291 (0.513)

0.9 (0.4)
1.0

0.8 (0.4)
1.0

-0.6553 (0.513)

Presence of asthma, % (n)

22.1% (572)

14.8% (137)

21.9751 (0.000)*

Use of Home oxygen therapy, %(n)

18.1% (167)

14.6% (378)

6.4451 (0.011)*

Mean # of Rx (SD)
Median

*p < 0.05
a
Excludes asthma
b
Includes hypercholesterolemia, hypertension, other heart disease, AIDS, rheumatoid arthritis, osteoarthritis,
gall bladder disease, depression and anxiety, and schizophrenia.
c
Short-acting beta-agonist: includes levalbuterol, albuterol, metaproterenol, bitolterol, terbutaline.
d
Short-acting bronchodilators: includes levalbuterol, albuterol, metaproterenol, bitolterol, terbutaline,
theophylline, and ipratropium.
d
Oral corticosteroids: includes prednisone, prednisolone, methylprednisolone, cortisone, hydrocortisone,
dexamethasone, betamethasone, oral triamcinolone, oral budesonide.
e
Includes COPD, asthma, upper respiratory tract infections, lower respiratory tract infections, septicemia,
allergic rhinitis, other diseases of the lung, congestive heart failure, and disorders of fluid, electrolyte, and acidbase imbalance.
1
t statistic; 2Chi-square test statistic; 3Mann-Whitney U-statistic

Research Objective 9: To conduct a mediation analysis to examine the relationship
between use of ICS, severe exacerbation and death (historical cohort study design).
Recipients who were prescribed an inhaled corticosteroid were significantly less likely to
have died in the follow-up period compared to recipients who were not prescribed and
inhaled corticosteroid (Table 40: 2.0% vs. 3.7%, p=0.005). Propensity scores were used to
account for this selection bias by incorporating it in the multivariate analyses as a covariate.
The logistic regression model used to obtain propensity scores in provided in Table 46.
Quintiles of the propensity score were created (Table 47), and differences in baseline
characteristics between the therapy groups were analyzed within each quintile using two-way
ANOVAs for continuous variables and Cochran-Mantel Haenzel statistics for categorical
variables. Table 48 shows that there were no significant differences in baseline
185

characteristics within each propensity score quintile. Hence the propensity score quintile was
used in the multivariate models. The survival advantage persisted for recipients being
prescribed an inhaled corticosteroid even after controlling for the propensity score quintile
and the recipient’s state (Table 49, Figure 19). Recipients prescribed an inhaled
corticosteroid were ~ 48 percent less likely to die in the follow-up period compared to those
who were not prescribed an inhaled corticosteroid. The log-rank test of time to death had a
power of 95.2% (Bauer D & Lavery R, 2004). The absolute risk reduction was
Objective 9 also wanted to assess if any survival advantage afforded by using inhaled
corticosteroids was mediated by the effect of inhaled corticosteroids on severe exacerbations.
Hence, the impact of inhaled corticosteroids on risk of a severe exacerbation in the follow-up
period was assessed. In univariate analyses, a slightly higher but insignificant proportion of
recipients prescribed an inhaled corticosteroid had a severe exacerbation compared to
recipients not being prescribed an inhaled corticosteroid (Table 45: 16.7% vs. 14.2%;
p=0.08). However, since this effect might be due to a selection bias, propensity scores were
used. Table 50 and Figure 20 shows that after controlling for propensity score quintile and
state, there was no effect of inhaled corticosteroids on severe exacerbations in the follow-up
period (HR=1.186; p=0.112). Since no effect was found, a mediation analysis was not
conducted. The log-rank test of time to death had a power of 58.0% (Bauer D et al., 2004)
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TABLE 45: Risk of mortality and severe exacerbation in follow-up period by drug therapy status
(ICS vs. no ICS: Phase III – Objective 9)
Characteristic

ICS
(N= 2,594)

No ICS
(N= 923)

Test Statistic
(p-value)

Died (%, n)

2.0% (52)

3.7% (34)

8.0451 (0.005)*

363 (0.5)

359 (1.3)

8.5862 (0.003)*

16.7% (432)

14.2% (131)

3.0671 (0.080)

335 (2.8)

327 (1.8)

3.2202 (0.073)

Time to death (days)
Mean (SE)
Severe exacerbations (%, n)
Time to severe exacerbation (days)
Mean (SE)
*p < 0.05
1
Chi-square test statistic; 2Log-rank test statistic
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TABLE 46: Logistic regression predicting the probability of being prescribed an inhaled
corticosteroid
DV: Probability of receiving ICS
Odds ratio (SE)

Variable

95% CI

p
value

Demographic
Age (years)

0.985 (0.006)

0.975-0.997

0.010*

Gender (Ref: Male)
Female

1.164 (0.100)

0.984-1.377

0.076

Race (Ref: non-White)
White

0.695 (0.182)

0.415-1.163

0.166

State (Ref: WV)
KY

0.930 (0.099)

0.755-1.146

0.498

County_Smokerate (Ref: <31%)
>=31%

0.823 (0.087)

0.669-1.012

0.065

D’Hoore-CCI

0.964 (0.023)

0.919-1.010

0.122

Number of other chronic conditions

1.132 (0.038)

1.060-1.209

0.000*

# of inhaled SABA canisters

1.013 (0.008)

0.998-1.028

0.098

# of inhaled IPR canisters

0.954 (0.008)

0.938-0.970

0.000*

# of other SABD prescriptions

0.979 (0.009)

0.961-0.998

0.027*

# of OCS prescriptions

0.998 (0.018)

0.963-1.034

0.915

Use of nebulized SABD

1.201 (0.126)

0.984-1.480

0.071

Presence of Hosp/ER visits for COPD or
COPD-related comorbid disorders

1.241 (0.109)

1.044-1.474

0.014*

# of Physician visits for COPD or COPDrelated comorbid disorders

1.004 (0.012)

0.980-1.029

0.734

Presence of asthma

1.402 (0.166)

1.112-1.768

0.004*

Use of Home oxygen therapy

0.809 (0.096)

0.640-1.022

0.075

Overall comorbidity

COPD severity

*p < 0.05
Log likelihood = -1760.54; χ2 = 124.07; p=0.000*
Pseudo R2: 3.4%
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TABLE 47: Propensity score distribution by drug therapy status (ICS vs. no ICS: Phase III –
Objective 9)
Characteristic

ICS
(N= 2,594)

No ICS
(N= 923)

0.75 (0.08)

0.71 (0.09)

1

0.61 (0.08)

0.60 (0.07)

2

0.70 (0.01)

0.70 (0.01)

3

0.75 (0.01)

0.75 (0.01)

4

0.79 (0.01)

0.78 (0.01)

5

0.84 (0.02)

0.84 (0.02)

Propensity score
Mean (SD)
Propensity score quintile

TABLE 48: Statistical tests of differences in characteristics within each propensity score quintile
Characteristic

Test Statistic
(p-value)
* = values <0.05

Demographic
Age

0.0701(0.795)

Female

0.0692 (0.793)

White

0.0052 (0.943)

State (KY)

0.056 (0.829)

Countysmokerate >=31%

0.0322 (0.859)

Overall Comorbidity
D’Hoore-CCIa

0.0001 (0.978)

Number of other chronic conditionsb

0.0401 (0.845)

COPD severity
# of inhaled SABAc canisters

0.6301 (0.427)

# of inhaled IPR canisters

3.3001 (0.069)
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1

# of other doseform SABD prescriptionsc

0.0001 (0.995)

# of OCS prescriptionsd

0.0001 (0.947)

Use of nebulized SABDc

0.0202 (0.893)

Presence of Hosp/ER for COPD or
COPD-related comorbid disorderse

0.0502 (0.816)

# of Physician visits for COPD or COPDrelated comorbid disorderse

0.0801 (0.780)

Presence of asthma

0.0302 (0.858)

Use of Home oxygen therapy

0.0402 (0.850)

Two-way ANOVA F statistic; 2Cochran-Mantel Haenzel test statistic
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TABLE 49: Cox-Proportional hazards regression of the impact of drug therapy (ICS vs. no ICS)
on time to death
DV: Time to death
Hazard ratio (SE)

Variable

95% CI

p
value

Drug therapy (Ref: no ICS)
ICS
Propensity score quintile

0.524 (0.130)

0.322-0.852

0.009*

0.924 (0.080)

0.780-1.095

0.361

0.577 (0.138)

0.361-0.923

0.022*

State (Ref: WV )
KY

*p < 0.05
Log likelihood = -556.48; χ2 =13.42; p=0.004*
Global test of proportional hazards assumption: χ2 = 1.73; p= 0.630
FIGURE 19: Adjusted Kaplan-Meier survival curve of time to death by drug therapy group
(ICS vs. no ICS: Phase III – Objective 9)
ICS
No
Yes

Proportion ALIVE during follow-up period

1.00

0.99

0.98

0.97

0.96
0

100

200

300

Time to Death (days)
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TABLE 50: Cox-Proportional hazards regression of the impact of drug therapy (ICS vs. no ICS)
on time to severe exacerbation
DV: Time to severe exacerbation
Hazard ratio (SE)

Variable

95% CI

p
value

Drug therapy (Ref: no ICS)
ICS
Propensity score quintile

1.186 (0.127)

0.961-1.462

0.112

1.006 (0.032)

0.944-1.071

0.852

0.872 (0.080)

0.730-1.043

0.135

State (Ref: WV )
KY

*p < 0.05
Log likelihood = -3986.97; χ2 = 5.18 p=0.159
Global test of proportional hazards assumption: χ2 = 0.43; p= 0.934
FIGURE 20: Adjusted Kaplan-Meier survival curve of time to severe exacerbation by drug
therapy group (ICS vs. no ICS: Phase III – Objective 9)

ICS
No
Yes

Proportion WITHOUT severe exacerbation
during follow-up period

1.00

0.95

0.90

0.85

0.80
0

100

200

300

Time to Severe Exacerbation (days)
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Discussion for Research Objectives 8 and 9
Research objectives 8 and 9 assessed the impact of ICS on all-cause mortality. The
analyses showed ICS to reduce the risk of death by 40 percent using a case-control design,
and by 48 percent using a cohort study design in recipients with COPD between 35-64 years
of age. Observational studies in the literature have assessed the impact of ICS on mortality
in patients with COPD who are generally over 50 years of age. In Ontario, the use of ICS
after hospital discharge was associated with a 21% reduction in mortality over one year of
follow-up, whereas in Alberta it was associated with a 25% reduction in mortality over three
years. Soriano et al. analyzed the UK General Practice Research Database (GPRD), and
found a 38 percent reduction in mortality over a three-year follow-up period. Another study
using HMO claims data in the U.S. found ICS to reduce the risk of death by 41 percent in
COPD patients at least 40 years of age.
Currently, a recently published study in September 2006 assessed the impact of ICS on
mortality in patients in two age groups, 35-64 years, and > 65 years. In this study, ICS was
found to reduce the risk of death by 25% in those > 65 years, and by 53% in those 35-64
years using a cohort study design (Macie, Wooldrage, Manfreda, & Anthonisen, 2006). In
the present study, a similarly higher magnitude of risk reduction (48%) was seen using the
cohort study design compared to using the case-control study design.
In contrast to the present study findings and the above study, not all observational studies
have found a beneficial effect of ICS on mortality. Two studies used time-dependent
methods when analyzing the data to account for immortal time bias (Suissa, 2004; Fan et al.,
2003). The results of these studies indicated a trend for reduced mortality that was not
significant. However, the use of time-dependent methods has been criticized in situations
where protopathic bias might exist (i.e. treatment may be strongly correlated with outcome)
(Sin et al., 2003b; Kiri, Vestbo, Pride, & Soriano, 2004).
The beneficial impact of ICS on mortality that has been seen in the present study and in
the majority of observational studies has yet to be validated in clinical trials. Four major
clinical trials have found a trend for reduced risk of mortality; however, none found a
significant effect (Vestbo et al., 1999; Pauwels et al., 1999; Burge et al., 2000; Lung Health
Study Group, 2000). The primary outcome of all these trials was the annual rate of FEV1
decline. None conducted a power analysis to determine if they had sufficient power to detect
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a difference in the mortality outcome. A meta-analysis by Alsaeedi et al. combined data
from these trials, and similarly found an overall trend for decreased risk of 0.84 (95% CI: 0.6
to 1.18) (Alsaeedi et al., 2002). Another scientific review pooled mortality data and found an
insignificant reduced risk for mortality of 0.78 (95%CI: 0.58 to 1.05) (Sin et al., 2003c).
Preliminary results from the Towards a Revolution in COPD Health (TORCH) trial report
that combination ICS/LABA (fluticasone/salmeterol) reduced the risk of all-cause mortality
by 17.5% (p=0.052) (Calverley PM, 2006).
Given the significant reduction seen in observational studies, and in the present study,
one of the objectives in the present study was also to explain if the reduction in mortality was
in fact mediated by the effect of ICS on the risk of severe exacerbations (MacKinnon, 1994).
The absence of an effect of ICS on the risk of severe exacerbations in the present study
precludes the possibility that ICSs reduce mortality risk by their reduction in severe
exacerbations at least in this study. The effect of ICS on mortality in this study can then be
explained by examining the causes of death for patients with COPD, and the effect of ICS on
these causes. COPD is an independent risk factor for cardiovascular mortality, with
cardiovascular diseases accounting for 25% of all deaths (Anthonisen, Connett, Enright, &
Manfreda, 2002; Zielinski et al., 1997). The link between COPD and cardiovascular events
can be attributed to the impact of the primary cause of COPD -- cigarette smoking. Cigarette
smoking causes not only lung inflammation but also systemic inflammation (Yasue et al.,
2006). Systemic inflammation plays an important role in pathogenesis of atherosclerosis and
plaque rupture leading to the increased prevalence of ischemic heart disease (Ross, 1999).
There is some evidence that inhaled corticosteroids reduce markers of systemic inflammation
(serum C-reactive protein and serum interleukin-6 levels) (Sin, Lacy, York, & Man, 2004;
Sadowska et al., 2005). Thus, it is possible that inhaled corticosteroids reduce systemic
inflammation and thereby ischemic events, thus exerting their beneficial effect on mortality.
This reasoning seems even more plausible with the publication of two recent studies. The
aforementioned study by Macie & colleagues found ICS to significantly reduce
cardiovascular deaths by 38% in patients over 65 years of age, and no significant reduction
for deaths due to COPD and asthma (Macie et al., 2006). A recent study by Huiart et al. has
also indicated that therapy with ICS is associated with a decreased risk of myocardial
infarction in patients with COPD (Huiart, Ernst, Ranouil, & Suissa, 2005).
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The relatively lower number of deaths in our study precluded testing whether the
reduction in deaths was driven by reduction in cardiovascular deaths. Still, a lower
proportion of those using ICS had died from cardiovascular causes compared to those not
using ICS (0.009% vs. 0.014%). Furthermore, the effect is probably more pronounced in our
study population because of the prevalence of cigarette smoking in our study population. As
of 2003, Kentucky and West Virginia were ranked #1 and #2 in the prevalence of current
cigarette smoking in the U.S. (WVBPH, 2005; KYDPH, 2004).
Contrary to the relative risk reduction that gives an indication of statistical significance,
the absolute risk reduction obtained from a cohort study design provides information of
practical significance. In the present cohort study design, recipients initiated on inhaled
corticosteroids had an absolute risk reduction of 1.7 percent, and indicates that 59 people
need to be treated with inhaled corticosteroids to avoid one death. It shoud be noted that this
effect was not merely restricted to a population of severe to very severe COPD since our
study design included recipients with varying severity levels between moderate to very
severe COPD. The number needed to treat may be lower in those who are severe. It should
also be noted that the incidence of adverse effects was not accounted for in this study, and it
is possible that the risk of adverse effects may eliminate the mortality benefit from using
inhaled corticosteroids. Thus, this information will be useful to Medicaid policymakers who
may want to consider increasing or decreasing the number of recipients being treated with
inhaled corticosteroids.
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CHAPTER 5: SUMMARY AND CONCLUSIONS
This chapter outlines a summary of the study results, lists study limitations, draws
conclusions and implications of the research, and provides recommendations for future
research.

Summary of Results for Phase I
The goal of Phase I was to estimate the costs incurred due to COPD in the West Virginia
and Kentucky Medicaid population and identify drivers of cost. The specific impact of
concomitant asthma on COPD-related costs was also examined.
Medicaid recipients with COPD incurred 1.5 times significantly higher total healthcare
costs than non-COPD recipients with the incremental cost due to COPD per recipient being
$3,952 and $4,979 in WV and KY, respectively. The greatest difference in costs was due to
differences in costs for hospitalizations and ER visits between recipients with and without
COPD. Nursing home costs was the only component where recipients with COPD were
found to incur lower costs. COPD-related costs accounted for 35 percent of total healthcare
costs, indicating that comorbidites have a much greater impact than COPD itself in
increasing costs for recipients with COPD recipients.
Recipients with COPD with concomitant asthma were found to incur 50 percent higher
costs than recipients with COPD without concomitant asthma. The marginal cost ranged
from $2,200 in WV Medicaid to $3,500 in KY Medicaid. Of note, asthma significantly
increased the odds of having a COPD-related hospitalization or ER visit for recipients in both
states by 50 percent.

Summary of Results for Phase II
The goal of Phase II was to assess the cost-effectiveness of maintenance
pharmacotherapy used by recipients with COPD. Part 1 compared the risk and frequency of
exacerbations, and costs between recipients initiating maintenance therapy with ipratropium
(defined as using the combination product of ipratropium/albuterol) or monotherapy with a
long-acting beta-agonist in a relatively less severe COPD population. Part 2 compared the
risk of a severe exacerbation, frequency of moderate exacerbations, and costs between
recipients initiating therapy with a combination of an inhaled corticosteroid with an inhaled
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long-acting beta-agonist, inhaled corticosteroid alone, inhaled long-acting beta-agonist alone,
or only short-acting bronchodilators.
Summary of Results for Part 1
Maintenance therapy with ipratropium was found to be as effective as using an inhaled
long-acting beta-agonist in reducing the risk and number of moderate to severe exacerbations
during a one year follow-up period for a relatively less severe COPD population. Except for
the prescription drug cost component, where recipients initiated on inhaled long-acting betaagonists were found to incur 24 percent (difference of $140) higher costs, total COPD-related
costs incurred during the follow-up period were not significantly different between the two
groups. Thus, the pharmacoecomic evaluation did not demonstrate any particular therapy to
have a significant advantage over the other.
Summary of Results for Part 2
Therapy with inhaled corticosteroids either alone or in combination with an inhaled longacting beta-agonist was not found to reduce either the risk of a severe exacerbation or the
frequency of moderate exacerbations in comparison to therapy with short-acting
bronchodilators. An increase in the number of moderate exacerbations was seen for those
using inhaled corticosteroids, but this effect was considered to result from residual
confounding rather than due to any detrimental effect of inhaled corticosteroids. The
addition of an inhaled corticosteroid to inhaled long-acting beta-agonist monotherapy did not
impact the risk of a severe exacerbation or frequency of moderate exacerbations. The
comparison of costs incurred during the follow-up reflected the results of the impact of
inhaled corticosteroids on exacerbations. Since no difference was seen in exacerbations, no
differences were observed in the hospitalization, ER, or outpatient cost components.
However, those using inhaled corticosteroids either alone or in combination with an inhaled
beta-agonist incurred significantly higher COPD-related prescription drug costs compared to
those using short-acting bronchodilators alone, which affected the difference in total COPDrelated costs

Summary of Results for Phase III
The goal of Phase III was to assess the effect of inhaled corticosteroids on mortality using
two study designs: a case-control and a cohort study. Additionally, one of the objectives was
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also to determine if the effect of inhaled corticosteroids on mortality was mediated by the
effect of inhaled corticosteroids on severe exacerbations.
Both the case-control and cohort study showed a benefical impact of inhaled
corticosteroids on mortality. The magnitude of mortality risk reduction ranged from 40
percent in the case-control study to 48 percent in the cohort study. The risk reduction was
significant for the cohort study as the analysis had 95% power to detect a difference.
However, the risk reduction was not statistically significant in the case-control study due to
lower power (45%). The mortality reduction was not mediated by reducing the risk of severe
exacerbations, as inhaled corticosteroids was not shown to have an effect on the risk of
severe exacerbation. Contrary to the relative risk reduction that gives an indication of
statistical significance, the absolute risk reduction obtained from a cohort study design
provides information of practical significance. In the present cohort study design, recipients
initiated on inhaled corticosteroids had an absolute risk reduction of 1.7 percent, and
indicates that 59 people need to be treated with inhaled corticosteroids to avoid one death.

Study Limitations
A majority of the limitations in this study can be attributed to the absence of information
on important variables in claims databases. Specifically, there was no information on
smoking status and use of pulmonary rehabilitation. Both smoking cessation and pulmonary
rehabilitation have been shown to impact outcomes of exacerbations and mortality in COPD,
and could be potential confounders. Smoking cessation products such as prescription
nicotine tablets and nasal sprays could have been obtained from prescription claims.
However, the inclusion of this variable does not adequately provide a measure of the
smoking status of an individual as those using it are still in the process of quitting. Those not
found to be using smoking cessation products can include two groups of COPD patients:
those who are still smoking and sustained quitters. Thus, inclusion of this variable would
have led to misclassification. Additionally, the claims would not have been able to capture
nicotine replacement products that are obtained over-the-counter such as gum and patches.
Studies of drug effects have not shown an interaction effect of smoking and the effect of
the drug. However, smoking is an independent predictor of the outcomes of mortality and
exacerbations, and could be a confounder. Thus, it is possible that ICS users who were more
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severe than those without ICS may have quit, since most health behavior changes occur when
a disease gets more severe. However, in COPD, the percent quitting smoking is low (~
22%), and sustained quitters at 11 years were more likely to have higher education among
other characateristics (being assigned to a smoking cessation intervention, older age, and
smoking fewer cigarettes at baseline) (Murray, Connett, Rand, Pan, & Anthonisen, 2002).
Disease severity as measured by FEV1 or other measure did not predict smoking cessation
status. Our study population was restricted to those in a lower socioeconomic status, and
therefore likely to have lesser education, and consequently more likely to be smoking. Thus,
a strong argument cannot be made that ICS users in Medicaid may have quit smoking solely
due to their higher severity.
There was also no information on clinical measures of disease severity, primarily FEV1,
and consequently the study methodology could not differentiate recipients who were in stage
3 or stage 4 COPD. This inability might have precluded assessing a beneficial effect of
inhaled corticosteroids on exacerbations, since inhaled corticosteroids have been shown to
reduce exacerbations in patients with COPD having lower FEV1 levels. Another important
aspect influencing outcomes in COPD could not be identified in the prescription claims data,
namely the receipt and cost of flu vaccinations. The reason might be that the vaccinations
are generally provided in doctor’s offices, and are possibly included in the cost of the visit.
In phase II, the pharmacoeconomic evaluation was done comparing therapies that were
available during the study time period. However, in 2004 a new long-acting bronchodilator,
tiotropium, was introduced that has demonstrated better lung function and lower exacerbation
rate compared to ipratropium and placebo. Thus, the cost-effectiveness analysis is limited as
this important comparator was not included in the analysis.
Propensity scores were used as an econometric technique to account for selection bias.
However, this method can only control for observed factors, and not unobserved factors.
Thus, there may still be confounding factors that have not been controlled for leading to
residual confounding.
The study population was restricted to a select COPD population enrolled in a Medicaid
program from two states in the U.S. that are primarily rural, have the highest smoking rates
in the country, and have a high chronic disease burden. Therefore, the study results may not
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be generalizable to findings from other state Medicaid programs that differ in these
characteristics.

Conclusions & Implications of the Research
The present study showed that recipients with COPD in the Medicaid system had almost
1.5 times significantly higher costs compared to a Medicaid recipient without COPD. This
ratio is comparable to the ratio found in other socioeconomic groups that receive healthcare
benefits in employer-sponsored insurance programs such as HMOs (Mapel et al., 2000a), and
thus the low socioeconomic status of the Medicaid population did not appear to exacerbate
the cost burden that may generally be imposed by a patient with COPD. All cost components
except for nursing home costs were higher for recipients with COPD compared to those
without COPD. The lower nursing home cost can probably be attributed to a policy initiative
by Medicaid of reducing costs by shifting to home-based care from nursing home care
(Wiener et al., 2002). Kentucky was one of seven states in the U.S. to participate in a home
and community based waiver system for older people and younger adults with physical
disabilities, and might explain why a significant difference was found in the nursing home
cost component as opposed to that seen in the West Virginia sample (Wiener et al., 2002).
A concomitant diagnosis of asthma significantly increased total COPD-related costs for
Medicaid recipients with COPD in both states. The incremental cost after adjusting for other
respiratory conditions and COPD-related comorbid disorders was still substantial with the
difference being almost 50% higher. The difference in hospitalizations and ER visit costs
was largest between those with and without asthma. Thus, policymakers may consider the
development of respiratory disease management interventions or other initiatives for this
subgroup of recipients with COPD.
Unlike trends in the past decade, prescription drug costs in the present study accounted
for a greater proportion of the total costs (almost 25%) due to the introduction of newer
drugs. Our study population was restricted to adults aged between 35 to 64 years excluding
those in the Medicare program. Thus, the Medicaid program is still the primary payer for
this subset, and should anticipate increasing prescription drug costs for recipients with
COPD. An increase is anticipated primarily because of the introduction of a new drug
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tiotropium, and that of another combination product of an inhaled corticosteroid (budesonide)
and an inhaled long-acting beta-agonist (formoterol) called Symbicort®.
The pharmacoeconomic evaluation of drugs available during the study period found that
no drug was significantly better than using short-acting bronchodilators alone in reducing
exacerbations of COPD, which is the primary cost driver in COPD. For a recipient with
moderate COPD, therapy with ipratropium was found to be equally effective as an inhaled
long-acting beta-agonist in reducing exacerbations. Except for higher COPD-related
prescription drug costs, total COPD-related costs incurred were found to be similar between
therapy groups. Patient preference, satisfactory adherence, and convenience of use (longacting beta-agonists are currently indicated to be used twice a day as opposed to ipratropium
which is to be used four times a day) may then be used to facilitate choice of therapy for a
relatively less severe COPD population.
COPD is the third or fourth leading cause of death in WV and KY. Therefore, one of the
Healthy 2010 objectives for COPD in both states is to reduce the death rate due to COPD,
primarily through smoking cessation programs. In the present study, therapy with inhaled
corticosteroids was found to reduce mortality rates by almost half. This finding is even more
significant considering the younger age group of the study population. Thus, the present
study has provided evidence of another treatment modality having a beneficial impact on
mortality, and consequently helping to achieve the states’ Healthy 2010 objectives.
Recommendations for Future Research
In the present study, the pharmacoeconomic evaluation did not include an important
addition to COPD pharmacotherapy, tiotropium, due to its unavailability during the study
period. Future pharmacoeconomic evaluations will be more comprehensive than the present
study with the inclusion of this comparator. In the present study, a concomitant diagnosis of
asthma was found to significantly increase direct costs for recipients with COPD. However,
only direct costs were included as it was relevant to Medicaid. Future studies may want to
incorporate an indirect cost component to determine the impact of these concomitant
respiratory disorders on work productivity.
Inhaled corticosteroids were shown to reduce mortality, but were not shown to reduce the
risk of severe exacerbations. Preliminary hypotheses in the literature suggest that inhaled
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corticosteroids exert their beneficial effect on mortality by reductions in COPD exacerbations
which produce hypoxia and instability that may predispose to cardiovascular events,
reduction in systemic inflammation, or due to reduced adaptive immune responses (Macie et
al., 2006). The current study assessed one of these explanations of whether the reduction in
mortality was mediated by the reduction in severe COPD exacerbation. The study did not
find any impact. However, the present study design was limited in being able to identify a
COPD population specifically with stage 3 and stage 4, in whom the current literature has
found a significant effect on exacerbations. Thus, future studies in severe COPD populations
using clinical-level data should be conducted to determine if the mortality reduction is
mediated by the impact on exacerbations. To account for smoking status, future claims
database research may consider validating the use of smoking cessation aids present in
prescription claims data with patient report so that an indicator of smoking status can be
created from claims data.
The impact of inhaled corticosteroids on systemic inflammation should also be assessed
to determine if mortality is reduced due to the anti-inflammatory properties of inhaled
corticosteroids. This mechanism seems more probable because the majority of death
reductions are due to cardiovascular deaths. Future research may benefit from conducting a
cause-specific mortality analysis. Also, basic clinical research should be conducted to assess
the impact of inhaled corticosteroids on markers of systemic inflammation. In addition, a
population-based study on the impact of inhaled corticosteroids on cardiovascular events
may further support the findings from basic clinical research.
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TABLE A1: [WV Medicaid] Two-part model of the impact of COPD on hospitalization costs
DV: Hospitalization costs
Part 1a
Odds Ratio
(SE)

Variable

p
value

Part 2b
β coefficient
(SE)

p
value

COPD (Ref: No)
Yes

3.635 (0.190)

0.000*

0.101 (0.031)

0.001*

Demographic
Race (Ref: non-White)
White

0.899 (0.109)

0.379

0.028 (0.064)

0.663

County_Smokerate(Re
f: <31%)
>=31%

0.705 (0.043)

0.000*

-0.009 (0.033)

0.783

D’Hoore-CCI

1.446 (0.019)

0.000*

0.095 (0.005)

0.000*

Number of other
chronic conditions

1.365 (0.027)

0.000*

0.078 (0.100)

0.000*

Overall comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood=-4814.97, χ2 = 2841.38, p=0.000; Pseudo R2= 22.78%
b
Part 2: GLM family (gamma) link(log): AIC = 20.04 Deviance=1482.27; (1/df) Deviance = 0.48
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TABLE A2: [WV Medicaid] Two-part model of the impact of COPD on ER costs
DV: ER costs
Part 1a
Odds Ratio
(SE)

p
value

Part 2b
β coefficient
(SE)

p
value

Yes

1.853 (0.080)

0.000*

0.295 (0.028)

0.000*

Demographic
Race (Ref: non-White)
White

0.800 (0.081)

0.028*

-0.159 (0.062)

0.010*

County_Smokerate(Ref:
<31%)
>=31%

0.904 (0.045)

0.044*

0.133 (0.032)

0.000*

D’Hoore-CCI

1.190 (0.014)

0.000*

0.082 (0.006)

0.000*

Number of other
chronic conditions

1.268 (0.022)

0.000*

0.204 (0.010)

0.000*

Variable

COPD (Ref: No)

Overall comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood= -6312.68, χ2 = 1107.01, p=0.000; Pseudo R2= 8.06%
b
Part 2: GLM family (gamma) link(log): AIC = 15.02 Deviance=5000.48; (1/df) Deviance = 1.05
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TABLE A3: [WV Medicaid] Generalized linear model (GLM) of the impact of COPD on Outpatient
costs
DV: Outpatient costs
β coefficient
(SE)

p
value

Yes

0.494 (0.021)

0.000*

Demographic
Race (Ref: non-White)
White

0.144 (0.050)

0.004*

-0.081 (0.001)

0.001*

D’Hoore-CCI

0.157 (0.005)

0.000*

Number of other chronic
conditionsa

0.243 (0.008)

0.000*

Variable

COPD (Ref: No)

County_Smokerate(Ref:
<31%)
>=31%
Overall comorbidity

* p < 0.05
GLM [family (gamma) link(log)]: AIC = 17.05; Deviance=12761.28; (1/df) Deviance = 1.32
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TABLE A4: [WV Medicaid] Two-part model of the impact of COPD on Physician visit costs
DV: Physician visit costs
Part 1a
Odds Ratio
(SE)

Variable

p
value

Part 2b
β coefficient
(SE)

p
value

COPD (Ref: No)
Yes

1.684 (0.105)

0.000*

0.173 (0.031)

0.000*

Demographic
Race (Ref: non-White)
White

0.888 (0.127)

0.405

0.130 (0.073)

0.073

County_Smokerate(Re
f: <31%)
>=31%

0.806 (0.055)

0.002*

0.164 (0.036)

0.000*

D’Hoore-CCI

1.231 (0.026)

0.000*

0.122 (0.007)

0.000*

Number of other
chronic conditions

1.544 (0.042)

0.000*

0.269 (0.012)

0.000*

Overall comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood= -3719.34, χ2 = 787.30, p=0.000; Pseudo R2= 9.57%
b
Part 2: Semi-log OLS: R2=14.05%; p=0.000; Test for heteroskedasticity (χ2 = 0.16, p=0.692)
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TABLE A5: [WV Medicaid] Two-part model of the impact of COPD on Prescription drug costs
DV: Physician visit costs
Part 1a
Odds Ratio
(SE)

Variable

p
value

Part 2b
β coefficient
(SE)

p
value

COPD (Ref: No)
Yes

1.095 (0.083)

0.232

0.304 (0.019)

0.000*

Demographic
Race (Ref: non-White)
White

1.358 (0.211)

0.048*

0.164 (0.046)

0.000*

County_Smokerate(Re
f: <31%)
>=31%

1.358 (0.128)

0.001*

-0.092 (0.022)

0.000*

D’Hoore-CCI

1.043 (0.021)

0.040*

0.078 (0.005)

0.000*

Number of other
chronic conditions

1.375 (0.044)

0.000*

0.154 (0.008)

0.000*

Overall comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood= -2744.33, χ2 = 173.40, p=0.000; Pseudo R2= 3.06%
b
Part 2: GLM family (gamma) link(log): AIC = 18.25 Deviance=7716.10; (1/df) Deviance = 0.84
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TABLE A6: [WV Medicaid] Two-part model of the impact of COPD on Nursing home costs
DV: Nursing home costs
Part 1a
Odds Ratio
(SE)

Variable

p
value

Part 2b
β coefficient
(SE)

p
value

COPD (Ref: No)
Yes

0.722 (0.078)

0.003*

-0.126 (0.075)

0.092

Demographic
Race (Ref: non-White)
White

1.451 (0.394)

0.171

-0.158 (0.172)

0.357

County_Smokerate(Re
f: <31%)
>=31%

0.709 (0.095)

0.011*

0.192 (0.087)

0.027*

D’Hoore-CCI

1.271 (0.023)

0.000*

-0.062 (0.012)

0.000*

Number of other
chronic conditions

0.863 (0.035)

0.000*

-0.097 (0.026)

0.000*

Overall comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood= -1599.97, χ2 = 157.94, p=0.000; Pseudo R2= 4.70%
b
Part 2: GLM family (gamma) link(log): AIC = 22.86 Deviance=297.86; (1/df) Deviance = 0.78

222

TABLE A7: [WV Medicaid] Generalized linear model (GLM) of the impact of COPD on total
healthcare costs
DV: Total healthcare costs
β coefficient
(SE)

Variable

p
value

COPD (Ref: No)
Yes

0.551 (0.018)

0.000*

Demographic
Race (Ref: non-White)
White

0.107 (0.042)

0.012*

-0.123 (0.209)

0.000*

D’Hoore-CCI

0.190 (0.004)

0.000*

Number of other chronic
conditionsa

0.229 (0.007)

0.000*

County_Smokerate(Ref:
<31%)
>=31%
Overall comorbidity

* p < 0.05
GLM [family (gamma) link(log)]: AIC = 19.74; Deviance=8630.85; (1/df) Deviance = 0.91.
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TABLE A8: [KY Medicaid] Two-part model of the impact of COPD on hospitalization costs
DV: Nursing home costs
Part 1a
Odds Ratio
(SE)

Variable

p
value

Part 2b
β coefficient
(SE)

p
value

COPD (Ref: No)
Yes

4.328 (0.215)

0.000*

0.236 (0.039)

0.000*

Demographic
Race (Ref: non-White)
White

0.918 (0.103)

0.448

-0.149 (0.079)

0.061

County_Smokerate(Re
f: <31%)
>=31%

1.163 (0.086)

0.041*

-0.048 (0.052)

0.358

D’Hoore-CCI

1.426 (0.018)

0.000*

0.139 (0.006)

0.000*

Number of other
chronic conditions

1.401 (0.025)

0.000*

0.031 (0.012)

0.011*

Overall comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood= -5722.11, χ2 = 3563.75, p=0.000; Pseudo R2= 23.75%
b
Part 2: Semi-log OLS: R2=14.39%; p=0.000; Test for heteroskedasticity (χ2 = 18.61, p=0.351)
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TABLE A9: [KY Medicaid] Two-part model of the impact of COPD on ER costs
DV: ER costs
Part 1a
Odds Ratio
(SE)

Variable

p
value

Part 2b
β coefficient
(SE)

p
value

COPD (Ref: No)
Yes

2.446 (0.097)

0.000*

0.413 (0.029)

0.000*

Demographic
Race (Ref: non-White)
White

0.817 (0.072)

0.022*

-0.142 (0.061)

0.020*

County_Smokerate(Re
f: <31%)
>=31%

0.845 (0.050)

0.004*

0.111 (0.040)

0.777

D’Hoore-CCI

1.143 (0.012)

0.000*

0.083 (0.006)

0.000*

Number of other
chronic conditions

1.314 (0.020)

0.000*

0.160 (0.010)

0.000*

Overall comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood= -7700.19, χ2 = 1655.41, p=0.000; Pseudo R2= 9.71%
b
Part 2: GLM family (gamma) link(log): AIC = 15.66 Deviance=4913.38; (1/df) Deviance = 0.90
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TABLE A10: [KY Medicaid] Generalized linear model (GLM) of the impact of COPD on Outpatient
costs
DV: Outpatient costs
β coefficient
(SE)

p
value

Yes

0.425 (0.024)

0.000*

Demographic
Race (Ref: non-White)
White

0.036 (0.055)

0.518

-0.168 (0.036)

0.000*

D’Hoore-CCI

0.218 (0.007)

0.000*

Number of other chronic
conditionsa

0.132 (0.009)

0.000*

Variable

COPD (Ref: No)

County_Smokerate(Ref:
<31%)
>=31%
Overall comorbidity

* p < 0.05
GLM [family (gamma) link(log)]: AIC = 18.27; Deviance=18340.62; (1/df) Deviance = 1.55
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TABLE A11: [KY Medicaid] Two-part model of the impact of COPD on Physician costs
DV: Physician costs
Part 1a
Odds Ratio
(SE)

Variable

p
value

Part 2b
β coefficient
(SE)

p
value

COPD (Ref: No)
Yes

2.940 (0.193)

0.000*

0.393 (0.016)

0.000*

Demographic
Race (Ref: non-White)
White

1.165 (0.136)

0.191

0.086 (0.037)

0.022*

County_Smokerate(Re
f: <31%)
>=31%

1.236 (0.100)

0.009*

0.035 (0.024)

0.154

D’Hoore-CCI

1.042 (0.021)

0.039*

0.129 (0.004)

0.000*

Number of other
chronic conditions

3.767 (0.146)

0.000*

0.213 (0.006)

0.000*

Overall comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood= -3794.30, χ2 = 2888.28, p=0.000; Pseudo R2= 27.57%
b
Part 2: GLM family (gamma) link(log): AIC = 14.92 Deviance=6934.20; (1/df) Deviance = 0.69
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TABLE A12: [KY Medicaid] Two-part model of the impact of COPD on Prescription drug costs
DV: Prescription drug costs
Part 1a
Odds Ratio
(SE)

Variable

p
value

Part 2b
β coefficient
(SE)

p
value

COPD (Ref: No)
Yes

2.271 (0.360)

0.000*

0.206 (0.018)

0.000*

Demographic
Race (Ref: non-White)
White

1.246 (0.301)

0.364

0.186 (0.039)

0.000*

County_Smokerate(Re
f: <31%)
>=31%

1.440 (0.239)

0.028*

0.087 (0.026)

0.001*

D’Hoore-CCI

1.128 (0.058)

0.019*

0.108 (0.005)

0.000*

Number of other
chronic conditions

2.020 (0.153)

0.000*

0.086 (0.007)

0.000*

Overall comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood= -1099.56, χ2 = 238.82, p=0.000; Pseudo R2= 9.80%
b
Part 2: GLM family (gamma) link(log): AIC = 18.70 Deviance=10514.38; (1/df) Deviance = 0.87
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TABLE A13: [KY Medicaid] Two-part model of the impact of COPD on nursing home costs
DV: Nursing home costs
Part 1a
Odds Ratio
(SE)

Variable

p
value

Part 2b
β coefficient
(SE)

p
value

COPD (Ref: No)
Yes

0.916 (0.098)

0.414

-0.524 (0.127)

0.000*

Demographic
Race (Ref: non-White)
White

0.780 (0.157)

0.218

-0.662 (0.245)

0.007*

County_Smokerate(Re
f: <31%)
>=31%

0.918 (0.133)

0.557

0.024 (0.168)

0.888

D’Hoore-CCI

1.271 (0.023)

0.000*

-0.043 (0.021)

0.046*

Number of other
chronic conditions

0.833 (0.034)

0.000*

-0.157 (0.048)

0.001*

Overall comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood= -1759.62, χ2 = 147.86, p=0.000; Pseudo R2= 4.03%
b
Part 2: Semi-log OLS: R2=20.8%; p=0.000; Test for heteroskedasticity (χ2 = 17.27, p=0.436)
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TABLE A14: [KY Medicaid] Generalized linear model (GLM) of the impact of COPD on total
healthcare costs
DV: Total healthcare costs
β coefficient
(SE)

Variable

p
value

COPD (Ref: No)
Yes

0.426 (0.017)

0.000*

Demographic
Race (Ref: non-White)
White

0.000 (0.038)

0.992

-0.069 (0.026)

0.006*

D’Hoore-CCI

0.207 (0.005)

0.000*

Number of other chronic
conditionsa

0.122 (0.007)

0.000*

County_Smokerate(Ref:
<31%)
>=31%
Overall comorbidity

* p < 0.05
GLM [family (gamma) link(log)]: AIC = 20.37; Deviance=9161.44; (1/df) Deviance = 0.77
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TABLE A15: [WV Medicaid] Two-part model of the impact of asthma on COPD-related
hospitalization costs
DV: COPD-related hospitalization costs
Part 1a
Odds Ratio
(SE)

Variable

p
value

Part 2b
β coefficient
(SE)

p
value

Concomitant asthma (Ref: No)
Yes

1.561 (0.130)

0.000*

0.057 (0.038)

0.140

Age (years)

1.012 (0.005)

0.010*

-0.001 (0.002)

0.720

Gender (Ref: Male)
Female

1.100 (0.079)

0.184

-0.011 (0.036)

0.753

Race (Ref: non-White)
White

0.850 (0.153)

0.367

0.058 (0.086)

0.502

County_Smokerate(Ref: <31%)
>=31%

0.771 (0.063)

0.002*

-0.013 (0.041)

0.757

D’Hoore-CCIa

1.071 (0.018)

0.000*

0.017 (0.007)

0.025*

Number of other chronic conditionsb

1.223 (0.032)

0.000*

0.042 (0.013)

0.001*

Presence of upper respiratory tract
infectionsc

1.074 (0.076)

0.313

0.033 (0.035)

0.346

Presence of lower respiratory tract
infectionsd

3.175 (0.263)

0.000*

0.225 (0.036)

0.000*

Presence of septicemia

0.567 (0.141)

0.023*

-0.079 (0.098)

0.421

Presence of allergic rhinitis

0.762 (0.082)

0.012

-0.091 (0.055)

0.097

Presence of other diseases of the lunge

2.060 (0.155)

0.000*

0.316 (0.036)

0.000*

Presence of congestive heart failure

1.485 (0.124)

0.000*

0.075 (0.037)

0.044*

Presence of disorders of fluid,
electrolyte, and acid-base balance

2.009 (0.170)

0.000*

0.240 (0.037)

0.000*

Demographic

Overall comorbidity

COPD-related comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood= -2616.02; χ2 = 1074.59; p=0.000; Pseudo R2= 17.04%
b
Part 2: Semi-log OLS: R2=17.00%; p=0.000; Test for heteroskedasticity (χ2 =65.51 , p=0.999)
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TABLE A16: [WV Medicaid] Two-part model of the impact of asthma on COPD-related ER costs
DV: COPD-related ER costs
Part 1a
Odds Ratio
(SE)

Variable

p
value

Part 2b
β coefficient
(SE)

p
value

Concomitant asthma (Ref: No)
Yes

1.608 (0.124)

0.000*

0.109 (0.059)

0.083

Age (years)

0.992 (0.004)

0.050

-0.009 (0.003)

0.008*

Gender (Ref: Male)
Female

0.865 (0.059)

0.032*

-0.052 (0.054)

0.342

Race (Ref: non-White)
White

1.009 (0.173)

0.957

-0.051 (0.138)

0.709

County_Smokerate(Ref: <31%)
>=31%

1.067 (0.079)

0.386

0.086 (0.060)

0.147

D’Hoore-CCIa

0.989 (0.016)

0.506

0.008 (0.013)

0.536

Number of other chronic conditionsb

1.118 (0.028)

0.000*

0.118 (0.021)

0.000*

Presence of upper respiratory tract
infectionsc

1.762 (0.119)

0.000*

0.065 (0.056)

0.244

Presence of lower respiratory tract
infectionsd

1.437 (0.117)

0.000*

0.112 (0.061)

0.066

Presence of septicemia

0.742 (0.174)

0.203

-0.025 (0.175)

0.887

Presence of allergic rhinitis

0.779 (0.079)

0.014*

0.009 (0.081)

0.916

Presence of other diseases of the lunge

1.688 (0.125)

0.000*

0.239 (0.057)

0.000*

Presence of congestive heart failure

1.120 (0.092)

0.166*

0.081 (0.064)

0.210

Presence of disorders of fluid,
electrolyte, and acid-base balance

1.578 (0.130)

0.000*

0.291 (0.062)

0.000*

Demographic

Overall comorbidity

COPD-related comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood= -2863.66; χ2 = 416.91; p=0.000; Pseudo R2= 6.79%
b
Part 2: Semi-log OLS: R2=9.59%; p=0.000; Test for heteroskedasticity (χ2 =111.81, p=0.382)
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TABLE A17: [WV Medicaid] Two-part model of the impact of asthma on COPD-related outpatient
costs
DV: COPD-related Outpatient costs
Part 1a
Odds Ratio
(SE)

Variable

p
value

Part 2b
β coefficient
(SE)

p
value

Concomitant asthma (Ref: No)
Yes

0.888 (0.116)

0.362

0.084 (0.061)

0.173

Age (years)

1.022 (0.007)

0.001*

-0.002 (0.003)

0.614

Gender (Ref: Male)
Female

1.085 (0.120)

0.461

0.031 (0.050)

0.540

Race (Ref: non-White)
White

1.382 (0.340)

0.189

0.288 (0.131)

0.029*

County_Smokerate(Ref: <31%)
>=31%

0.843 (0.100)

0.150

0.084 (0.056)

0.137

D’Hoore-CCIa

0.960 (0.026)

0.126

0.015 (0.012)

0.226

Number of other chronic conditionsb

1.022 (0.042)

0.600

0.067 (0.019)

0.000*

Presence of upper respiratory tract
infectionsc

0.735 (0.082)

0.006*

0.144 (0.050)

0.004*

Presence of lower respiratory tract
infectionsd

1.310 (0.203)

0.081

0.317 (0.064)

0.000*

Presence of septicemia

0.600 (0.216)

0.156

-0.016 (0.186)

0.930

Presence of allergic rhinitis

1.887 (0.370)

0.001*

0.125 (0.074)

0.091

Presence of other diseases of the lunge

1.465 (0.202)

0.006*

0.404 (0.058)

0.000*

Presence of congestive heart failure

1.419 (0.219)

0.023*

0.523 (0.063)

0.000*

Presence of disorders of fluid,
electrolyte, and acid-base balance

0.885 (0.128)

0.401

0.142 (0.065)

0.030*

Demographic

Overall comorbidity

COPD-related comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood= -1344.62; χ2 = 63.29; p=0.000; Pseudo R2= 2.30%
b
Part 2: Semi-log OLS: R2=8.25%; p=0.000; Test for heteroskedasticity (χ2 =123.16, p=0.151)
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TABLE A18: [WV Medicaid] Two-part model of the impact of asthma on COPD-related physician
costs
DV: COPD-related Physician costs
Part 1a
Odds Ratio
(SE)

Variable

p
value

Part 2b
β coefficient
(SE)

p
value

Concomitant asthma (Ref: No)
Yes

1.079 (0.082)

0.315

0.062 (0.042)

0.147

Age (years)

1.007 (0.004)

0.061

-0.011 (0.002)

0.000*

Gender (Ref: Male)
Female

1.008 (0.062)

0.899

-0.061 (0.037)

0.094

Race (Ref: non-White)
White

1.234 (0.192)

0.177

0.349 (0.097)

0.000*

County_Smokerate(Ref: <31%)
>=31%

0.885 (0.061)

0.077

0.047 (0.040)

0.250

D’Hoore-CCIa

0.960 (0.015)

0.005*

0.034 (0.009)

0.000*

Number of other chronic conditionsb

1.089 (0.025)

0.000*

0.098 (0.014)

0.000*

Presence of upper respiratory tract
infectionsc

1.062 (0.066)

0.333

0.070 (0.036)

0.050

Presence of lower respiratory tract
infectionsd

1.214 (0.098)

0.017*

0.146 (0.046)

0.001*

Presence of septicemia

0.676 (0.148)

0.073

-0.192 (0.139)

0.166

Presence of allergic rhinitis

1.268 (0.122)

0.013*

0.185 (0.051)

0.000*

Presence of other diseases of the lunge

1.140 (0.083)

0.072

0.134 (0.041)

0.001*

Presence of congestive heart failure

0.911 (0.071)

0.231

0.146 (0.046)

0.002*

Presence of disorders of fluid,
electrolyte, and acid-base balance

0.869 (0.070)

0.080

0.053 (0.047)

0.265

Demographic

Overall comorbidity

COPD-related comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood= -3232.30; χ2 = 57.14; p=0.000; Pseudo R2= 0.88%
b
Part 2: GLM family (gamma) link(log): AIC = 12.80 Deviance=2103.94; (1/df) Deviance = 0.80

234

TABLE A19: [WV Medicaid] Two-part model of the impact of asthma on COPD-related
prescription drug costs
DV: COPD-related Prescription drug costs
Part 1a
Odds Ratio
(SE)

Variable

p
value

Part 2b
β coefficient
(SE)

p
value

Concomitant asthma (Ref: No)
Yes

1.279 (0.183)

0.085

0.376 (0.040)

0.000*

Age (years)

0.954 (0.006)

0.000*

0.017 (0.002)

0.000*

Gender (Ref: Male)
Female

1.493 (0.147)

0.000*

-0.025 (0.034)

0.456

Race (Ref: non-White)
White

1.590 (0.370)

0.046*

0.461 (0.088)

0.000*

County_Smokerate(Ref: <31%)
>=31%

1.440 (0.179)

0.003*

0.042 (0.037)

0.255

D’Hoore-CCIa

1.014 (0.027)

0.587

-0.034 (0.008)

0.000*

Number of other chronic conditionsb

1.239 (0.049)

0.000*

-0.045 (0.013)

0.000*

Presence of upper respiratory tract
infectionsc

1.976 (0.207)

0.000*

0.112 (0.034)

0.001*

Presence of lower respiratory tract
infectionsd

1.024 (0.140)

0.862

0.285 (0.043)

0.000*

Presence of septicemia

1.344 (0.599)

0.508

0.043 (0.119)

0.719

Presence of allergic rhinitis

1.062 (0.181)

0.722

0.108 (0.050)

0.031*

Presence of other diseases of the lunge

1.137 (0.139)

0.293

0.189 (0.038)

0.000*

Presence of congestive heart failure

1.102 (0.147)

0.465

0.112 (0.042)

0.007*

Presence of disorders of fluid,
electrolyte, and acid-base balance

1.191 (0.172)

0.229

0.028 (0.043)

0.514

Demographic

Overall comorbidity

COPD-related comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood= -1518.54; χ2 = 241.23; p=0.000; Pseudo R2= 7.36%
b
Part 2: GLM family (gamma) link(log): AIC = 15.76 Deviance=5085.86 (1/df) Deviance = 1.14
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TABLE A20: [WV Medicaid] Semi-log OLS model of the impact of asthma on total COPD-related
costs
DV: Total COPD-related costs
β coefficient
(SE)

Variable

p
value

Concomitant asthma (Ref: No)
Yes

0.392 (0.045)

0.000*

Age (years)

0.006 (0.002)

0.018*

Gender (Ref: Male)
Female

0.061 (0.037)

0.102

Race (Ref: non-White)
White

0.196 (0.096)

0.042*

-0.033 (0.042)

0.430

D’Hoore-CCIa

0.034 (0.009)

0.000*

Number of other chronic conditionsb

0.101 (0.014)

0.000*

Presence of upper respiratory tract infectionsc

0.149 (0.037)

0.000*

Presence of lower respiratory tract infectionsd

0.673 (0.048)

0.000*

Presence of septicemia

-0.345 (0.156)

0.011*

Presence of allergic rhinitis

-0.007 (0.056)

0.905

Presence of other diseases of the lunge

0.530 (0.043)

0.000*

Presence of congestive heart failure

0.351 (0.047)

0.000*

Presence of disorders of fluid, electrolyte, and
acid-base balance

0.433 (0.049)

0.000*

Demographic

County_Smokerate(Ref: <31%)
>=31%
Overall comorbidity

COPD-related comorbidity

* p < 0.05
Semi-log OLS: R2=23.82%; p=0.000; Test for heteroskedasticity (χ2 =0.64, p=0.423)
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TABLE A21: [KY Medicaid] Two-part model of the impact of asthma on COPD-related
hospitalization costs
DV: COPD-related hospitalization costs
Part 1a
Odds Ratio
(SE)

Variable

p
value

Part 2b
β coefficient
(SE)

p
value

Concomitant asthma (Ref: No)
Yes

1.633 (0.122)

0.000*

0.155 (0.042)

0.000*

Age (years)

1.008 (0.004)

0.048*

0.009 (0.003)

0.001*

Gender (Ref: Male)
Female

1.007 (0.066)

0.913

0.014 (0.039)

0.713

Race (Ref: non-White)
White

1.166 (0.205)

0.381

-0.084 (0.106)

0.430

County_Smokerate(Ref: <31%)
>=31%

1.191 (0.121)

0.084

0.088 (0.059)

0.135

D’Hoore-CCIa

1.089 (0.017)

0.000*

0.025 (0.008)

0.002*

Number of other chronic conditionsb

1.207 (0.029)

0.000*

0.010 (0.014)

0.458

Presence of upper respiratory tract
infectionsc

1.339 (0.090)

0.000*

-0.034 (0.042)

0.413

Presence of lower respiratory tract
infectionsd

2.976 (0.217)

0.000*

0.244 (0.039)

0.000*

Presence of septicemia

0.684 (0.150)

0.083

0.446 (0.098)

0.000*

Presence of allergic rhinitis

0.681 (0.063)

0.000*

-0.008 (0.056)

0.887

Presence of other diseases of the lunge

2.090 (0.142)

0.000*

0.493 (0.039)

0.000*

Presence of congestive heart failure

1.520 (0.117)

0.000*

0.160 (0.042)

0.000*

Presence of disorders of fluid,
electrolyte, and acid-base balance

2.458 (0.194)

0.000*

0.304 (0.040)

0.000*

Demographic

Overall comorbidity

COPD-related comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood= -3233.46; χ2 = 1436.42; p=0.000; Pseudo R2= 18.17%
b
Part 2: Semi-log OLS: R2=22.96%; p=0.000; Test for heteroskedasticity (χ2 =112.26, p=0.370)
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TABLE A22: [KY Medicaid] Two-part model of the impact of asthma on COPD-related ER costs
DV: COPD-related ER costs
Part 1a
Odds Ratio
(SE)

Variable

p
value

Part 2b
β coefficient
(SE)

p
value

Concomitant asthma (Ref: No)
Yes

1.448 (0.101)

0.000*

0.197 (0.047)

0.000*

Age (years)

0.989 (0.004)

0.005*

0.001 (0.003)

0.679

Gender (Ref: Male)
Female

1.044 (0.065)

0.487

-0.132 (0.045)

0.003*

Race (Ref: non-White)
White

0.896 (0.144)

0.494

0.100 (0.113)

0.374

County_Smokerate(Ref: <31%)
>=31%

0.788 (0.072)

0.009*

0.116 (0.062)

0.062

D’Hoore-CCIa

0.994 (0.015)

0.689

0.017 (0.010)

0.096

Number of other chronic conditionsb

1.062 (0.024)

0.008*

0.113 (0.016)

0.000*

Presence of upper respiratory tract
infectionsc

2.037 (0.135)

0.000*

-0.019 (0.050)

0.699

Presence of lower respiratory tract
infectionsd

1.311 (0.094)

0.000*

0.129 (0.048)

0.007*

Presence of septicemia

0.856 (0.168)

0.429

-0.133 (0.130)

0.304

Presence of allergic rhinitis

0.806 (0.069)

0.011*

-0.046 (0.061)

0.449

Presence of other diseases of the lunge

1.621 (0.108)

0.000*

0.141 (0.045)

0.002*

Presence of congestive heart failure

1.144 (0.086)

0.073

0.085 (0.052)

0.102

Presence of disorders of fluid,
electrolyte, and acid-base balance

1.440 (0.110)

0.000*

0.235 (0.051)

0.000*

Demographic

Overall comorbidity

COPD-related comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood= -3517.78; χ2 = 465.49; p=0.000; Pseudo R2= 6.21%
b
Part 2: Semi-log OLS: R2=10.91%; p=0.000; Test for heteroskedasticity (χ2 =152.69, p=0.003) Semi-log OLS
model was used because GLM model was not a good fit.

238

TABLE A23: [KY Medicaid] Two-part model of the impact of asthma on COPD-related Outpatient
costs
DV: COPD-related outpatient costs
Part 1a
Odds Ratio
(SE)

Variable

p
value

Part 2b
β coefficient
(SE)

p
value

Concomitant asthma (Ref: No)
Yes

1.045 (0.093)

0.619

0.223 (0.052)

0.019*

Age (years)

1.031 (0.005)

0.000*

0.038 (0.003)

0.000*

Gender (Ref: Male)
Female

0.796 (0.060)

0.003*

0.244 (0.043)

0.000*

Race (Ref: non-White)
White

1.254 (0.229)

0.214

0.366 (0.117)

0.002*

County_Smokerate(Ref: <31%)
>=31%

1.075 (0.121)

0.522

-0.109 (0.066)

0.100

D’Hoore-CCIa

0.925 (0.016)

0.000*

0.070 (0.011)

0.000*

Number of other chronic conditionsb

1.003 (0.028)

0.901

-0.017 (0.016)

0.000*

Presence of upper respiratory tract
infectionsc

1.091 (0.082)

0.251

-0.159 (0.045)

0.000*

Presence of lower respiratory tract
infectionsd

1.633 (0.163)

0.000*

0.452 (0.052)

0.000*

Presence of septicemia

0.757 (0.179)

0.240

0.116 (0.151)

0.442

Presence of allergic rhinitis

1.343 (0.148)

0.008*

-0.130 (0.060)

0.029*

Presence of other diseases of the lunge

1.072 (0.092)

0.418

0.534 (0.049)

0.000*

Presence of congestive heart failure

0.873 (0.080)

0.140

0.574 (0.054)

0.000*

Presence of disorders of fluid,
electrolyte, and acid-base balance

1.053 (0.104)

0.601

0.211 (0.057)

0.000*

Demographic

Overall comorbidity

COPD-related comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood= -2669.95; χ2 = 110.01; p=0.000; Pseudo R2= 2.02%
b
Part 2: Semi-log OLS: R2=19.23%; p=0.000; Test for heteroskedasticity (χ2 =10.40, p=0.001) Semi-log OLS
model was used because GLM model was not a good fit.
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TABLE A24: [KY Medicaid] Two-part model of the impact of asthma on COPD-related Physician
costs
DV: COPD-related physician costs
Part 1a
Odds Ratio
(SE)

Variable

p
value

Part 2b
β coefficient
(SE)

p
value

Concomitant asthma (Ref: No)
Yes

1.086 (0.086)

0.300

0.045 (0.032)

0.159

Age (years)

0.997 (0.004)

0.397

0.004 (0.002)

0.036*

Gender (Ref: Male)
Female

0.613 (0.040)

0.000*

-0.012 (0.026)

0.641

Race (Ref: non-White)
White

1.435 (0.228)

0.023*

0.201 (0.075)

0.054

County_Smokerate(Ref: <31%)
>=31%

1.101 (0.105)

0.313

-0.031 (0.042)

0.459

D’Hoore-CCIa

0.922 (0.014)

0.000*

0.029 (0.007)

0.000*

Number of other chronic conditionsb

1.263 (0.032)

0.000*

0.058 (0.010)

0.000*

Presence of upper respiratory tract
infectionsc

1.745 (0.113)

0.000*

0.158 (0.028)

0.000*

Presence of lower respiratory tract
infectionsd

1.235 (0.101)

0.010*

0.129 (0.033)

0.000*

Presence of septicemia

0.388 (0.075)

0.000*

0.184 (0.111)

0.097

Presence of allergic rhinitis

1.747 (0.183)

0.000*

0.122 (0.035)

0.001*

Presence of other diseases of the lunge

1.096 (0.082)

0.225

0.295 (0.030)

0.000*

Presence of congestive heart failure

0.805 (0.064)

0.006*

0.168 (0.035)

0.000*

Presence of disorders of fluid,
electrolyte, and acid-base balance

0.793 (0.066)

0.006*

-0.044 (0.036)

0.213

Demographic

Overall comorbidity

COPD-related comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood= -3272.99; χ2 = 367.78; p=0.000; Pseudo R2= 5.32%
b
Part 2: GLM family (gamma) link(log): AIC = 13.29 Deviance=2206.52 (1/df) Deviance = 0.76
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TABLE A25: [KY Medicaid] Two-part model of the impact of asthma on COPD-related
Prescription drug costs
DV: COPD-related prescription drug costs
Part 1a
Odds Ratio
(SE)

Variable

p
value

Part 2b
β coefficient
(SE)

p
value

Concomitant asthma (Ref: No)
Yes

2.470 (0.758)

0.003*

0.397 (0.033)

0.000*

Age (years)

1.006 (0.010)

0.498

0.019 (0.002)

0.000*

Gender (Ref: Male)
Female

2.519 (0.392)

0.000*

-0.021 (0.028)

0.459

Race (Ref: non-White)
White

2.013 (0.647)

0.029*

0.303 (0.075)

0.000*

County_Smokerate(Ref: <31%)
>=31%

2.005 (0.382)

0.000*

0.028 (0.043)

0.514

D’Hoore-CCIa

1.005 (0.043)

0.899

-0.026 (0.007)

0.000*

Number of other chronic conditionsb

1.105 (0.068)

0.103

-0.017 (0.010)

0.090

Presence of upper respiratory tract
infectionsc

4.183 (0.752)

0.000*

0.129 (0.029)

0.000*

Presence of lower respiratory tract
infectionsd

1.635 (0.411)

0.051

0.170 (0.034)

0.000*

Presence of septicemia

1.178 (0.742)

0.794

-0.095 (0.094)

0.311

Presence of allergic rhinitis

1.550 (0.497)

0.172

0.094 (0.039)

0.016*

Presence of other diseases of the lunge

1.523 (0.320)

0.045*

0.129 (0.032)

0.000*

Presence of congestive heart failure

0.809 (0.158)

0.278

0.112 (0.035)

0.002*

Presence of disorders of fluid,
electrolyte, and acid-base balance

0.829 (0.187)

0.405

-0.004 (0.036)

0.899

Demographic

Overall comorbidity

COPD-related comorbidity

* p < 0.05
a
Part 1: Logistic regression: -2loglikelihood= -776.73; χ2 = 231.71; p=0.000; Pseudo R2= 12.98%
b
Part 2: GLM family (gamma) link(log): AIC = 16.37 Deviance=6597.31 (1/df) Deviance = 1.11
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TABLE A26: [KY Medicaid] Semi-log OLS model of the impact of asthma on total COPD-related
costs
DV: Total COPD-related costs
β coefficient
(SE)

Variable

p
value

Concomitant asthma (Ref: No)
Yes

0.472 (0.037)

0.000*

Age (years)

0.025 (0.002)

0.000*

Gender (Ref: Male)
Female

0.127 (0.031)

0.000*

Race (Ref: non-White)
White

0.224 (0.082)

0.006*

County_Smokerate(Ref: <31%)
>=31%

0.021 (0.047)

0.661

D’Hoore-CCIa

0.054 (0.008)

0.000*

Number of other chronic conditionsb

0.028 (0.012)

0.017*

Presence of upper respiratory tract infectionsc

0.026 (0.032)

0.408

Presence of lower respiratory tract infectionsd

0.498 (0.038)

0.000*

Presence of septicemia

0.147 (0.105)

0.163

-0.053 (0.043)

0.216

Presence of other diseases of the lunge

0.454 (0.035)

0.000*

Presence of congestive heart failure

0.430 (0.039)

0.000*

Presence of disorders of fluid, electrolyte, and
acid-base balance

0.334 (0.041)

0.000*

Demographic

Overall comorbidity

COPD-related comorbidity

Presence of allergic rhinitis

* p < 0.05
Semi-log OLS: R2=24.89%; p=0.000; Test for heteroskedasticity (χ2 =2.44, p=0.119)
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Appendix B: Logistic Regression Models for Obtaining Propensity Scores
for Phase II – Part 2
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TABLE B1: Logistic regression predicting the probability of being prescribed ICS/LABA vs.
SABD
DV: Probability of receiving ICS/LABA
Odds ratio (SE)

Variable

95% CI

p
value

Demographic
Age (years)

0.963 (0.009)

0.945-0.981

0.000*

Gender (Ref: Male)
Female

1.123 (0.164)

0.844-1.495

0.427

Race (Ref: non-White)
White

0.560 (0.270)

0.248-1.450

0.256

State (Ref: WV)
KY

1.040 (0.189)

0.729-1.485

0.828

County_Smokerate (Ref: <31%)
>=31%

0.449 (0.081)

0.314-0.640

0.000*

D’Hoore-CCI

0.976 (0.041)

0.890-1.059

0.561

Number of other chronic conditions

1.433 (0.083)

1.280-1.605

0.000*

# of inhaled SABA canisters

1.036 (0.015)

1.007-1.066

0.014*

# of inhaled IPR canisters

0.861 (0.015)

0.832-0.892

0.000*

# of other SABD prescriptions

0.936 (0.015)

0.907-0.966

0.000*

# of OCS prescriptions

1.037 (0.033)

0.975-1.103

0.245

Use of nebulized SABD

1.129 (0.192)

0.809-1.576

0.475

Presence of Hosp/ER visits for COPD or
COPD-related comorbid disorders

1.029 (0.155)

0.766-1.381

0.850

# of Physician visits for COPD or COPDrelated comorbid disorders

1.012 (0.020)

0.974-1.053

0.538

Presence of asthma

1.468 (0.295)

0.990-2.178

0.056

Use of Home oxygen therapy

1.114 (0.231)

0.743-1.672

0.600

Overall comorbidity

COPD severity

*p < 0.05
Log likelihood = -617.86; χ2 = 239.48; p=0.000*
Pseudo R2: 16.2%
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TABLE B2: Logistic regression predicting the probability of being prescribed ICS vs. SABD
DV: Probability of receiving ICS
Odds ratio (SE)

Variable

95% CI

p
value

Demographic
Age (years)

0.984 (0.007)

0.969-0.999

0.038*

Gender (Ref: Male)
Female

1.171 (0.136)

0.932-1.472

0.174

Race (Ref: non-White)
White

0.598 (0.236)

0.276-1.295

0.192

State (Ref: WV)
KY

0.764 (0.112)

0.573-1.020

0.068

County_Smokerate(Ref: <31%)
>=31%

0.772 (0.114)

0.578-1.032

0.081

D’Hoore-CCI

0.989 (0.035)

0.923-1.060

0.759

Number of other chronic conditions

1.245 (0.060)

1.133-1.368

0.000*

# of inhaled SABA canisters

1.047 (0.013)

1.023-1.073

0.000*

# of inhaled IPR canisters

0.910 (0.011)

0.888-0.932

0.000*

# of other SABD prescriptions

0.959 (0.012)

0.936-0.982

0.000*

# of OCS prescriptions

0.997 (0.025)

0.950-1.046

0.896

Use of nebulized SABD

0.949 (0.131)

0.725-1.243

0.706

Presence of Hosp/ER visits for COPD or
COPD-related comorbid disorders

1.370 (0.165)

1.083-1.734

0.009*

# of Physician visits for COPD or COPDrelated comorbid disorders

0.993 (0.017)

0.960-1.027

0.685

Presence of asthma

1.385 (0.225)

1.007-1.905

0.045*

Use of Home oxygen therapy

0.792 (0.130)

0.574-1.093

0.156

Overall comorbidity

COPD severity

*p < 0.05
Log likelihood = -992.27; χ2 = 175.06; p=0.000*
Pseudo R2: 8.1%
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TABLE B3: Logistic regression predicting the probability of being prescribed ICS/LABA vs.
LABA
DV: Probability of receiving ICS/LABA
Odds ratio (SE)

Variable

95% CI

p
value

Demographic
Age (years)

0.977 (0.008)

0.960-0.994

0.010*

Gender (Ref: Male)
Female

1.175 (0.164)

0.893-1.545

0.250

Race (Ref: non-White)
White

0.763 (0.303)

0.350-1.663

0.496

State (Ref: WV)
KY

1.336 (0.227)

0.957-1.865

0.089

County_Smokerate (Ref: <31%)
>=31%

0.674 (0.114)

0.485-0.938

0.019*

D’Hoore-CCI

0.936 (0.035)

0.870-1.008

0.079

Number of other chronic conditions

1.097 (0.057)

0.990-1.215

0.076

# of inhaled SABA canisters

0.990 (0.010)

0.970-1.010

0.334

# of inhaled IPR canisters

0.986 (0.015)

0.957-1.015

0.345

# of other SABD prescriptions

1.008 (0.017)

0.975-1.042

0.651

# of OCS prescriptions

0.985 (0.028)

0.931-1.042

0.608

Use of nebulized SABD

1.740 (0.303)

1.237-2.449

0.001*

Presence of Hosp/ER visits for COPD or
COPD-related comorbid disorders

1.074 (0.153)

0.813-1.420

0.614

# of Physician visits for COPD or COPDrelated comorbid disorders

1.024 (0.020)

0.985-1.065

0.227

Presence of asthma

1.320 (0.246)

0.916-1.902

0.137

Use of Home oxygen therapy

1.049 (0.205)

0.715-1.538

0.808

Overall comorbidity

COPD severity

*p < 0.05
Log likelihood = -651.71; χ2 = 43.19; p=0.000*
Pseudo R2: 3.2%
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